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Abstract 
Identification of body fluids and tissues is an essential step in forensic investigation because it 
can be used as strong evidence in identifying suspects and victims. Currently in forensic 
investigations, catalytic, enzymatic and immunological techniques are used to identify body 
fluids, however, are limited due to lack of sensitivity and specificity. Hence, researchers are 
always on the lookout for novel methods that can be used to identify and analyse body fluids. 
Recently, DNA methylation-based markers have proven to be more sensitive and specific than 
conventional methods   for body fluid identification. Genome-wide methylation studies have 
demonstrated that tissue specific differentially methylated regions (tDMRs) vary in 
methylation profiles in various cell types and tissues. The differences in methylation profiles 
of tDMRs can be targeted to be used as biomarkers to differentiate between body fluids and 
tissues. To date, only a few DNA methylation-based markers have been reported to identify 
body fluids. To enhance the specificity and robustness of DNA methylation-based 
identification, novel markers are required. Additionally, methylation-based markers require 
further interrogation, to evaluate the stability of their methylation profiles under simulated 
forensics conditions such as UV light, temperature, rain and microbes, which could cause DNA 
degradation and affect DNA recovery as well as the methylation status of body fluids. In a 
previous study, based on differential gene expression in blood, saliva, semen and vaginal fluid, 
gene body CpG islands were selected, in genes Zinc finger protein 282 (ZNF282), Protein 
tyrosine phosphatase, receptor S (PTPRS) and Hippocalcin like 1 (HPCAL1), that have 
potential tDMRs to differentiate between, blood, saliva, semen and vaginal fluid. It was 
proposed that differential gene expression could be possibly due to differences in methylation 
patterns. The present study was undertaken to establish the methylation status of potential 
tDMRs in target body fluids by using methylation specific PCR (MSP) and bisulfite sequencing 
(BS). In both MSP and BS, the methylation status of 3 genes ZNF282, PTPRS and HPCAL1 
were analysed in 10 samples of each body fluid. With MSP analysis the ZNF282 and PTPRS1 
tDMR displayed semen-specific hypomethylation while HPCAL1 tDMR showed saliva-
specific hypomethylation. The PTPRS 2 tDMR did not differentiate between any body fluids 
due to presence of methylation and unmethylation for all body fluids. With quantitative 
analysis by BS the ZNF282 tDMR showed statistically significant difference in overall 
methylation status between semen and all other body fluids as well as at individual CpG sites 
(p < 0.05).  Therefore, ZNF282 tDMR has the potential to be used to be a semen-specific 
hypomethylated marker. However, no statistically significant difference in methylation profiles 
was observed for PTPRS 1 and PTPRS 2 tDMR between body fluids or at individual CpG sites 
iv 
 
(p > 0.05). The BS study showed that the tDMR for the HPCAL1 gene displayed non-specific 
amplification therefore was not further analysed. Furthermore, a sensitivity and forensic 
simulation study was conducted to determine the stability of methylation profiles. To determine 
the lowest DNA concentration that can be evaluated with MSP, a sensitivity study was 
conducted using five-fold serial dilution (25, 20, 15, 10, 5, 1 ng) of blood DNA samples. Each 
DNA dilution was subjected to bisulfite modification, followed by amplification with ZNF282, 
PTPRS 1, PTPRS 2, and HPCAL1 primers. The results showed that the detection limits were 
10 ng for ZNF282 tDMR, 5 ng for PTPRS 1, 15 ng for PTPRS 2, and 5 ng for HPCAL1 tDMR. 
Thus, it was concluded that a DNA concentration greater than 10 ng would yield successful 
results with MSP analyses. To evaluate whether environmental conditions has an effect on the 
stability of methylation profiles of the ZNF282 tDMR, five samples of each body fluid were 
subjected to five different forensic simulated conditions (dry at room temperature, wet in an 
exsiccator, outside on the ground, sprayed with alcohol and sprayed with bleach) for 50 days. 
Following the 50 days, vaginal fluid showed highest DNA recovery under all conditions while 
semen had least DNA quantity. Under outside on the ground condition, all body fluids except 
semen showed decrease in methylation level, however, significant decrease in methylation 
level was observed for saliva. A statistical significant difference was observed for saliva and 
semen (p < 0.05) in the outside on the ground condition. No differences in methylation level 
were observed for the ZNF282 tDMR under all conditions for vaginal fluid samples. Thus, 
ZNF282 tDMR is stable under environmental insults and can be used as reliable semen-specific 
hypomethylated marker. The analysis of tDMRs represents a unique, efficient and reliable 
technique that can be used to differentiate between human body fluids. In the future, 
identification and validation of new tDMRs based markers as well as determining methylation 
differences in other forensically relevant body fluids will be beneficial for forensics 
applications.  
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Experimental Design 
In order to achieve the stated objectives, the present research was divided into the relevant 
chapters described below. A precise description of each phase will be described in the chapters 
which will include all rationale, challenges experienced and deviations from reported methods. 
Chapter One 
This chapter entails an introduction to the study. 
Chapter Two 
This chapter entails a detailed explanation on the various aspects of this study.  
Chapter Three 
This chapter involved the determination of methylation profile of candidate tDMRs in blood, 
saliva, semen and vaginal fluid using methylation specific PCR (MSP) and Bisulfite 
sequencing (BS). Specific primers targeting the gene body CpG islands were designed for 
methylation profiling.  
Chapter Four 
This chapter investigated the sensitivity of MSP method and stability of methylation profile of 
tDMRs in blood, saliva, semen and vaginal fluid under simulated forensic conditions.  
Chapter Five 
The final chapter, includes the general discussion and conclusion, which provides an overview 
of the main objectives and findings described in each of the chapters of the dissertation. 
Possible limitations are acknowledged and a scope for future improvement and development 
is provided. 
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Figure 2.1:  Basic overview of DNA methylation. A methyl group (CH3) 
attaches covalently to a cytosine residue (Vidaki et al., 2013). 
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Figure 2.2: Regulation of gene expression by DNA methylation. (A) 
Absence of methyl groups in the CpG island promoter permits 
binding of transcription factors which facilitates transcription 
initiation (B) Presence of methyl groups hinders binding of 
transcription factors which prevents gene expression (Lim and 
Maher, 2010). 
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Figure 2.3: Diagrammatic representation of immunoprecipitation 
techniques. Genomic DNA is first fragmented by sonication and 
then undergoes denaturation. The DNA is then separated into two 
fractions, namely the input DNA and immunoprecipitated 
DNA(IP).  Primary antibody (anti-methylcytosine) and methyl-
CpG binding protein (MBD) fusion protein are incubated with 
single-stranded DNA in MeDIP and MCIp, respectively. The 
methylated DNA–antibody complex is captured by a secondary 
antibody that is specific to the primary antibody (Thu et al., 
2010). 
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Figure 2.4: Schematic representation of bisulfite conversion. In methylated 
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and methylated cytosine remain the same (underlined CG) after 
bisulfite treatment (Hernández et al., 2013). 
 
 
 
 
 
 
26 
Figure 2.5: A diagrammatic representation of Ms-SNuPE. Target DNA 
undergoes bisulfite treatment and amplification, which is 
followed by the SNuPE assay. SNuPE products are then analysed 
by electrophoresis. Methylated cytosine (represented by red- 
mC) and non-methylated cytosine (represented by green C) at a 
CpG site. Non- methylated cytosine is reproduced as T (blue) 
following PCR amplification. Arrows at the 3- or 5’- represent 
PCR primers that amplify the bisulfite treated target DNA. 
Arrows at S1, S2 or S3 are representative the oligonucleotide 
primers for the Ms-SNuPE analysis (Gonzalgo and Liang, 2007). 
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Figure 2.6: A diagrammatic representation of cloned based bisulfite 
sequencing. Genomic DNA is bisulfite treated, followed by PCR 
amplification. PCR products are ligated into a vector. The ligated 
DNA product is then transformed into competent bacterial cells 
and grown in non-selective liquid culture. A selective media is 
used to plate transformed cells which are grown overnight. 
Blue/white selection method is used for selection of (white) 
colonies which contain the PCR amplicons as inserts. A PCR 
reaction followed by agarose gel electrophoresis is used to 
determine if selected positive colonies have the correct insert 
size. Positive amplicons are purified and sequenced. Sequenced 
results are used to establish methylation status. The rows 
represent a single clone and the columns individual CpG 
dinucleotides within the sequenced region of interest. Black dots 
represent methylated CpG sites and white dots represent 
unmethylated CpG sites (Huang et al., 2013a). 
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Figure 2.7: MSP primer design for methylated and unmethylated DNA. The 
DNA sequence (left) is modified based on the methylation status. 
The modified sequence is used to design the forward primer by 
replacing Us with Ts (Hernández et al., 2013). 
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Figure 2.8: A diagrammatic representation of methylation specific 
polymerase chain reaction. In MSP, two sets of primer pairs are 
designed to target the methylated cytosine (black circles) and 
non-methylated cytosine (white circles) of the bisulfite converted 
genomic DNA. After PCR amplification, the amplicons are 
analysed by agarose gel electrophoresis. M represents 
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DNA ladder (Huang et al., 2013b). 
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Figure 2.9: Chromosomal location of the ZNF282 gene. 
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Figure 2.10: Chromosomal location of the PTPRS gene. 
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Figure 2.11: Chromosomal location of the HPCAL1 gene. 
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Figure 3.1: Target CpG island of ZNF282 gene for primer design a) MSP: 
Visual representation of the location of the primers designed 
within the CpG island (blue colored area). Two primer sets are 
indicated by the purple boxes (MF1- methylated forward primer 
and MR1- methylated reverse primer) and green boxes (UF1- 
unmethylated forward primer and UR1- unmethylated reverse 
primer). Horizontal red line indicates the input sequence and 
vertical red lines represent CpG sites. b) BS: Visual 
representation of the location of the primers designed out of the 
CpG island. Primers are indicated by red boxes (F1- forward 
primer and R1- reverse primer). c) UCSC genome browser view 
of chromosomal location of the target CpG island within the gene 
indicated by the green bar and the position of the CpG island in 
relation to the introns and exons indicated by the blue horizontal 
line and box. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
49 
Figure 3.2: Target CpG island of PTPRS (PTPRS 1) gene for primer design 
a) MSP: Visual representation of the location of the primers 
designed within the CpG island (blue colored area). Two primer 
sets are indicated by the purple boxes (MF1- methylated forward 
primer and MR1- methylated reverse primer) and green boxes 
(UF1- unmethylated forward primer and UR1- unmethylated 
reverse primer). Horizontal red line indicates the input sequence 
and vertical red lines represent CpG sites. b) BS: Visual 
representation of the location of the primers designed out of the 
CpG island. Primers are indicated by red boxes (F1- forward 
primer and R1- reverse primer). c) UCSC genome browser view 
of chromosomal location of the target CpG island within the gene 
indicated by the green bar and the position of the CpG island in 
relation to the introns and exons indicated by the blue horizontal 
line and box 
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Figure 3.3: Target CpG island of PTPRS (PTPRS 2) gene for primer design 
a) MSP: Visual representation of the location of the primers 
designed within the CpG island (blue colored area). Two primer 
sets are indicated by the purple boxes (MF1- methylated forward 
primer and MR1- methylated reverse primer) and green boxes 
(UF1- unmethylated forward primer and UR1- unmethylated 
reverse primer). Horizontal red line indicates the input sequence 
and vertical red lines represent CpG sites. b) BS: Visual 
representation of the location of the primers designed. Primers 
are indicated by red boxes (F1- forward primer and R1- reverse 
primer). c) UCSC genome browser view of chromosomal 
location of the target CpG island within the gene indicated by the 
green bar and the position of the CpG island in relation to the 
introns and exons indicated by the blue horizontal line and box. 
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Figure 3.4:   Target CpG island of HPCAL1 gene for primer design a) MSP: 
Visual representation of the location of the primers designed 
within the CpG island (blue colored area). Two primer sets are 
indicated by the purple boxes (MF1- methylated forward primer 
and MR1- methylated reverse primer) and green boxes (UF1- 
unmethylated forward primer and UR1- unmethylated reverse 
primer). Horizontal red line indicates the input sequence and 
vertical red lines represent CpG sites. b) BS: Visual 
representation of the location of the primers designed. Primers 
are indicated by red boxes (F1- forward primer and R1- reverse 
primer). c) UCSC genome browser view of chromosomal 
location of the target CpG island within the gene indicated by by 
the green bar and the position of the CpG island in relation to the 
introns and exons indicated by the blue horizontal line and box. 
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Figure 3.5: Flowchart showing the overview of the BS protocol. 
 
 
 
 
57 
Figure 3.6: MSP based methylation profile of blood for the ZNF282 tDMR 
primer set. a) Products with primers specific for methylated 
cytosine (210 bp). Lane 1 – 100 bp ladder (Thermo Scientific). 
Lane 2 – Lane 11- blood DNA samples. Lane 12-  No template 
control. Lane 13- Universal Methylated Human DNA Standard 
(Zymo Research). b) Products with primers specific for 
unmethylated cytosine (210 bp). Lane 1 – 100 bp ladder (Thermo 
Scientific). Lane 2 – Lane 11- blood DNA samples. Lane 12-  No 
template control.  
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Figure 3.7: MSP based methylation profile of vaginal fluid for the ZNF282 
tDMR primer set. a) Products with primers specific for 
methylated cytosine (210 bp). Lane 1 – 100 bp ladder (Thermo 
Scientific). Lane 2 – Lane 11- vaginal fluid DNA samples. Lane 
12-  No template  control. b) Products with primers specific for 
unmethylated cytosine (210 bp). Lane 1 – 100 bp ladder (Thermo 
Scientific). Lane 2 – Lane 11- vaginal fluid DNA samples. Lane 
12-  No template control. 
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Figure 3.8: MSP based methylation profile of semen for the ZNF282 tDMR 
primer set. a) Products with primers specific for methylated 
cytosine (210 bp). Lane 1 – 100 bp ladder (Thermo Scientific). 
Lane 2 – Lane 11- semen DNA samples. Lane 12-  No template 
control. b) Products with primers specific for unmethylated 
cytosine (210 bp). Lane 1 – 100 bp ladder (Thermo Scientific). 
Lane 2 – Lane 11- semen DNA samples. Lane 12-  No template 
control 
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Figure 3.9: MSP based methylation profile of saliva for the ZNF282 tDMR 
primer set. a) Products with primers specific for methylated 
cytosine (210 bp). Lane 1 – 100 bp ladder (Thermo Scientific). 
Lane 2 – Lane 11- saliva DNA samples. Lane 12- No template 
control. b) Products with primers specific for unmethylated 
cytosine (210 bp). Lane 1 – 100 bp ladder (Thermo Scientific). 
Lane 2 – Lane 11- saliva DNA samples. Lane 12-  No template 
control. 
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Figure 3.10: MSP based methylation profile of blood for the PTPRS 1 tDMR 
primer set. a) Products with primers specific for methylated 
cytosine (216 bp). Lane 1 – 100 bp ladder (Thermo Scientific). 
Lane 2 – Lane 11- blood DNA samples. Lane 12- No template 
control. Lane 13- Universal Methylated Human DNA Standard 
(Zymo Research). b) Products with primers specific for 
unmethylated cytosine (215 bp). Lane 1 – 100 bp ladder (Thermo 
Scientific). Lane 2 – Lane 11- blood DNA samples. Lane 12- No 
template control.  
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Figure 3.11:   MSP based methylation profile of vaginal fluid for the PTPRS 1 
tDMR primer set. a) Products with primers specific for 
methylated cytosine (216 bp). Lane 1 – 100 bp ladder (Thermo 
Scientific). Lane 2 – Lane 11- vaginal fluid DNA samples. Lane 
12- No template control. b) Products with primers specific for 
unmethylated cytosine (215 bp). Lane 1 – 100 bp ladder (Thermo 
Scientific). Lane 2 – Lane 11- vaginal fluid DNA samples. Lane 
12- No template control. 
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Figure 3.12:   MSP based methylation profile of semen for the PTPRS 1 tDMR 
primer set. a) Products with primers specific for methylated 
cytosine (216 bp). Lane 1 – 100 bp ladder (Thermo Scientific). 
Lane 2 – Lane 11- semen DNA samples. Lane 12- No template 
control. b) Products with primers specific for unmethylated 
cytosine (215 bp). Lane 1 – 100 bp ladder (Thermo Scientific). 
Lane 2 – Lane 11- semen DNA samples. Lane 12- No template 
control. 
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Figure 3.13:   MSP based methylation profile of saliva for the PTPRS 1 tDMR 
primer set. a) Products with primers specific for methylated 
cytosine (216 bp). Lane 1 – 100 bp ladder (Thermo Scientific). 
Lane 2 – Lane 11- saliva DNA samples. Lane 12- No template 
control. b) Products with primers specific for unmethylated 
cytosine (215 bp). Lane 1 – 100 bp ladder (Thermo Scientific). 
Lane 2 – Lane 11- saliva DNA samples. Lane 12- No template 
control. 
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Figure 3.14 MSP based methylation profile of blood for the PTPRS 2 tDMR 
primer set. a) Products with primers specific for methylated 
cytosine (168 bp). Lane 1 – 100 bp ladder (Thermo Scientific). 
Lane 2 – Lane 11- blood DNA samples. Lane 12-  No template 
control. Lane 13- Universal Methylated Human DNA Standard 
(Zymo Research) b) Products with primers specific for 
unmethylated cytosine (169 bp). Lane 1 – 100 bp ladder (Thermo 
Scientific). Lane 2 – Lane 11- blood DNA samples. Lane 12-  No 
template control. 
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Figure 3.15: MSP based methylation profile of vaginal fluid for the PTPRS 2 
tDMR primer set. a) Products with primers specific for 
methylated cytosine (168 bp). Lane 1 – 100 bp ladder (Thermo 
Scientific). Lane 2 – Lane 11- vaginal fluid DNA samples. Lane 
12-  No template control. b) Products with primers specific for 
unmethylated cytosine (169 bp). Lane 1 – 100 bp ladder (Thermo 
Scientific). Lane 2 – Lane 11- vaginal fluid DNA samples. Lane 
12-  No template control. 
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Figure 3.16: MSP based methylation profile of semen for the PTPRS 2 tDMR 
primer set. a) Products with primers specific for methylated 
cytosine (168 bp). Lane 1 – 100 bp ladder (Thermo Scientific). 
Lane 2 – Lane 11- semen DNA samples. Lane 12-  No template 
control. b) Products with primers specific for unmethylated 
cytosine (169 bp). Lane 1 – 100 bp ladder (Thermo Scientific). 
Lane 2 – Lane 11- semen DNA samples. Lane 12-  No template 
control. 
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Figure 3.17: MSP based methylation profile of saliva for the PTPRS 2 tDMR 
primer set. a) Products with primers specific for methylated 
cytosine (168 bp). Lane 1 – 100 bp ladder (Thermo Scientific). 
Lane 2 – Lane 11- saliva DNA samples. Lane 12-  No template 
control. b) Products with primers specific for unmethylated 
cytosine (169 bp). Lane 1 – 100 bp ladder (Thermo Scientific). 
Lane 2 – Lane 11- saliva DNA samples. Lane 12- No template 
control.  
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Figure 3.18: MSP based methylation profile of blood for the HPCAL1 tDMR 
primer set. a) Products with primers specific for methylated 
cytosine (113 bp). Lane 1 – 100 bp ladder (Thermo Scientific). 
Lane 2 – Lane 11- blood DNA samples. Lane 12- No template 
control. Lane 13- Universal Methylated Human DNA Standard 
(Zymo Research). b) Products with primers specific for 
unmethylated cytosine (114 bp). Lane 1 – 100 bp ladder (Thermo 
Scientific). Lane 2 – Lane 11- blood DNA samples. Lane 12- No 
template control 
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Figure 3.19: MSP based methylation profile of vaginal fluid for the HPCAL1 
tDMR primer set. a) Products with primers specific for 
methylated cytosine (113 bp). Lane 1 – 100 bp ladder (Thermo 
Scientific). Lane 2 – Lane 11- vaginal fluid DNA samples. Lane 
12- No template control. b) Products with primers specific for 
unmethylated cytosine (114 bp). Lane 1 – 100 bp ladder (Thermo 
Scientific). Lane 2 – Lane 11- vaginal fluid DNA samples. Lane 
12- No template control. 
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Figure 3.20: MSP based methylation profile of semen for the HPCAL1 tDMR 
primer set. a) Products with primers specific for methylated 
cytosine (113 bp). Lane 1 – 100 bp ladder (Thermo Scientific). 
Lane 2 – Lane 11- semen DNA samples. Lane 12- No template 
control. b) Products with primers specific for unmethylated 
cytosine (114 bp). Lane 1 – 100 bp ladder (Thermo Scientific). 
Lane 2 – Lane 11- semen DNA samples. Lane 12- No template 
control. 
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Figure 3.21: MSP based methylation profile of saliva for the HPCAL1 tDMR 
primer set. a) Products with primers specific for methylated 
cytosine (113 bp). Lane 1 – 100 bp ladder (Thermo Scientific). 
Lane 2 – Lane 11- saliva DNA samples. Lane 12- No template 
control. b) Products with primers specific for unmethylated 
cytosine (114 bp). Lane 1 – 100 bp ladder (Thermo Scientific). 
Lane 2 – Lane 11- saliva DNA samples. Lane 12- No template 
control. 
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Figure 3.22: Body fluid specific methylation of the ZNF282 tDMR. Each row 
indicates a single clone of bisulfite PCR products and each 
column indicates individual CpG site in the region of interest. 
Different methylation states of the CpG sites are indicated by 
colours (blue represents unmethylated; red represents 
methylated; white represents unknown). 
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Figure 3.23: Body fluid specific methylation of the PTPRS 1 tDMR. Each row 
indicates a single clone of bisulfite PCR products and each 
column indicates individual CpG site in the region of interest. 
Different methylation states of the CpG sites are indicated by 
colours (blue represents unmethylated; red represents 
methylated; white represents unknown). 
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Figure 3.24: Body fluid specific methylation of the PTPRS 2 tDMR.  Each 
row indicates a single clone of bisulfite PCR products and each 
column indicates individual CpG site in the region of interest. 
Different methylation states of the CpG sites are indicated by 
colours (blue represents unmethylated; red represents 
methylated; white represents unknown). 
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Figure 4.1: Flowchart showing the overview of the BS protocol. 
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Figure 4.2: Evaluation of senstivity of MSP reaction. Products with primers 
specific for methylated cytosine. a) HPCAL1 tDMR b) PTPRS 1 
tDMR c) PTPRS 2 tDMR d) ZNF282 tDMR. Lane 1 (a, b, c, d): 
100bp ladder (Thermo scientific), Lane 2 – Lane 7 (a, b, c, d): 
The five-fold dilutions of blood with DNA concentrations (25, 
20, 15, 10, 5, to 1 ng) and Lane 8: No template control. 
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Figure 4.3:   Bisulfite sequencing results for the ZNF282 tDMR marker at t0 
days.  Each row indicates a single clone of bisulfite PCR products 
and each column indicates individual CpG site in the region of 
interest. Different methylation states of the CpG sites are 
indicated by colours (blue represents unmethylated; red 
represents methylated; white represents unknown). Overall 
methylation results for all 8 CpG sites were: 100% for blood, 
100% for saliva, 0% for semen and 98% for vaginal fluid.  
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Figure 4.4: Bisulfite sequencing results of the ZNF282 tDMR marker for 
outside on the ground (condition C). Each row indicates a single 
clone of bisulfite PCR products and each column indicates 
individual CpG site in the region of interest. Different 
methylation states of the CpG sites are indicated by colours (blue 
represents unmethylated; red represents methylated; white 
represents unknown). Overall methylation results for all 8 CpG 
sites were:  96% for blood, 72% for saliva, 0% for semen and 
94% for vaginal fluid. 
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Figure 4.5:   Bisulfite sequencing results for the ZNF282 tDMR in vaginal 
fluid under all forensic simulation conditions: dry at room 
temperature (condition A), wet in an exsiccator (condition B) 
outside on the ground (condition C), sprayed with alcohol 
(Condition D) and sprayed with bleach (Condition E). Each row 
indicates a single clone of bisulfite PCR products and each 
column indicates individual CpG site in the region of interest. 
Different methylation states of the CpG sites are indicated by 
colours (blue represents unmethylated; red represents 
methylated; white represents unknown). Overall methylation 
results for all 8 CpG sites in vaginal fluid samples were:  81% 
for condition A, 98% for condition B, 94% for condition C, 98% 
for condition D and 98% for condition E. 
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Epigenetics involves heritable changes in gene activity and expression, without alteration of 
the DNA sequence. In the human body every cell has a unique epigenome which is a result of 
histone modification, chromatin remodelling and DNA methylation, all of which have a role in 
the regulation of gene expression (Ng and Gurdon, 2008). DNA methylation is a well 
characterized epigenetic modification which is essential for normal development and plays an 
important role in genome imprinting and X–chromosome inactivation, among other functions. 
(Sant et al., 2012). DNA methylation is the attachment of a methyl group to 5’-cytosine 
pyrimidine ring by DNA methyltransferases. In mammals, DNA methylation occurs at CpG 
sites, however not all cytosine residues are methylated. CpG islands are regions that are rich in 
CpG sites.  
 
DNA methylation patterns are tissue-specific and there are regions of DNA in the genome that 
display differential methylation. Regions found in chromosomes which display differences in 
methylation pattern depending on the tissue or cell type are known as tissue-specific 
differentially methylated regions (tDMRs) (An et al., 2013; Choi et al., 2014; Lee et al., 2012; 
Rakyan et al., 2008). tDMRs are broadly distributed in intragenic and intergenic regions which 
include both CpG islands, and non-CpG island regions (Deaton and Bird, 2011; Song et al., 
2009) as well as CpG shores (Irizarry et al., 2009). A study by Eckhardt et al. (2006) 
demonstrated that methylation status at tDMRs is stable and specific, therefore can be used as 
excellent markers for tissue identification.  
 
Every person has a unique DNA profile which can be used to identify individuals that are 
involved in criminal investigations by analysing body fluids that are found at a crime scene 
which enables individuals of interest to be questioned or to eliminate suspects (Frumkin et al., 
2010; Orphanou, 2015). Blood, vaginal fluid, semen and saliva are the most common body 
fluids found at crime scenes and vary in their appearance. It is possible to distinguish blood 
from other body fluids, however, differentiation between vaginal fluid, semen and saliva is 
difficult as they all appear creamy white or colorless (Orphanou, 2015). Identifying the source 
of biological material that is found at crime scenes provide important information in forensic 
investigations (Budowle and van Daal, 2009; Fleming and Harbison, 2010; Gaensslen, 1983; 
Juusola and Ballantyne, 2003). Currently, there are presumptive tests which are used as 
screening tests and confirmatory tests which are used for absolute identification of body fluids 
(Frumkin et al., 2011; Virkler and Lednev, 2009). These tests are based on catalytic, enzymatic, 
immunological or visual testing, thus depend on the stability of the target molecule to detect 
3 
 
the presence or activity of the specific protein found in the tissue of interest (Frumkin et al., 
2011). Although these tests have been useful in forensic analyses, there are many limitations 
associated, such as low specificity due to cross reactions with other molecular species or 
tissues, lack of sensitivity, time consuming, use a large amount of sample and proteins are less 
stable than DNA (Frumkin et al., 2011; Haas et al., 2009). Differentiating between body fluids 
using RNA expression differences is possible (Bauer and Patselt, 2002; Juusola and Ballantyne, 
2003; Juusola and Ballantyne, 2005; Nussbaumer et al., 2006; Setzer et al., 2008; Zubakov et 
al., 2008), however RNA molecules are not stable for long periods of time. Identifying DNA 
methylation differences in human tissues and body fluids is emerging as a new method for 
body fluid discrimination. DNA is stable and methylation analysis methods are compatible 
with short tandem repeat (STR) analysis (Lee et al., 2016b). 
 
A difference in methylation patterns is a unique characteristic displayed by tDMRs, thus 
suggesting that tDMRs can be used as candidate biomarkers in forensic research. Many 
researchers have successfully used tDMRs to differentiate between body fluids and tissues (An 
et al., 2013; Frumkin et al., 2011; Lee et al., 2012; Madi et al., 2012; Park et al., 2014).  
 
Identification of human body fluids using DNA methylation methods in forensic application is 
relatively new. Thus, the present study endeavoured to validate potential gene-specific tDMRs 
that have been previously identified in the human genome, for differentiation of four body 
fluids (blood, saliva, semen and vaginal fluid). Validation of the candidate tDMRs will enable 
the tDMRs to be used as novel markers for the identification and differentiation of human body 
fluids in forensic casework. Sensitivity of the methods used for methylation analysis will also 
be tested to determine the minimum amount of DNA required for a reliable result. 
Environmental factors such as climate conditions (sunlight, rain, humidity) and non-climate 
conditions (diet, lifestyle, growth of microorganisms) may alter DNA methylation patterns. 
Thus, determining whether the methylation profiles of tDMRs are stable to identify human 
body fluids when exposed to environmental conditions will also be beneficial. 
 
There are many tDMRs that are present in the mammalian genome, thus, the identification and 
/or validation of novel body fluid tDMRs is expected to spur the development of DNA 
methylation markers database for medical and forensic applications. 
 
 
4 
 
 
 
 
Chapter 2 
 Literature Review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
2.1 Epigenetics  
A British embryologist and geneticist, Conrad Hal Waddington was the first person to 
introduce the term epigenetics in the early 1940s (Hall, 2012; Slack, 2002). He defined 
epigenetics as “the branch of biology which studies causal interactions between genes and their 
products, which bring the phenotype into being” (Waddington, 1942).  However, today the 
definition of epigenetics has developed to: the heritable changes in gene expression and 
function without altering the DNA sequence (Dupont et al., 2009; Galm et al., 2006; Wu and 
Morris, 2001). Epigenetics includes functional modifications such as, histone modification, 
chromatin structuring, non–coding RNAs and DNA methylation (Collins et al., 2011; Sijen, 
2015). These modifications play a role in regulation of gene activity and expression during 
development and differentiation or in response to environmental influences (Jaenisch and Bird, 
2003; Loscalzo and Handy, 2014; Sant et al., 2012). Epigenetic patterns are preserved during 
cell division and are inherited across generations as DNA is inherited from generation to 
generation (Sen et al., 2015). Epigenetic changes are influenced by environmental and genetic 
factors which result in the alteration of gene expression. It has been observed that an 
individual’s epigenetic pattern may modify over time due to response to environmental factors, 
such as diet, smoking and consumption of alcohol or genetic factors, such as mutations (Dupont 
et al., 2009; Kader and Ghai, 2015). All cells in an organism contain the same genetic 
information, however epigenetic mechanisms result in differential gene expression profiles in 
all tissues and cells (Moore et al., 2012). In this study, the focus will be on DNA methylation. 
2.2 DNA methylation 
DNA methylation is a biochemical process that occurs in both prokaryotic and eukaryotic 
organisms which involves a methyl group (-CH3) attaching to the 5’ position of a cytosine 
pyrimidine ring (Figure 2.1). DNA methylation is involved in cellular processes such as 
regulation of gene expression, cellular development, genomic imprinting and X chromosome 
inactivation (Moore et al., 2012; Smith and Meissner, 2013). DNA methylation patterns change 
during development, for instance, during early embryogenesis methylation patterns in the 
genome are removed and later on re-established (Paulsen and Ferguson-Smith, 2001; Sant et 
al., 2012). In a DNA sequence, a cytosine nucleotide is followed by a guanine nucleotide which 
forms the CpG dinucleotide. In mammals, ~60-90% of CpG dinucleotides are methylated and 
only 15% are found in clusters known as CpG islands (Ghosh et al., 2010). CpG islands are 
>200 bp long, have a GC content that is greater than 50% and have an observed to expected 
ratio of CpG ≥ 0.6 (Bird, 1986; Espada and Esteller, 2010; Gardiner-Garden and Frommer, 
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1987; Zhang et al., 2015). In CpG islands, the frequency of CpG sites is 10 times greater than 
the average distribution of CpGs (Wang et al., 2016). CpG sites that are found outside CpG 
islands are generally methylated, however, majority of CpG sites found within CpG islands are 
unmethylated. CpG islands account for 1−2% of the genome and are mostly found in promoter 
and exonic regions (Larsen et al., 1992; Shen et al., 2007). Most studies focus on methylation 
patterns in CpG islands found in promoter regions have shown that methylation patterns differ 
from other regions in the genome, suggesting a specific biological role for these promoter CpG 
islands (Jones, 2012). 
DNA methyltransferases (DNMT) are enzymes that catalyse DNA methylation, namely, 
DNMT1, DNMT3A and DNMT3B. DNMT1 maintains methylation after each cellular DNA 
replication cycle and DNMT3A and DNMT3B catalyse de novo methylation to establish new 
DNA methylation patterns in early developmental stages (Fernandez et al., 2012; He et al., 
2011). The fourth DNA methyltransferase known as DNA methyltransferase 3 like 
(DNMT3L), shares homology and has similar activity to DNMT3A and DNMT3B. However, 
DNMT3L does not function in the same way as there are no amino acids present for 
methyltransferase activity (Borghese et al., 2012). The DNMT3L may be involved in 
establishment of maternal genomic imprints by stimulation of de novo methylation by DNA 
cytosine methyltransferases 3 alpha (Chédin et al., 2002).  
 
Figure 2.1: Basic overview of DNA methylation. A methyl group (CH3) attaches covalently to a cytosine 
residue (Vidaki et al., 2013). 
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2.3 Role of DNA methylation in gene regulation 
The genetic basis of gene regulation has been studied across tissues and populations and has 
suggested that genetic variations are associated with gene regulation and primarily occur in 
close proximity to the transcription start sites (Bell et al., 2011; Stranger et al., 2007). 
Epigenetic modifications such as DNA methylation and the interaction with transcription 
factors may play a critical role in the regulation of gene expression in humans (Hellman and 
Chess, 2007; Lister et al., 2009; Messerschmidt et al., 2014; Rivenbark et al., 2012). Gene 
expression may be directly or indirectly controlled by the DNA methylation levels at specific 
loci which results in silencing of genes or activation of genes (Antunes et al., 2016a).  
Promoter regions that are highly methylated have weak binding capabilities with transcription 
factors which results in a decrease in expression of the genes (Kapoor et al., 2005; van Eijk et 
al., 2012). DNA methylation has the ability to directly prevent the transcription factors from 
binding resulting in change of chromatin structure which limits the accessibility of the 
transcription factors to the gene promoter (Figure 2.2) (Lim and Maher, 2010). Methyl-CpG-
binding protein 2 (MePC2) is a protein that binds to methylated DNA through a methyl-CpG-
binding domain (MBD) (Bird, 2002). The MBD-protein complex facilitates transcriptional 
repression which results in deacetylated repressive chromatin structure (Bird, 2002). 
Environmental and genetic factors play a role in gene expression which results in varied 
methylation patterns, however, these factors are not completely understood (Tammen et al., 
2013; van Eijk et al., 2012; Wagner et al., 2014).  
Martino and Saffery. (2015) examined the association between DNA methylation and gene 
regulation. In this study, the gene expression was separated into low expression and high 
expression. The methylation levels at all CpG sites in highly expressed genes and low 
expressed genes were determined using the IlluminaHumanMethylation450K.db annotation 
package. It was observed that CpGs in genes that had high expression levels have a greater 
unmethylated area (0-20% methylated) and CpGs in genes that had low expression levels have 
a greater methylated area (80-100% methylated). The association between DNA methylation 
and the transcription start site was also examined. It was found that within 200bp of the 
transcription start site (near the promoter) and the first exon, there was an inverse correlation 
between DNA methylation and gene expression (Martino and Saffery, 2015).  
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Figure 2.2: Regulation of gene expression by DNA methylation. (A) Absence of methyl groups in the CpG 
island promoter permits binding of transcription factors which facilitates transcription initiation (B) Presence 
of methyl groups hinders binding of transcription factors which prevents gene expression (Lim and Maher, 
2010). 
 
2.4 Gene body methylation and gene expression 
The transcribed portions of genes are known as gene bodies which display hypermethylated 
patterns in comparison to the rest of the genome (Aran et al., 2010). DNA methylation has 
contradicting effects on promoters and gene bodies known as the DNA methylation paradox. 
According to the DNA methylation paradox, DNA methylation has an inverse correlation with 
gene expression in promoters (Jones, 1999; Jjingo et al., 2012; Klose and Bird, 2006) whereas 
in gene bodies there is a positive correlation with gene expression (Ball et al., 2009; Laurent et 
al., 2010). Gene expression patterns are maintained through DNA methylation (Aran et al., 
2010) which occurs in CpG islands located in gene promoter sites as well as gene bodies which 
are located away from promoter sites (Ball et al., 2009). Research by Neri et al. (2017) indicates 
that in embryonic stem cells, intragenic methylation may serve to confine transcription 
initiation to canonical promoters thereby inhibiting production of aberrant transcripts. In 
vertebrates, invertebrates and plants it has been observed that the methylation profile of gene 
bodies are conserved which suggests that it plays an important role in multicellular organisms 
(Feng et al., 2010; Suzuki and Bird, 2008; Zemach et al., 2010). It has been suggested that 
transcription elongation is stimulated by DNA methylation and that the trimethylated histone 
H3 at lysine 36 (H3K36me3 - has an association with elongation) possibly recruits DNMTs 
(Hahn et al., 2011) thus, despite the fact that majority of gene bodies are CpG poor and highly 
methylated, transcription elongation still pursues (Jones, 2012). Whole-genome studies have 
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demonstrated that the exons in gene bodies are hypermethylated in comparison to the introns 
and transitions in the degree of methylation that occur at exon–intron boundaries. Suggesting 
that methylation may play a role in regulation of splicing (Laurent et al., 2010). In a study by 
Hellman and Chess. (2007) methylation patterns of the gene body in X chromosomes were 
analysed using Affymetrix 500000 (500K) single-nucleotide polymorphism (SNP) mapping 
array. An allele-specific analysis was performed along the human X chromosome in which the 
active X chromosome displayed more than twice as much allele-specific methylation in 
comparison to the inactive X chromosome. Majority of the methylation was observed in the 
gene body sites (Hellman and Chess, 2007).  
2.5 Tissue-specific differentially methylated regions (tDMRs) 
DNA methylation patterns are established via cellular differentiation as a result all cells and 
tissues have a unique DNA methylation profile (Bird, 2002; Nagase and Ghosh, 2008). 
Epigenetics studies have identified specific regions found within the genome which have 
varying methylation patterns depending on the cell type (Slieker et al., 2013; Song et al., 2009). 
These specific regions are known as tissue-specific differentially methylated regions (tDMRs) 
and have been observed in the human genome (Antunes et al., 2016b; Igarashi et al., 2008; 
Kitamura et al., 2007; Song et al., 2009). tDMRs are found in non-CpG island, CpG island 
promoters, intragenic and intergenic regions (Choufani et al., 2011). It is believed that tDMRs 
that are found at CpG islands are involved in development and tissue differentiation. These 
tDMRS generate cell or tissue-specific methylation patterns (hypo-/hypermethylation) 
(Illingworth et al., 2008; Kader and Ghai, 2015). As DNA fingerprints are unique, several 
studies have shown that DNA methylation profiles are specific to tissues and cells and can be 
used for identification of different cells or tissues in organisms (Choi et al., 2014; Christensen 
et al., 2009; Day et al., 2013; Ohgane et al., 2008; Rakyan et al., 2008). Therefore, the 
methylation profiles observed in tDMRs can be used to differentiate between the tissue and 
cells.  
2.6 Identification of tDMRs 
A minor but significant proportion of CpG islands are differentially methylated between 
various tissues and cell types (Eckhardt et al., 2006; Illingworth et al., 2008; Shiota et al., 
2002). Characterisation of these differences may determine the function of tissue-specific CpG 
island methylation pattern (Irizarry et al., 2009; Ladd-Acosta et al., 2007). Many studies have 
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identified tDMRs by comparing DNA methylation patterns of various cells and tissues 
(Christensen et al., 2009; Day et al., 2013; Rakyan et al., 2008). 
To study the difference in methylation patterns, Slieker et al. (2013) developed an algorithm 
based on 450K methylation data to identify tDMRs. Genome-wide data was obtained for four 
peripheral tissues (buccal swabs, hair follicles, saliva and blood) and six internal tissues 
(pancreas, liver, omentum, muscle, spleen and subcutaneous fat) using Illumina 450K DNA 
methylation chips. The criteria for identification of tDMRs was that CpG sites had to display 
an average methylation difference of >10% between the target tissue and other tissues, should 
contain a minimum of three differentially methylated CpG sites with an inter-CpG distance 
that is ≤ 1 kb and interrupted by a maximum of three non-differentially methylated positions. 
Using the developed algorithm, 3 533 putative tDMRs in the peripheral tissues were identified 
and 5 382 putative tDMRs in the internal tissues were identified (Slieker et al., 2013).   
In a study by Ghosh et al. (2010), 12 samples were collected from different brain tissues and 
non-brain tissues of seven autopsy patients that were tissue donors to determine methylation 
patterns. Brain tissues were collected from basal ganglia, the cerebellum and the frontal and 
temporal lobes of the cerebrum and non-brain tissues were collected from kidney, lung, 
prostate, spleen, stomach and thyroid. Restriction landmark genomic scanning (RLGS) was 
used to generate each patient’s methylation profile for all tissues. A total of 33 RLGS profiles 
were generated and 34 differentially methylated CpG islands were identified. A total of 141 
RLGS spots showed tissue-specific methylation differences within all tissues of at least a single 
patient. From the 141 spots, 82 of the spots were present or partially methylated in one tissue 
of each patient. A cluster analysis of the RLGS data showed that the brain tissue clustered 
together the strongest and were distinct from non-brain tissues which showed limited clustering 
(Ghosh et al., 2010). 
In a study by Lokk et al. (2014), tissue-specific DNA methylation patterns were studied in 17 
somatic tissues of post-mortem humans. The different somatic tissue used were: abdominal and 
subcutaneous adipose tissue, bone, joint cartilage, yellow and red bone marrow, coronary and 
splenic artery, abdominal and thoracic aorta, gastric mucosa, lymph node, tonsils, bladder, gall 
bladder, medulla oblongata, and ischiatic nerve. A total of 14 441 tDMRs were identified in 
which 11 242 (77.8%) were found in genes. From the 11 242 tDMRs, 4688 tDMRs (41.7%) 
were found in gene promoter regions in which 35.6% were found in CpG island regions and 6 
554 (58.3%) were found in gene body regions in which 44.1% were found in CpG island 
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regions. Majority of the tDMRs were found in the gene body regions which may be an 
indication of alternate promoters being present (Maunakea et al., 2010). The number of tDMRs 
that were identified varied significantly between tissues that have different functions. The 
tonsils showed the highest number of hypermethylated tDMRs and red and yellow bone 
marrow showed that highest number of hypomethylated tDMRs. Genes that indicate 
hypomethylation in some tissues are at most times associated with a tissue-specific function. 
For example, genes that were detected in arteries as being hypomethylated are known as 
mediators of blood vessel development and for morphogenesis. Hypomethylated genes were 
also detected in tonsils and were found to be associated with immune response and leukocyte 
activation. Thus, this study has shown that hypomethylation of genes is associated with tissue-
specific function (Lokk et al., 2014).  
2.7 Genetic factors that influence DNA methylation 
DNA methylation patterns can be altered by genetic factors which can affect transcription and 
phenotypic variation (Feil and Fraga, 2012; Murrell et al., 2004; Schübeler, 2015). Studies 
have identified that the DNA methylation state of a locus depends on the DNA sequence of an 
individual (Bock et al., 2006; Chandler et al., 1987; Silva and White, 1988). The degree to 
which genetic variation affects DNA methylation is not known. Furthermore, the extent to 
which the variation in DNA methylation causes variation in gene expression in individuals is 
also unknown (Bell et al., 2011; Schübeler, 2015).  Examining methylation patterns in families 
and twins enables the examination of the effects that genetic variation has on methylation 
patterns (Bjornsson et al., 2008; Gertz et al., 2011; Kaminsky et al., 2009), however 
environmental influences may also effect methylation patterns (Feil and Fraga, 2012). Studies 
on monozygotic and dizygotic twin pairs by Kaminsky et al. (2009) and Ollikainen et al. (2010) 
have demonstrated that epigenetic differences are more prominent in dizygotic twin pairs 
compared to monozygotic twin pairs. 
2.8 Environmental factors that influence DNA methylation 
Epigenetic processes regulate the interaction between the environment and the genome 
(Bonasio et al., 2010; Feil and Fraga, 2012). The establishment and maintenance of DNA 
methylation can be altered by environmental factors such as diet and nutrition, life experiences 
and age, however, the extent to which these factors alter DNA methylation is yet to be 
determined (Jirtle and Skinner, 2007; van Dongen et al., 2014). This may be an indication that 
alterations in DNA methylation status is possibly the step between the environment and human 
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diseases. Monozygotic twin studies have investigated the effects of age on epigenetic 
differences and have demonstrated that changes in DNA methylation patterns are associated 
with age (Christiansen et al., 2016; Fraga et al., 2005; Martino et al., 2013; Wong et al., 2010). 
Dietary and nutrition factors have an inevitable impact on epigenetic patterns (Herceg, 2007). 
For example, a study by Jirtle and Skinner. (2007) has shown that changes in folate diets can 
alter DNA methylation. However, determining the relationship between diet and epigenetic 
patterns is difficult as these factors show subtle changes over time. Studies have also shown 
that unfavourable living conditions such as famine, chemical and environmental pollutants or 
smoking can have an impact on an individual’s DNA methylation pattern without altering the 
genetic sequence (Lee and Pausova, 2013; Tobi et al., 2009).  
2.9 DNA methylation and its application in forensic science 
DNA analysis provides an important tool in solving cases in forensic, such as identifying 
victims from disasters or crimes, exonerating innocent people that are convicted and 
identification of suspected perpetrators (Dumache et al., 2016). In particular DNA from 
biological material such as blood, semen, saliva, vaginal fluid and urine are commonly found 
at crime scenes and serve as evidence which provides important information (Kader and Ghai, 
2015). It is essential that methods used to analyse biological material are not destructive 
because most times a minute amount of evidence is available for analysis. There are methods 
available for identifying biological material, however the sensitivity and specificity of the 
methods are limited. Analysis of DNA methylation profiles provide an alternative method to 
the current methods used for forensic applications and shows great potential because it does 
not use a large amount of sample, there is no additional destruction of the samples as DNA 
isolated for short tandem repeat (STR) typing can be used for methylation analysis (Frumkin 
et al., 2011).  
2.9.1 Identification of artificial DNA 
Detection of artificial DNA is important as any individual with the understanding of DNA and 
equipment would be able to produce specific DNA fragments with a genetic profile. The 
artificially synthesized DNA can be combined with actual human tissue and planted at crime 
scenes. Artificial DNA produces a typical profile after forensic analysis.  
A study by Frumkin et al. (2010), amplified five loci, one was a reference Combined DNA 
Index System (CODIS) locus (FGAref) and the other four were non-CODIS loci (NT18, 
ADD6, MS53, SW14). After polymerase chain reaction (PCR) amplification of the natural 
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DNA which was extracted from blood and saliva and artificial DNA extracted from hair using 
organic extraction, the artificial DNA was indicated by amplification of the reference locus and 
no amplification of the non-CODIS loci. Natural DNA was indicated when all five loci were 
amplified and the FGAref loci was amplified in both the natural and artificial DNA. The 
amplified loci were sequenced and these results showed the artificial DNA was unmethylated 
compared to the natural DNA, thus the artificial and natural DNA can be distinguished 
(Frumkin et al., 2010). 
 A study by Wang et al. (2015) used a methylation sensitive restriction enzyme assay to 
distinguish artificial and natural DNA from blood samples. Artificial blood was created to 
determine whether it can be distinguished from natural blood. Peripheral blood samples were 
collected from three healthy participants which included two males and one female. Seven loci 
were included in this study (L1-L7): L2-L6 contained recognition sites for the methylation 
sensitive restriction enzyme HhaI and L1 and L7 were used as positive controls as these loci 
do not have a recognition site for HhaI. In the artificial blood sample L3 and L6 loci displayed 
unmethylated patterns and in the natural blood sample L4 and L5 loci show patterns of 
methylation (Wang et al., 2015). Initially, DNA STR profiles were generated for the natural 
and artificial bloodstain samples. The DNA STR profiles demonstrated that the artificial blood 
could not be distinguished from the natural blood.  
2.9.2 Parent of origin  
Parentage testing and individual identification can be analysed using DNA methylation 
markers that are specific to imprinted loci because alleles from maternal and paternal origin 
are differentially imprinted at these loci (Gršković et al., 2013; Nakayashiki et al., 2009). 
Parent of origin is a specific expression that is also known as genomic imprinting which is a 
result of maternal and paternal alleles from a subset of genes being expressed differentially 
(Bartolomei and Ferguson-Smith, 2011; Hata et al., 2002; Reik and Walter, 2001). There is a 
subset of genes which are known as imprinted genes: H19, IGF2R, P57, SNRPN, PEG 1 and 
PEG3. The H19, IGF2R and P57 genes are expressed when inherited from the maternal 
genome and the SNRPN, PEG 1 and PEG 3 genes are expressed when inherited from the 
paternal genome (Hata et al., 2002). These imprinted genes are involved in developmental 
processes such as fetal growth, placenta function, regulation of embryonic development and 
maternal behaviours (Barlow, 1995; Jaenisch, 1997; Moore and Haig, 1991; Tilghman, 1999). 
Differentially methylated regions in the maternal and paternal alleles of the imprinted genes 
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have a molecular basis for regulation of the imprinted genes expression, thus, it is believed that 
DNA methylation controls genomic imprinting in mammals (Ferguson-Smith and Surani, 
2001; Neumann and Barlow, 1996; Xie et al., 2012). 
A methylation sensitive restriction enzyme analysis was done by Lefebvre et al. (1997) to 
determine whether the CpG island of the PEG 1 imprinted gene displayed a parental-specific 
methylation pattern.  It was observed that in embryos and undifferentiated stem cells the PEG 
1 gene cytosine residues were partially methylated. The embryos used had carried a targeted 
mutation at the PEG 1 locus, thus the partial promoter methylation pattern showed a strict 
parent of origin specific differential methylation. The paternal allele showed unmethylated 
patterns and the maternal allele showed complete methylation patterns at the CpG sites 
(Lefebvre et al., 1997). 
A study by Zhao et al. (2005) determined the parental origin of alleles by using parent of origin 
specific DNA methylation markers. An imprinted single nucleotide polymorphism (SNP) 
(locus rs220028) was used for this analysis. In order to distinguish between the maternal and 
paternal allele, a mutagenically separated PCR and SNP typing technique was developed and 
performed on 18 heterozygous children to analyse one imprinted SNP. The imprinted SNP was 
detected specifically on the maternal allele. Thus, parent of origin alleles can be detected using 
parent of origin specific DNA methylation markers (Zhao et al., 2005).  
2.9.3 Age estimation 
Aging is a developmentally regulated process that is in part mediated by epigenetic 
modifications, such as DNA methylation which is involved in cellular senescence (Marciniak-
Czochra et al., 2009; Schellenberg et al., 2011). Determining the age of an individual can 
provide essential leads in identifying unknown persons in criminal investigations, disaster 
victim identification as well as cases in which there is identity fraud (Zubakov et al., 2016). 
Research has shown that aging is associated with DNA damage and telomere shortening (Fraga 
and Esteller, 2007; Koch and Wagner, 2011; Schellenberg et al., 2011). An individual’s age 
can be determined by analysing osteal markers such as bones and teeth. However, this would 
only be possible in cases in which a skeleton exists (Thevissen et al., 2012). During the aging 
process an individual’s methylation profile is continually changing, therefore, the age of a 
biological trace can be analysed using DNA methylation (Gršković et al., 2013). Studies have 
observed that the CpG sites that are hypermethylated or hypomethylated form a linear 
correlation of aging in terms of DNA methylation (Christensen et al., 2009; Meißner et al., 
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1997). Determining the age of an unknown biological trace would be beneficial for personal 
identification and forensic cases (Koch and Wagner, 2011).  
A study by Bocklandt et al. (2011) identified CpG methylation in saliva using high density 
genome-wide screening. The saliva samples were obtained from 34 identical male twins 
between the ages of 21-55. A total of 88 CpG sites were identified in or close to 80 genes that 
are involved in age-related diseases. From the 88 CpG sites, 10 sites were previously reported 
to be correlated with age in whole blood and in isolated CD4+ and CD14+ (Rakyan et al., 2010). 
This study went one step further and included individuals that were between the ages of 18-70 
and consisted of 31 men and 29 women for identification of methylation patterns of promoter 
sites of three genes, namely, EDAR associated death domain (EDARADD), target of myb1 
(chicken)-like 1 (TOM1L1) and neuronal pentraxin II (NPTX2). The methylation patterns 
observed at the three promoter sites showed a linear correlation with age over a period of five 
decades, thus, an individual’s age could be predicted with an accuracy of 5.2 years (Bocklandt 
et al., 2011). 
A multi-tissue predictor of age was developed by Horvath (2013) to allow the estimation of 
DNA methylation age of most tissue and cell types. The predictor was developed using 7 844 
samples from 51 healthy tissue and cells types from 82 individuals by Illumina DNA 
methylation array datasets. There were 353 CpG sites that formed the age clock. From the 353 
CpG sites, 193 CpG sites showed a positive correlation with age and 160 CpG sites showed a 
negative correlation with age. The accuracy of the age predictor was tested using three accuracy 
measures: Pearson correlation coefficient, median error and average age acceleration. An 
analysis using the age predictor was performed on 5 826 cancer samples from 32 individual 
cancer datasets. There was a large correlation between DNA methylation age and patient age 
in some of the cancer tissue, however the correlation between DNA methylation and 
chronological age was not strong. Every cancer tissue showed a significant age acceleration 
with a mean age acceleration of 36.2 years. Age acceleration was also determined in genes that 
had mutations. The TP53 mutation showed a lower age acceleration in five different cancer 
types (acute myeloid leukemia, breast cancer, ovarian cancer, uterine corpus endometrioid and 
lung squamous cell carcinoma).  The TP53 gene showed significant mutation in four out of the 
13 cancer datasets. It was concluded that the model was able to predict the age of most tissues 
and cell types and performs well in heterogeneous tissues (Horvath, 2013). 
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Another age estimation-based study Zbieć-Piekarska et al. (2015) collected blood stains from 
45 individuals between the ages of one-81 years. The samples were stored at room conditions 
for five, 10 and 15 years and thereafter, the ELOVL2 locus was analysed by bisulfite treatment 
and pyrosequencing. Interestingly, methylation of the locus was proven to provide a powerful 
and reliable estimation of age in the forensic samples, ranging between 60–78% (Zbieć-
Piekarska et al., 2015). 
2.9.4 Differentiation between monozygotic/dizygotic twins  
Monozygotic twins can be used to determine how environmental factors play a role in 
determining differences in phenotypes and complex disease (Fraga et al., 2005; Ribel-Madsen 
et al., 2012). Monozygotic twins have the same genetic material and their methylation patterns 
at birth are nearly identical, however, as they each are exposed to environmental factors, their 
methylation patterns may differ (Bocklandt et al., 2011; Martino et al., 2013; Ye et al., 2013).  
In a study by Fraga et al. (2005) epithelial skin cells, intra-abdominal fat, and skeletal muscle 
biopsies were collected from eight caucasian twin pairs. It was observed that in the older 
monozygotic twin pairs, these three tissues showed epigenetic differences as a result of 
different lifestyles and not spending their lives together. Thus, the DNA methylation patterns 
of different tissues in monozygotic twins are distinct due to different lifestyles and may explain 
some of the differences in phenotypes and the differential frequency or onset of common 
diseases (Fraga et al., 2005). A DNA methylation study using the Infinium Human- 
Methylation450 BeadChip platform was conducted on buccal swabs from 10 monozygotic twin 
pairs and five dizygoyic twin pairs from birth to the age of 18 months. It was evident that large 
epigenetic changes occur during the first 18 months (Martino et al., 2013). 
Coolen et al. (2011) performed a quantitative mass spectrometric assay on 128 pairs of 
monozygotic twins and 128 pairs of dizygotic twins to determine DNA methylation patterns in 
four imprinted control region genes (IGF2, H19, KCNQ1 and GNAS) and a single non-
imprinted gene (RUNX1). It was observed that the DNA methylation patterns between each 
twin group was similar. The monozygotic twin pairs and the dizygotic twin pairs both displayed 
great variation in the DNA methylation patterns in the H19 and IGF2 genes. The RUNX1 gene 
differed as DNA methylation levels were low. A non-parametric Spearman correlation test was 
performed to determine the association of DNA methylation levels at various CpG sites within 
an individual. The H19 showed a strong association and the RUNX1 showed a random 
association to DNA methylation. This suggests that within individuals the degree of DNA 
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methylation at specific CpG sites is a function of the degree of methylation of neighbouring 
sites. A Kruskal-Wallis one-way analysis of variance test (ANOVA) and a post hoc Dunn's test 
was performed to determine the DNA methylation difference in monozygotic and dizygotic 
twin pairs. It was observed that there was a significant difference between monozygotic and 
dizygotic twin pair methylation patterns. In the H19 gene, monozygotic twin pairs showed less 
methylation differences as compared to dizygotic twin pairs (Coolen et al., 2011).  
In a study by Li et al. (2011) a high throughput epigenome microarray analysis known as 
Illumina’s HumanMethylation27 BeadChip was performed to identify epigenetic differences 
in adult monozygotic twin pairs. There were 377 CpG sites selected that showed variation in 
the methylation patterns which suggests that the CpG sites could be used as a biomarker to 
distinguish between monozygotic twins. This study demonstrates the potential of using 
epigenetic markers to differentiate monozygotic twin pairs (Li et al., 2011). 
2.9.5 Human body fluid identification 
In my present study, the focus is on human body fluid identification by methylation analysis. 
In forensic investigations, biological samples such as body fluids that are obtained from crime 
scenes have proven to provide important information that can link the evidence and the crime 
(Forat et al., 2016; Lee et al., 2012). The DNA extracted from the body fluid can be useful in 
reconstruction of the crime scene by determining the type and origin of the biological sample 
as well as identifying the donor of the biological sample (Lee et al., 2012). For example, if 
semen was present at a crime scene this could indicate sexual assault.  
The first DNA methylation-based assay to identify forensic tissue was done by Frumkin et al. 
(2011) in which methylation sensitive restriction enzyme PCR (MSRE-PCR) was used to 
differentiate body fluids such as semen, blood, saliva, vaginal fluid, skin, urine and menstrual 
blood. In this study, the potential of the DNA methylation-based assays was observed by 
analysing tissue identification at 15 loci that show differentially methylated patterns. A 
methylation ratio was calculated for each locus to distinguish the biological fluids. The 
methylation ratio in semen samples for L91762 /L68346 was low. In all other body fluids for 
L91762/L68346, the methylation ratio was high. The methylation ratio of L76138/L26688 was 
high in semen and epidermis samples and low in blood and saliva. The study concluded that 
L76138/L26688 and L91762/L68346 could precisely identify semen and skin epidermis 
sample respectively (Frumkin et al., 2011). 
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 A study by Lee et al. (2012) generated DNA methylation profiles to determine differential 
DNA methylation for body fluid identification using bisulfite sequencing. Five tDMRs (tDMRs 
for USP49, DACT1, PFN3, PRMT2 and HOXA4 genes) were used to generate methylation 
profiles for saliva, semen, vaginal fluid, menstrual blood and blood. The USP49 and DACT1 
gene tDMRs were selected as semen-specific markers and tDMRs for genes PFN3, PRMT2 
and HOXA4 could be used as markers for blood. The tDMR for USP49 and DACT1 genes 
showed hypomethylation in majority of the semen samples and hypermethylation in all other 
body fluid samples. Chi-square test or Fisher’s exact test was performed to determine pairwise 
comparison of methylation at each marker. The results showed that for USP49 and DACT1 
markers, semen differed from all other body fluids. Therefore, these tDMRs can be used to 
identify semen samples positively. The HOXA4 tDMR showed high levels of methylation in 
female saliva and in blood, however, the methylation patterns did not differ enough to 
differentiate the fluids accurately (Lee et al., 2012). In the PFN3 tDMR, hypermethylation 
patterns were observed for majority of the body fluids. Statistical analysis showed that vaginal 
fluid DNA methylation could be significantly differentiated from all other body fluids, thus, 
PFN3 tDMR has the potential to distinguish vaginal fluid. Hypomethylation patterns were 
observed for the PRMT2 tDMR in majority of semen samples, however, hypermethylation 
patterns were observed in menstrual blood and vaginal fluid. This marker has the potential to 
distinguish semen from other body fluids as well as distinguish menstrual blood and vaginal 
fluid from other body fluids based on the observed methylation patterns.  
A study by An et al. (2013) used three tDMRs that were specific for semen (DACT1, USP49 
and PRMT2) to determine the effect of age on DNA methylation patterns using bisulfite 
sequencing. Samples included: blood, saliva and semen. The semen samples were obtained 
from young and old men and this analysis showed that three tDMRs showed unmethylated 
patterns in most of the samples and methylation patterns in blood and saliva samples. Chi-
square test or Fisher’s exact test was performed to determine pairwise comparison of 
methylation at each marker. There was no significant difference observed in all body fluids for 
DACT1 and USP49 tDMRs, however, the PRMT2 tDMR showed significant differences for 
six CpG sites (1, 2, 3, 15, 17 and 19) in blood samples between young and elderly men (An et 
al., 2013).  
A set of four markers that differentiated between blood, saliva, semen and epithelial cells: 
C20orf117, ZC3H12D, BCAS4, and FGF7 were used to demonstrate differential methylation 
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in blood, saliva and semen (Madi et al., 2012). Two of the markers have been previously 
reported by Eckhardt et al. (2006), C20orf117 identified hypermethylation patterns in white 
blood cells and BCAS4 identified hypermethylation patterns in sperm. The ZC3H12D and 
FGF7 markers were used to identify semen and epithelial cells, respectively. In this study the 
C20orf117 marker demonstrated that the blood samples were hypermethylated in comparison 
to the other body fluids that were examined which is in agreement with results observed in the 
study conducted by Eckhardt et al. (2006). The ZC3H12D marker was successful in 
differentiating the semen samples from all other tissue that were examined. All semen samples 
showed hypomethylation patterns and all other tissue samples showed hypermethylation 
patterns. Based on the study by Eckhardt et al. (2006) the BCAS4 marker was expected to 
display hypermethylation patterns in semen compared to the other tissues, however, the study 
by Madi et al. (2012) showed that this marker was hypermethylated in saliva. The FGF7 marker 
showed hypermethylation patterns in semen relative to the other tissues which displayed 
hypomethylation patterns. Based on the results observed in this study and with further analyses, 
the ZC3H12D and C20orf117 epigenetic markers show great potential for identifying semen 
and blood, respectively (Madi et al., 2012). 
In a recent study by Vidaki et al. (2016) identification and validation of 11 potential tDMRs, 
previously identified in methylation analysis (Rakyan et al., 2008; Rakyan et al., 2010) of 
blood, buccal cells and semen, was analysed in order to identify markers for blood, saliva and 
semen using bisulfite pyrosequencing. The markers selected for saliva and blood did not 
display a significant methylation difference to be proposed as saliva and blood markers due to 
some CpGs showing great inter-individual variation. The markers, cg04382920 and 
cg11768416 that were selected for identification of semen were successful in differentiation of 
semen from saliva and blood. These markers were further validated using a larger sample size 
and showed a high sensitivity (detected with 50 pg) and stability. Therefore, DNA methylation 
analysis holds a promising future for detection of body fluids (Vidaki et al., 2016).  
A study by Ma et al. (2013) screened and identified tDMRs for forensic casework. DNA 
samples were collected from blood, saliva, semen and vaginal fluid. The DNA was pooled for 
each body fluid in an equal mixture and differentially methylated fragments were isolated using 
methylation sensitive represent difference analysis (MS-RDA). There were six tDMRs 
obtained that were blood-specific. Sequenom mass array quantitative analysis of methylation 
was used to quantify the methylation levels in the tDMRs. Two of the six tDMRs showed 
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hypomethylation patterns in blood compared to other body fluids and the remaining four 
tDMRs showed hypermethylation patterns in blood compared to other body fluids. A Chi-
square test was performed for pairwise comparisons which showed a statistical difference 
between blood and other body fluids. Therefore, the differential methylation patterns of tDMRs 
makes it possible to distinguish between blood and other body fluids (Ma et al., 2013). 
A study by Park et al. (2014) investigated novel DNA markers for the identification of blood, 
saliva, semen and vaginal fluid using Illumina Human Methylation 450K bead array. There 
were 16 samples collected for each body fluid. Using the methylation data, 2986 
hypermethylated or hypomethylated regions that were specific for each type of body fluid were 
selected. Eight CpG sites were selected as being novel and forensically relevant DNA 
methylation markers, namely, cg26107890 and cg20691722 for saliva, cg06379435 and 
cg08792630 for blood, cg01774894 and cg14991487 for vaginal secretions and cg23521140 
and cg17610929 for semen were identified. Pyrosequencing was used to analyse the eight novel 
markers in 80 body fluid samples. It was detected that each marker exhibited great sensitivity 
and specificity for identification of the target body fluid. This study suggests that the eight 
novel DNA methylation markers have the potential to differentiate body fluids in forensic 
casework (Park et al., 2014). 
Antunes et al. (2016b) examined the PFN3A locus using pyrosequencing to decipher if it could 
be used to differentiate vaginal epithelia from other body fluids. The results showed that 
vaginal epithelia were able to be discriminated from other body fluids using the PFN3A primers 
using as little as 5ng of DNA. The study went a step further and performed mixture analysis to 
simulate sexual assault cases and to determine if the primers were specific to humans and 
higher primates. In the mixture analysis, DNA samples were selected from blood, semen and 
vaginal epithelia were mixed in ratios 75:25, 50:50 and 25:75. The results showed that when 
the DNA content of blood decreased from vaginal epithelia, the percentage methylation 
decreased and this was also observed for blood and semen mixtures. In vaginal epithelia and 
semen mixtures, when DNA content decreased in vaginal epithelia compared to semen, the 
percentage methylation also decreased. To test the specificity of the primers to humans, DNA 
from cat, mouse, chicken, cow, dog, bacterial pool (Pseudomonas aeruginosa, Enterococcus 
faecali, Staphylococcus aureus, and Escherichia coli), horse, chimpanzee, orangutan, and 
gorilla was isolated. The results showed that the PFN3A primers were specific to humans. 
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Thus, the PFN3A locus can be used to differentiate vaginal epithelia in forensic cases (Antunes 
et al., 2016b).  
Silva et al. (2016) examined 15 samples of different body fluids blood, saliva, semen, 
menstrual blood, nasal epithelia and vaginal epithelia in a validation test using pyrosequencing. 
Three markers were used for identification of body fluids: ZC3H12D which is semen specific, 
cg06379435 which is specific for blood and BCAS4 which is specific for saliva. Majority of 
the CpG sites displayed a significant difference in methylation levels when being compared to 
different body fluids. A one-way ANOVA test was used to determine a statistical difference in 
methylation values across markers. The BCAS4 marker showed no significant difference (p > 
0.05) in methylation level at CpG 5 when saliva and vaginal epithelia samples were compared 
and the cg06379435 marker showed no significant difference (p > 0.05) in methylation level 
at CpG 2 when blood and menstrual blood samples were compared. However, most of the CpG 
sites for each marker showed different average methylation values between the target body 
fluid and all other body fluid. A reproducibility test was performed on eight samples of three 
body fluids (blood, saliva and semen) in two different laboratories in which the pyrosequencing 
data was analysed and compared to determine the reliability of the results for the markers. A t-
test analysis was performed and it was found that there was no significant difference when 
methylation values were compared for each CpG site in either laboratory (Silva et al., 2016). 
2.10 Stability of DNA methylation markers  
In order to use DNA methylation markers in forensic investigations, the markers are required 
to be extensively validated using different methylation techniques (Vidaki et al., 2016). 
Validation will involve testing the accuracy, sensitivity and the applicability in cold case 
samples, for identification of forensically relevant body fluid (Forat et al., 2016).  
Three different forensic environmental influences were simulated to analyse 75 body fluid 
(peripheral blood, menstrual blood vaginal fluid, saliva and sperm) samples to determine the 
stability of methylation levels (Forat et al., 2016).  The three different environmental conditions 
were: dry at room temperature, wet in an exsiccator and outside on the ground. All samples 
were analysed immediately after collection and analysed one, two, three and six months after 
storage. The main difference in methylation levels were caused by humidity and majority of 
samples remained stable after six months of storage.  All body fluid samples in the dry at room 
temperature condition remained stable for all markers throughout the study (Forat et al., 2016).  
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An et al. (2013) exposed blood, saliva, semen, menstrual blood, and vaginal fluid samples to 
an environmental condition which was ambient temperature in the shade for a period of 75 
days to determine whether DNA methylation profiles could be established using damaged 
DNA. It was observed that once DNA was extracted from all body fluids after the 75-day 
period, all body fluids were successfully analysed except saliva samples. 
 To assess the robustness and stability of the markers: ZC3H12D, BCAS4, and cg06379435 to 
detect semen, blood and saliva, respectively, Silva et al. (2016) simulated natural DNA 
fragmentation by heating genomic DNA extract samples in deionized water at 95°C for 10, 15, 
20, and 25 minutes. The study went one step further to analyse DNA from three simulated case-
type samples which were blood on cotton fabric, semen on cotton fabric and a saliva swab from 
the lid of a coffee drink. The results displayed that under the degradation condition, all markers 
were stable and primers successfully amplified the target sequence. Additionally, there were 
no significant differences observed in methylation levels of degraded samples when compared 
to those samples that were not exposed to degradation conditions. The three simulated case-
type samples were successfully modified, amplified and pyrosequenced. Thus, each marker 
was able to successfully amplify the body fluid it was selected for: the ZCH12D marker showed 
low levels on methylation in the semen samples and high methylation in blood and saliva, the 
cg06379435 marker showed higher methylation levels in blood compared to semen and saliva 
and the BCAS4 marker showed higher methylation levels saliva compared to semen and blood. 
2.11 Techniques used for DNA methylation analysis 
Several techniques have been developed to specifically identify DNA methylation patterns. 
There are three broad categorizations of methods that enable the identification of methylation 
profiles which are: immunoprecipitation, endonuclease digestion and chemical modification of 
cytosine residue based methods (Silva et al., 2016).  
2.11.1 Affinity enrichment  
The affinity enrichment also known as immunoprecipitation techniques involve specific 
interactions between proteins and methylated DNA (Jacinto et al., 2008). These methods are 
based on using methyl-CpG binding protein 2 (MeCP2 and MBD2) or antibodies that bind to 
methylated DNA (Figure 2.3) (Laird, 2010). The two most widely used immunoprecipitation 
methods are, methyl-CpG immunoprecipitation (MCIp) and methylated DNA immuno-
precipitation (MeDIP). These methods are simple, there is no digestion or bisulfite treatment 
of the genomic DNA and the results of the analysis are relatively easy to deduce.  
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2.11.1.1 Methyl-CpG immunoprecipitation (MCIp) 
The methyl-CpG immunoprecipitation (MCIp) method uses an immobilized recombinant 
protein which consists of a methyl binding domain fused to human immunoglobulin G (IgG) 
(Gebhard et al., 2006a; Gebhard et al., 2006b; Schmidl et al., 2009). The antibody-fused 
protein binds to the methylated CpG regions on double stranded DNA (Sonnet et al., 2013). 
Initially, double stranded DNA is digested and denatured, followed by incubation with 
sephrose beads (Schilling and Rehli, 2007). Unbound DNA is removed using centrifugation. 
Next the beads with bound DNA are washed with increasing salt concentrations to elute 
fragments that contain methylated CpG. The methylation status is analysed based on the salt 
fractionation (Gebhard et al., 2006a; Klose et al., 2005). Therefore, fragments that have a low 
methylation status will be a result of low salt fractions and fragments that have a high 
methylation status will be a result of high salt fractions.  
2.11.1.2 Methyl-DNA Immunoprecipitation (MeDIP) 
An immunocapturing technique that is based on direct immunoprecipitation of methylated 
DNA is known as methyl-DNA Immunoprecipitation (MeDIP) which uses monoclonal 
antibody specific for 5-methylcytidine (5mC) to purify methylated DNA (Weber et al., 2005).  
The genomic DNA is sheared through sonication resulting in the production of random sized 
fragments that range between 300-600bp. The fragmented DNA is denatured into single-
stranded DNA as the antibody has a greater affinity with this form of the methylated DNA. 
This is followed by immunoprecipitation, in which proteins are coupled with standard or 
magnetic beads, incubated with the anti-5mC antibody and several wash steps to remove the 
excess antibodies. The methylated status of the immunoprecipitated DNA can be analysed 
using PCR, in which primers are designed to target a specific gene of interest. 
Immunoprecipitation techniques require an antibody that is of high quality. An antibody that 
does not have a high quality will result in an inadequate DNA-protein enrichment (Bulyk, 2006; 
Minard et al., 2009). This method however has low sensitivity and specificity, and requires 
high quality of DNA.  
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Figure 2.3: Diagrammatic representation of immunoprecipitation techniques. Genomic DNA is first 
fragmented by sonication and then undergoes denaturation. The DNA is then separated into two fractions, 
namely the input DNA and immunoprecipitated DNA(IP).  Primary antibody (anti-methylcytosine) and methyl-
CpG binding protein (MBD) fusion protein are incubated with single-stranded DNA in MeDIP and MCIp, 
respectively. The methylated DNA–antibody complex is captured by a secondary antibody that is specific to 
the primary antibody (Thu et al., 2010). 
 
2.11.2 Endonuclease digestion 
Restriction enzymes can be used to provide information on methylation patterns. Each 
sequence specific restriction enzyme that is used in the endonuclease digestion method has a 
DNA methyl transferase that prevents DNA from being restricted at the recognition site of the 
enzyme by methylation of the bases in the restriction site (Laird, 2010). There are some 
restriction enzymes that are sensitive and are unable to cleave a DNA sequence when the 
recognition site lies at a methylated CpG. Thus, endonuclease digestion method is used to 
determine DNA methylation patterns (Gršković et al., 2013). There are also enzymes that are 
not sensitive to methylation and will cleave methylated DNA (Bird, 1986). This method 
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depends on the presence of a recognition site at a specific CpG, thus, the enzyme used in this 
method will only cleave at the CpG which is not methylated.  
2.11.2.1 Methylation sensitive restriction enzyme 
The most widely used endonuclease digestion method is methylation sensitive restriction 
enzyme-polymerase chain reaction (MSRE-PCR) (Melnikov et al., 2005). In this method, a 
restriction enzyme such as HpaII is used, because it has an isoschizomer or neoschizomer that 
is not inhibited by methylated CpGs (Laird, 2010). Thus, this enzyme leaves the methylated 
sites intact (Gršković et al., 2013; Hua et al., 2011; Sijen, 2015). The digested DNA is subjected 
to PCR analysis using primers that are fluorescently labelled followed by the amplicons being 
separated using capillary electrophoresis. To confirm that all unmethylated DNA is cleaved, 
the extracted DNA undergoes extensive restriction enzyme digestion. It is not possible to 
determine the amount of methylation that is present at these CpG sites using this method, 
however, it does give information on the presence or absence of methylation. This is a simple 
and robust method, however, the analysis and interpretation is hindered by differences in the 
enzyme activity or in case of incomplete digestion. The major limitation that is associated with 
this method is the dependency on specific recognition sites at the CpG of interest for the 
restriction enzymes that are used (Melnikov et al., 2005).  
2.11.2.2 Restriction Landmark Genomic Scanning (RLGS) 
Restriction Landmark Genomic Scanning (RLGS) is a quantitative method that is used to 
determine the methylation status of CpG islands in a genome (Costello et al., 2000). This 
method involves two-dimensional separation of radioactively labelled genomic DNA. The 
extracted genomic DNA is digested with methylation sensitive restriction enzymes such as 
NotI, which cleaves at methylated regions usually in CpG islands (Costello et al., 2002; Laird, 
2010). The digested DNA is radioactively labelled at the cleaved ends and is followed by a 
second digestion with secondary enzymes, like, EcoRV  (Dhingra et al., 2014). Once the second 
digestion is completed the digested DNA is electrophoresed in an agarose tube gel, where, the 
DNA is digested by a third restriction enzyme which is followed by electrophoresis in a 
perpendicular direction to the first, separation on a polyacrylamide gel and then auto-
radiographed (Costello et al., 2002). The RLGS profile that is obtained shows the copy number 
and the methylation status of the CpG islands. Although this method is sensitive it uses a large 
amount of DNA, is time consuming and labour intensive (Dhingra et al., 2014; Laird, 2010).  
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2.11.3 Chemical Modification 
Bisulfite treatment or conversion is a chemical modification of cytosine residues developed by 
Frommer et al. (1992). It is an efficient approach that provides qualitative and quantitative 
results for DNA methylation analysis. In this method, the extracted DNA is treated with high 
concentrations of sodium bisulfite (Figure 2.4) in which cytosine nucleotides that are 
unmethylated are converted to uracil and methylated cytosine remain unchanged in genomic 
DNA sequences. Several studies have used sodium bisulfite treatment to determine DNA 
methylation profiles based on CpG dinucleotides that are methylated or unmethylated (Brena 
et al., 2006; Kristensen., et al 2008; Yang et al., 2006). Bisulfite conversion is generally 
followed by PCR and analysis of the PCR products which enables one to distinguish between 
the methylated and unmethylated DNA (Shen and Waterland, 2007; Leontiou et al., 2015). 
When the gene of interest is amplified during PCR amplification the PCR product will result 
in a thymine being present for an unmethylated cytosine and a cytosine being present at a 
methylated cytosine location. For my study the focus will be on techniques that use chemical 
modification.  
 
 
Figure 2.4: Schematic representation of bisulfite conversion. In methylated DNA, non-methylated cytosine is 
converted to uracil (blue U) and methylated cytosine remain the same (underlined CG) after bisulfite treatment 
(Hernández et al., 2013). 
 
2.11.3.1 Methylation-sensitive single nucleotide primer extension (Ms-
SNuPE) 
The methylation-sensitive single nucleotide primer extension (Ms-SNuPE) is a quantitative 
and fast technique to determine differences in methylation patterns at specific CpG sites on 
DNA that has undergone bisulfite conversion which is followed by single nucleotide primer 
extension (Figure 2.5) (Gonzalgo and Jones, 1997; Gonzalgo and Liang, 2007; Tost et al., 
2003). Specific primers bind upstream from the nucleotide position of interest, following 
incorporation of a labelled nucleoside triphosphate which results in termination of the reaction. 
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The ratio of unmethylated and methylated cytosine can be determined by running the PCR 
products that are generated on a denaturing polyacrylamide gel electrophoresis (Dhingra et al., 
2014). Ms-SNuPE based methods have been demonstrated to be sensitive, fast and robust. 
Multiple CpG sites can be analysed in a single reaction by using a multiplex strategy to 
determine the quantity of methylation, therefore, the use of restriction enzymes is eliminated 
(Dhingra et al., 2014). 
 
Figure 2.5: A diagrammatic representation of Ms-SNuPE. Target DNA undergoes bisulfite treatment and 
amplification, which is followed by the SNuPE assay. SNuPE products are then analysed by electrophoresis. 
Methylated cytosine (represented by red- mC) and non-methylated cytosine (represented by green C) at a CpG 
site. Non- methylated cytosine is reproduced as T (blue) following PCR amplification. Arrows at the 3- or 5’- 
represent PCR primers that amplify the bisulfite treated target DNA. Arrows at S1, S2 or S3 are representative 
the oligonucleotide primers for the Ms-SNuPE analysis (Gonzalgo and Liang, 2007). 
2.11.3.2 Bisulfite sequencing (BS) 
The gold standard method for analysis of methylation patterns post bisulfite conversion is 
bisulfite sequencing (BS) (Frommer et al., 1992). This method has improved DNA methylation 
research in which the presence and absence of methylation is identified. The converted DNA 
is amplified at a specific region using PCR primers that do not overlap at CpG sites resulting 
in amplification of methylated and unmethylated alleles. The primers that are designed for BS 
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should not have any CpG sites within the sequence to avoid discrimination between methylated 
or unmethylated DNA and the primer pair should span the maximum number of CpG sites (Li 
and Dahiya, 2002). The resulting PCR amplicons can be analysed in two ways: using direct 
sequencing or clone based sequencing (Hernández et al., 2013). In the direct sequencing 
method, the PCR amplicons are sequenced using a method such as Sanger sequencing which 
is followed by analysis of methylation patterns. This method is very effective in determining 
the amount of methylation at each CpG site and also determines the effect of DNA methylation 
on the expression of the gene of interest (Parrish et al., 2012). Although the direct sequencing 
method is not time consuming it is unable to distinguish methylation patterns between 5-
Methylcytosine and 5-Hydroxymethylcytosine (Parrish et al., 2012). The products that are sent 
for direct sequencing may produce unambiguous results and is more difficult to analyse 
compared to clone based sequencing. In the cloned based sequencing method (Figure 2.6) the 
PCR amplicons are ligated into a cloning vector followed by transformation into competent 
cell (Shen and Waterland, 2007). Agar plates are then used to grow the antibiotic resistant 
colonies which are then selected individually followed by growth in Luria-Bertani (LB) 
medium. The plasmid DNA is then isolated and sequenced. The bisulfite sequencing method 
can be quantitative if a large number of clones are sequenced. A single allele is represented by 
each clone, thus, providing allele-specific methylation information. This method is widely used 
in studies for site specific methylation or allele-specific methylation due to the fact that it is 
straightforward and generates detailed methylation information. However, this method is 
expensive if there is a large sample size and is very labour intensive (Shen and Waterland, 
2007). After bisulfite treatment the DNA is prone to degradation which affects the detection 
limit and the complementary strand is lost as a result of cytosine being converted to uracil 
(Dhingra et al., 2014). 
2.11.3.3 Methylation Specific Polymerase Chain Reaction (MSP) 
Herman et al. (1996) was first to use the methylation specific polymerase chain reaction (MSP) 
method. MSP is a sensitive and fast method used to determine methylation patterns by 
amplifying the methylated and unmethylated alleles at a region of interest (Figure 2.8) (Herman 
et al., 1996; Hernández et al., 2013).  Following bisulfite conversion, a PCR is carried out using 
two sets of primers that are designed using software such as Methprimer (Li and Dahiya, 2002). 
The two sets of primers either amplify methylated or unmethylated alleles (Shen and 
Waterland, 2007). MSP is a beneficial method as it is very sensitive and can detect one 
methylated allele in more than one thousand unmethylated alleles (Shen and Waterland, 2007). 
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This technique can also be used on DNA samples that have a low quantity and quality as well 
as paraffin embedded samples (Herman et al., 1996; Dhingra et al., 2014). Primer design is 
crucial in MSP to ensure that reliable results are produced (Figure 2.7). The MSP method is 
able to recognise CpG sites without using methylation sensitive restriction enzymes, thus, the 
number of CpG sites that can be analysed is increased (Herman et al., 1996). In methods that 
use methylation sensitive enzymes false positive results may be produced due to partial 
digestion, however, MSP overcomes this limitation. The BS method is time consuming due to 
cloning and sequencing can take days to complete, whereas, MSP can be done within 1-2 days 
(Ohashi, 2002). 
 
 
Figure 2.6: A diagrammatic representation of cloned based bisulfite sequencing. Genomic DNA is bisulfite 
treated, followed by PCR amplification. PCR products are ligated into a vector. The ligated DNA product is 
then transformed into competent bacterial cells and grown in non-selective liquid culture. A selective media is 
used to plate transformed cells which are grown overnight. Blue/white selection method is used for selection 
of (white) colonies which contain the PCR amplicons as inserts. A PCR reaction followed by agarose gel 
electrophoresis is used to determine if selected positive colonies have the correct insert size. Positive amplicons 
are purified and sequenced. Sequenced results are used to establish methylation status. The rows represent a 
single clone and the columns individual CpG dinucleotides within the sequenced region of interest. Black dots 
represent methylated CpG sites and white dots represent unmethylated CpG sites (Huang et al., 2013a). 
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Figure 2.7: MSP primer design for methylated and unmethylated DNA. The DNA sequence (left) is modified 
based on the methylation status. The modified sequence is used to design the forward primer by replacing Us 
with Ts (Hernández et al., 2013). 
 
 
Figure 2.8: A diagrammatic representation of methylation specific polymerase chain reaction. In MSP, two 
sets of primer pairs are designed to target the methylated cytosine (black circles) and non-methylated cytosine 
(white circles) of the bisulfite converted genomic DNA. After PCR amplification, the amplicons are analysed 
by agarose gel electrophoresis. M represents methylated, U represents non-methylated and L represents the 
DNA ladder (Huang et al., 2013b). 
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Combining the above mentioned techniques with DNA microarrays or high throughput 
sequencing enables genome-wide profiling of DNA methylation (Bock, 2012; Zilberman and 
Henikoff, 2007). The design and technology that is used to develop microarrays influences 
their applicability in methylation analysis, for example, Illumina arrays are best suited for DNA 
that has been bisulfite converted and other arrays such as short oligonucleotide arrays and long 
oligonucleotide arrays are better suited for restriction enzyme and affinity based techniques. In 
the Illumina arrays, two primers (one primer binds to methylated cytosine and the other primer 
binds to a converted sequence) that are fluorescently labelled are used in a PCR reaction with 
the bisulfite converted DNA followed by the Illumina assay (Bibikova et al., 2006; Fan et al., 
2006). The ratio of the PCR products are established using Illuminas SEntrix Array Matrix 
bead array platform which can assay up to 1536 sites in 96 samples in a single experiment. 
This method is able to provide quantitative evaluation of specific cytosines in many samples, 
thus, it is suitable to compare a set of known methylated loci in many cell lines to determine 
the methylation profiles (Yousefi et al., 2013). However, the method has low coverage in 
comparison to other array based method. Development of a large set of selective primers is 
necessary, thus, limiting its usefulness for de novo genomes (Zilberman and Henikoff, 2007). 
The short oligonucleotide arrays use photolithographic technology in which millions of probes 
per chip are used to achieve very high feature density (Dalma-Weiszhausz et al., 2006). Short 
probes that are made up of 25 nucleotides and the chips are designed so that it only hybridizes 
to one sample at a time. Arrays have an excellent specificity, however, it has low sensitivity 
and high random signal variation due to the length of the probes (Kreil et al., 2006). To ensure 
statistical significance each sample is hybridized in triplicate. An adaptive photolithographic 
method is employed to produce the long oligonucleotide arrays (Nuwaysir et al., 2002). The 
probes consist of 60 oligonucleotides and have a dual channel in which two samples can be 
labelled with different fluorescent dyes and hybridized to a single chip. This is advantageous 
because it reduces the need for replicates. The longer probes provide a good balance between 
specificity, sensitivity and noise (Kreil et al., 2006).  
DNA methylation can also be analysed by a sequencing-by-synthesis fluorescent nucleotide 
based system that can produce approximately 400 000 reads of over 100 bases in a single run 
(Madi et al., 2012; Park et al., 2014). Pyrosequencing produces great amounts of sequencing 
information, quicker and at a more cost effective rate than conventional Sanger sequencing, 
which eliminates the cloning steps. This technique can be used as an alternative to DNA 
microarrays. High throughput sequencing provides a quantitative measure of methylation 
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(Kottaridi et al., 2015). In comparison to array based techniques which provide a relative 
measure, biases that affect hybridization such as sequence composition do not have an effect 
on high throughput sequencing. However, a high quality reference sequence is required 
because the short reads that are produced by this technique is difficult to assemble de novo. 
These techniques are very informative, however, are also expensive and labor intensive and 
most laboratories are not capable of performing these techniques (Zilberman and Henikoff, 
2007). 
2.12 Rationale of the study 
Determination of the type and origin of body fluids can provide important clues for crime scene 
reconstruction by linking donors and actual crime acts. Presumptive and confirmatory methods 
used for identification of body fluids include, catalytic, immunological and enzymatic tests. 
These methods have an increased risk of cross contamination and possess low sensitivity as 
well as low specificity (Hernández et al., 2013). In addition, there is no single method for all 
body fluids which results in extra sample consumption and makes samples incompatible with 
subsequent DNA STR typing. Approaches based on RNA expression offers high specificity 
however, the stability of RNA molecules is a problem (Akutsu et al., 2015; Vidaki et al., 2016). 
Recent studies have demonstrated that human tissues and forensically relevant body fluids can 
be identified based on their tissue-specific differential methylation pattern. In human genomes, 
tDMRs display varying methylation profiles according to cell or tissue type. DNA methylation 
analysis is compatible with STR analysis as DNA extracted for STR typing can also be used 
for methylation analysis (Watanabe et al., 2016). tDMRs show a great potential for 
identification of human body fluids in forensic investigations, however limited tDMRs have 
been verified so far (An et al., 2012; Choi et al., 2014; Fu et al., 2015). At the University of 
KwaZulu-Natal, Kader. (2015, MSc Genetics dissertation) identified novel candidate gene 
based tDMRs for semen, saliva, blood and vaginal fluid identification based on differential 
gene expression in body fluids and surrogate tissues of body fluids. The present study aims to 
validate the methylation profile of candidate tDMRs and assess their suitability by testing their 
stability under simulated forensic conditions. The validated tDMR markers will add to the 
growing list of epigenetic markers for body fluid identification as the candidate tDMRs targeted 
in present study have not been reported previously.  
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2.13 Genes of interest studied in the present research 
2.13.1 ZNF282 gene (Zinc finger protein 282) 
The ZNF282 gene is also known as HUB1. It is a protein coding gene that contains nine exons 
and is located on chromosome seven on the long arm (q) on band three, sub-band six, sub-sub-
band one (7q36.1) (Figure 2.9) (https://www.ncbi.nlm.nih.gov/gene/8427; ZNF282, 2004). 
The genomic size of the ZNF282 gene is 30 787 bases and the protein size is 671 amino acids 
with a molecular mass of 74 295 Da (http://www.genecards.org/cgi-bin/carddisp.pl? 
gene=znf282; Fishilevich et al., 2016). The proteins that are encoded by the ZNF282 gene 
belong to the krueppel C2H2-type zinc finger protein family (Okumura et al., 1997).  The 
proteins found in ZNF282 gene bind to the U5 repressive element (U5RE) in the T-cells 
leukemia virus type I long terminal repeat in humans (Yeo et al., 2014). A study by Yu et al. 
(2013) showed that ZNF282 gene functions as an Era co-activator by an interaction with 
oestrogen receptor in breast cancer cells. There are two transcript variants that have been 
reported for ZNF282 gene. The proteins recognize a sequence (5’-TCCACCCC-3’) as its core 
motif and exerts a strong repressive effect on HTLV-I LTR-mediated expression. Other known 
functions include: DNA and zinc-ion binding and regulation of transcription 
(http://www.uniprot.org/uniprot /Q9UDV7; Breuza et al., 2016). According to the Genotype-
Tissue Expression Consortium (GTEx), this gene is highly expressed in the prostate showing 
18.1 RPKM (reads per kilobase of transcripts per million mapped reads) based on the RNA 
expression. In the vagina and cervix, the GTEx showed 10.1 RPKM and 11.5 RPKM 
respectively for RNA expression. In the salivary glands the GTEx showed 9.7 RPKM for RNA 
expression (https://www.proteinatlas.org/ENSG00000170265-ZNF282/tissue; Uhlén et al., 
2015). There was no available expression data on peripheral blood. Based on the tissue-specific 
(Tissue-specific Gene Expression and Regulation) gene expression profiles of the TiGER 
database, ZNF282 is highly expressed in the cervix (http://bioinfo.wilmer.jhu. 
edu/tiger/db_gene /ZNF282- index.html; Liu et al., 2008).  
 
Figure 2.9: Chromosomal location of the ZNF282 gene.  
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2.13.2 PTPRS gene (Protein tyrosine phosphatase, receptor S) 
The PTPRS gene is also known as R-PTP-S, PTPSIGMA AND R-PTP-sigma. It is a protein 
coding gene that contains 41 exons and is located on chromosome 19 on the short arm (p) on 
band one, sub-band three and sub-sub-band three (19p13.3) (Figure 2.10) (https://www. 
ncbi.nlm.nih.gov/gene/5802; PTPRS, 2004). The genomic size of the PTPRS gene is 182 309 
bases and has a protein size of 1 948 amino acids with a molecular mass of 217 041 Da 
(http://www.genecards. org/cgi-bin/carddisp.pl?gene=ptprs; Fishilevich et al., 2016). The 
proteins encoded by the PTPRS gene belong to the protein tyrosine phosphatase (PTP) family. 
PTPs are identified as signalling molecules that are involved in regulation of various cellular 
processes, such as cell growth, differentiation, mitotic cycle and oncogenic transformation. 
Other known functions of PTPRS gene include, interaction with LAR-interacting protein 
(LIP.1), transmembrane receptor protein tyrosine phosphatase activity, cell adhesion, the 
development of spinal cord, cerebellum, cerebral cortex and synaptic transmission 
(http://www.uniprot.org/uniprot /Q13332; Breuza et al., 2016). There are four alternatively 
spliced transcript variants that have been reported which encode unique proteins (PTPRS, 
2004). The PTPRS gene is expressed in all tissue excluding placenta and liver tissue. According 
to the GTEx, this gene is highly expressed in the cerebellum showing an average 31.2 RPKM 
(reads per kilobase of transcripts per million mapped reads) based on the RNA expression. In 
the vagina and cervix, the GTEx showed 20.8 RPKM and 23.5RPKM respectively for RNA 
expression. In the prostate and salivary glands, the GTEx showed 23.1 RPKM and 10 RPKM 
respectively for RNA expression (https://www.proteinatlas.org /ENSG00000105426-
PTPRS/tissue; Uhlén et al., 2015). There was no expression data available on peripheral blood. 
Based on the tissue-specific (Tissue-specific Gene Expression and Regulation) gene 
expression profiles of the TiGER database, PTPRS is highly expressed in the small intestine 
(http://bioinfo.wilmer.jhu.edu/tiger/ db_gene/PTPRS-index.html; Liu et al., 2008). 
 
Figure 2.10: Chromosomal location of the PTPRS gene. 
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2.13.3 HPCAL1 gene (Hippocalcin like 1) 
The HPCAL1 gene is also known as calcium-binding protein (BDR1), hippocalcin-like protein 
1 (HLP2) and visinin-like protein 3 (VILIP-3). It is a protein coding gene that contains 17 exons 
and is located on chromosome two on the short arm (p) on band two, sub-band five, sub-sub-
band one (2p25.1) (Figure 2.11) (https://www.ncbi.nlm.nih.gov/gene/?term=hpcal1; HPCAL1, 
2004). The genomic size of the HPCAL1 gene is 124 729 bases and has a protein size of 193 
amino acids with a molecular mass of 22 313 Da (http://www.genecards.org/Search/ 
Keyword?Query String=hpcal1; Fishilevich et al., 2016). There are eight alternatively spliced 
transcript variants that have been reported that encode the same protein 
(https://www.ensembl.org/Homosapiens/Gene/Summary?db=core;g=ENSG00000115756;r=2
:10302889-10427617; Aken et al., 2016).  The proteins that are encoded by the HPCAL1 gene 
belong to the neuron-specific calcium-binding proteins family that are found in the retina and 
brain. The HPCAL1 gene could possibly be involved in calcium-dependent regulation of 
rhodopsin phosphorylation and may be relevant in neuronal signalling in the central nervous 
system. Other known functions include, calcium-ion binding (http://www.uniprot.org/uniprot/? 
query=hpcal1&sort=score; Breuza et al., 2016). The HPCAL1 gene is highly expressed in the 
Purkinje cells of the cerebellum (https://www.proteinatlas.org/ENSG00000115756-
HPCAL1/tissue; Uhlén et al., 2015). The expression of HPCAL1 gene occurs mainly in the 
cerebellum during late development (Spilker et al., 2000). According to the GTEx, this gene is 
highly expressed in the cerebellum showing 87.3 RPKM based on the RNA expression. In the 
vagina and cervix, the GTEx showed 6.4 RPKM and 11 RPKM respectively for RNA 
expression. In the prostate and salivary glands, the GTEx showed 6.5 RPKM and 5 RPKM 
respectively for RNA expression (Uhlén et al., 2015). There was no available data on peripheral 
blood. If the expression of HPCAL1 gene is increased it could result in an increase of ERK2 
activation and ERK2 protein expression (Spilker and Braunewell, 2003). Based on the tissue-
specific (Tissue-specific Gene Expression and Regulation) gene expression profiles of the 
TiGER database, ZNF282 is highly expressed in the cervix (http://bioinfo.wilmer.jhu.edu/ 
tiger/db_ gene/HPCAL1-index.html; Liu et al., 2008). 
 
 
Figure 2.11: Chromosomal location of the HPCAL1 gene. 
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2.14 Hypothesis, objectives and aims 
2.14.1 Hypothesis:  
 The candidate tDMRs for genes ZNF282, PTPRS and HPCAL1 will be differentially 
methylated in human blood, saliva, semen, and vaginal fluid. 
 The validated tDMRs markers will maintain a stable methylation profile under forensic 
simulation conditions. 
2.14.2 Objectives:  
 Methylation profiling of candidate tDMRs in blood, saliva, semen and vaginal fluid by 
Methylation Specific Polymerase Chain Reaction (MSP). 
 Methylation profiling of candidate tDMRs in blood, saliva, semen and vaginal fluid by 
Bisulfite Sequencing (BS). 
 Sensitivity testing of candidate tDMRs by Methylation Specific Polymerase Chain 
Reaction (MSP). 
 Methylation profiling of candidate tDMR in blood, saliva, semen and vaginal fluid 
exposed to dry, wet and outside conditions (forensic simulation) by Bisulfite 
Sequencing (BS). 
 Methylation profiling of candidate tDMR in blood, saliva, vaginal fluid and semen 
exposed to bleach and alcohol (forensic simulation) by Bisulfite Sequencing (BS). 
2.14.3 Aims: 
 Methylation profiling and validation of candidate tDMRs for identification of human 
body fluids. 
 To analyse the effect of external environmental factors on methylation profile of 
validated tDMR markers. 
2.14.4 Key Question:  
 Do the candidate tDMRs present a differential methylation profile to differentiate 
between human blood, saliva, semen and vaginal fluid? 
 Is the methylation profile of identified tDMRs markers stable under simulated forensic 
conditions? 
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Chapter 3 
 Validation of tissue-specific 
differential DNA methylation in 
gene-specific tDMRs by methylation 
specific PCR and bisulfite sequencing 
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Abstract 
Identification of body fluids found at crime scenes is a critical step in forensic investigations.  
DNA methylation analysis is emerging as a reliable approach to differentiate between body 
fluids. Regions known as tissue-specific differential methylated regions (tDMRs) in the human 
genome display differential methylation patterns in various tissues or cells, hence, tDMRs can 
be targeted to differentiate between body fluids. To date only a few tDMRs markers have been 
developed for body fluid differentiation. In a previous study at the University of KwaZulu-
Natal, based on differential gene expression in blood, saliva, semen and vaginal fluid candidate 
tDMRs in genes ZNF282, PTPRS and HPCAL1 were identified to differentiate between blood, 
saliva, semen and vaginal fluid. It was proposed that differential gene expression could be 
possibly due to differences in methylation patterns. The present study was undertaken to 
examine the methylation profile of candidate tDMRs by methylation specific PCR (MSP) and 
bisulfite sequencing (BS) analysis. CpG islands in the gene body were targeted to design 
primers for both MSP and BS. The ZNF282 tDMR displayed hypomethylation in semen and 
hypermethylation in blood, saliva and vaginal fluid with both MSP and BS analysis. Statistical 
analysis by Fisher’s exact test showed significant difference in overall methylation status and 
at individual CpG sites between semen and all other body fluids (p < 0.05) for the ZNF282 
tDMR. Therefore, the ZNF282 tDMR could be successfully used as a semen-specific 
hypomethylation marker. The PTPRS 1 tDMR displayed hypermethylation for blood, vaginal 
fluid and saliva. In semen for PTPRS 1 tDMR both methylation and unmethylation was 
observed. Therefore, PTPRS 1 tDMR has the potential to be used as a semen-specific marker. 
However, BS analysis could not differentiate semen from other body fluids due to a fewer 
number of clones that were analysed. Both MSP and BS analysis showed no significant 
difference in overall methylation pattern and at individual CpG sites between body fluid for 
PTPRS 2 tDMR (p > 0.05) thus PTPRS 2 cannot be used to differentiate body fluids. The 
HPCAL1 tDMR showed hypomethylation in saliva and hypermethylation in other body fluids 
by MSP, however, the results could not be validated by BS due to non-specific amplification 
with bisulfite PCR primers. The present study reports methylation profiling and validation of 
novel gene based tDMRs which will add to the growing list of methylation markers for 
identification of forensically relevant body fluids. Future research would aim to re-analyse 
PTPRS 1 and HPCAL1 tDMR on a larger sample size for significant methylation differences. 
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3.1 Introduction 
In forensic investigations, human body fluids are amidst the most significant types of evidence 
that are found at crime scenes (Greenfield and Sloan, 2003). Analysis of body fluids present at 
a crime scene have the potential to influence the outcome of the case by assisting in 
identification of victims and perpetrators, reconstruction of the crime scene events and can 
provide a link between the evidence and the crime committed (Akutsu et al., 2015; Virkler and 
Lednev, 2009; Lee et al., 2012). Body fluids are not always visible to the naked eye and are 
sometimes indistinguishable from other fluids or substances.  
Presumptive and confirmatory tests are used to identify body fluids found at crime scenes (An 
et al., 2012; Frumkin et al., 2011; Gršković et al., 2013; Sinelnikov et al., 2013). Presumptive 
tests are used as screening tests to identify specific proteins, however, these tests are limited in 
their specificity, sensitivity, proteins are susceptible to degradation and inactivity (Casey and 
Price, 2010; Frumkin et al., 2011; Lin et al., 2016; Shaler, 1981; Virkler and Lednev, 2009). 
Confirmatory tests are used for absolute identification of body fluids or tissue. The presumptive 
and confirmatory tests commonly used are summarized in Table 3.1. 
Majority of these tests rely on colour changing reactions which are difficult to interpret when 
coloured extracts or samples are required to be identified (Haas et al., 2009; Lindenbergh et 
al., 2012). Present tests are destructive for specific constituents that are found in the various 
body fluids. Body fluids that are found at crime scenes need to be identified accurately without 
destroying or degrading the biological sample, thus a technique that is able to do this as well 
as use a small amount of sample will prove to be advantageous.  
 
 
Table 3.1: Current methods used for body fluid identification (Gaensslen, 1983; Greenfield and Sloan, 2003; 
Shaler, 2002; Spalding, 2003; Virkler and Lednev, 2009).  
 Blood Saliva Semen Vaginal fluid 
Presumptive 
tests 
Alternate light source 
(ALS), luminol test, 
benzidine test and 
Kastle-Meyer test 
 
Alternate light source 
(ALS -based on the 
activity of amylase) 
 
Seminal acid 
phosphatase 
(SAP) and 
Florence test 
 
Periodic Acid-
Schiff (PAS- 
based on 
glycogenated 
epithelial cells) 
 
Confirmatory 
tests 
Microscope tests or 
chromatographic 
technique 
None Microscopic 
identification 
and prostate-
specific antigen 
(PSA) 
None 
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Although body fluids and tissue can be identified using mRNA profiling (Bauer and Patzelt, 
2002; Juusola and Ballantyne, 2003; Lindenbergh et al., 2012; Zubakov et al., 2008; Zubakov 
et al., 2010), RNA has a shorter half-life and is less stable than DNA (An et al., 2012; Phang 
et al., 1994). MicroRNAs (miRNAs) have a greater stability and longer half-life compared to 
mRNA and has better characteristics for identifying forensic biological material (Bail et al., 
2010; Hanson et al., 2009; Sato et al., 2009; Zubakov et al., 2010). Identification of body fluids 
using mRNA and miRNA provides valuable information however these methods require a 
large amount of sample, are labour intensive and time consuming (Fleming and Harbison, 
2010; Zubakov et al., 2010).  
Analysis of differential DNA methylation patterns in cells and tissue is a promising method for 
identification of forensically relevant body fluids because DNA is more stable than RNA and 
proteins (An et al., 2013; Choi et al., 2014; Gršković et al., 2013; Lee et al., 2012; Lee et al., 
2015; Lee et al., 2016a; Li et al., 2012; Silva et al., 2016; Park et al., 2016). DNA methylation 
analyses is beneficial because it has higher specificity, can be used in conjunction with the 
current forensic DNA protocols, thus, has the ability to be used in old cases in which only the 
DNA extracts are available (An et al., 2012). 
DNA methylation occurs in CpG dinucleotides which are enriched in DNA regions known as 
CpG islands (Bird, 1986; Feltus et al., 2003). CpG islands are defined as: having approximately 
200 base pairs, a GC content greater than 50% and the observed/expected CpG ratio must be 
greater than 60% (Derks et al., 2004; Gardiner-Garden and Frommer, 1987). CpG islands are 
associated with gene promoters and gene bodies (Deaton and Bird, 2011; Maunakea et al., 
2010). Gene body methylation has a positive correlation with gene expression, conversely, 
methylation at promoter regions has an inverse correlation (Ball et al., 2009; Goll and Bestor, 
2005; Klose and Bird, 2006; Laurent et al., 2010; Lister et al., 2009). CpG islands extend 
downstream of transcript regions which explains the high CpG density at the exon 5' end of the 
transcript flanked with the transcription start site (Choi, 2010). Genome-wide studies have 
shown that exons are more highly methylated in comparison to introns as well as transitions in 
the methylation status that occur at the exon-intron boundaries, this suggests that the 
methylation status plays a role in regulation of splicing (Laurent et al., 2010). Therefore, DNA 
methylation has an alternate function in gene bodies (Jones, 2012).  
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There are several regions in the human genome that display different methylation patterns 
depending on the cell or tissue type known as tissue-specific differentially methylated regions 
(tDMRs) (Kitamura et al., 2007; Slieker et al., 2013; Song et al., 2009). tDMRs are broadly 
distributed in intragenic and intergenic regions which include both CpG islands, and non-CpG 
islands regions (Song et al., 2009) as well as CpG shores (Irizarry et al., 2009). Since 
methylation patterns of tDMRs vary between tissues and body fluids, tDMRs have the potential 
to be used as biomarkers to differentiate between human body fluids based on the methylation 
patterns (Ghosh et al., 2010; Lokk et al., 2014).   
Recent studies have identified tDMRs either within a gene or at other genomic locations. 
Genome-wide methylation studies have also identified differentially methylated CpG sites 
which can distinguish between body fluids. A study by Lee et al. (2012) used five tDMRs with 
multiple CpG sites within genes DACT1, USP49, HOXA4, PFN3, and PRMT2 for 
differentiation of body fluids by bisulfite sequencing (BS). Semen-specific hypomethylation 
patterns were observed for DACT1 and USP49. The HOXA4, PFN3, and PRMT2 tDMRs 
showed varying degrees of methylation in each body fluid. Other studies have also identified 
tDMRs for body fluid identification, BCAS4 (saliva marker), FGF7 and ZC3H12D (semen 
markers), PFN3A (vaginal epithelia marker) all have multiple CpG sites and C20orf117 (blood 
marker) and cg0969411 (menstrual blood marker) show differential methylation at a single 
CpG site (Antunes et al., 2016b; Forat et al., 2016; Madi et al., 2012). Table 3.2 to 3.6 depicts 
tDMRs and CpG sites reported to date for body fluid identification.  
Sodium bisulfite conversion methods are widely used to distinguish between methylated and 
unmethylated cytosine residues (Clark et al., 1994; Derks et al., 2004; Frommer et al., 1992; 
Herman et al., 1996). In the conversion reaction, DNA is treated with sodium bisulfite which 
results in unmethylated cytosine residues being converted to uracil and methylated cytosine 
residues remain unaffected in single-stranded DNA (Sasaki et al., 2003). The methylation level 
can be determined using polymerase chain reaction (PCR) based techniques such as, 
methylation specific PCR (MSP) and bisulfite sequencing (BS) which was used in the present 
study. 
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Table 3.2: Methylation markers for identification of blood reported to date. 
tDMR/CpG site 
(cg represents a single 
CpG site and chr 
represents a chromosomal 
location) 
 
 
Status 
 
 
Proposed fluid of 
specificity 
 
 
Reference 
cg06379435 High Blood Lee et al., 2016a 
cg08792630 
cg06379435 High Blood Watanabe et al., 2016 
cg26285698 Low Blood Forat et al., 2016 
 cg03363565 High 
 
chr22:37705345- 37705493 Low Blood Fu et al., 2015 
 
chr22:29708295- 29708444 High Blood 
cg08792630 High Blood Park et al., 2014 
 
 
cg06379435 
cg241244443 High Blood Lin et al., 2016 
cg01607849   
C20orf117 High Blood Madi et al., 2012; 
Eckhardt et al., 2006 
cg06379435 High Blood Lee et al., 2015 
cg01543184 
 
 
Table 3.3: Methylation markers for identification of menstrual blood reported to date. 
tDMR/CpG site 
(cg represents a single 
CpG site and chr 
represents a chromosomal 
location) 
 
 
Status 
 
 
Proposed fluid of 
specificity 
 
 
Reference 
cg18069290 High Menstrual blood Lee et al., 2016a 
cg09696411 
cg0969411 High Menstrual blood 
 
Forat et al., 2016 
chr6:4160458-41604650 Low Menstrual blood Fu et al., 2015 
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Table 3.4: Methylation markers for identification of saliva reported to date. 
tDMR/CpG site 
(cg represents a single 
CpG site) 
Status Proposed fluid of 
specificity 
Reference 
cg09652652-2d High Saliva Lee et al., 2016a 
cg21597595 High Saliva Forat et al., 2016 
 cg15227982 
cg26107890 High Saliva Park et al., 2014 
 cg20691722 
BCAS4 tDMR High Saliva Madi et al., 2012 
cg09107912 High Saliva Lin et al., 2016 
 cg16732616 
cg09652652 High Saliva Lee et al., 2015 
 
 
Table 3.5: Methylation markers for identification of vaginal fluid reported to date. 
tDMR/CpG site 
(cg represents a single 
CpG site) 
Status Proposed fluid of 
specificity 
Reference 
cg09765089-231d 
cg26079753-7d 
High Vaginal fluid Lee et al., 2016a 
cg14991487 
cg03874199 
High Vaginal fluid Forat et al., 2016 
cg14991487 
cg01774894 
High Vaginal fluid Park et al., 2014 
PFN3 tDMR Low Vaginal Fluid An et al., 2013; Choi et 
al., 2014 
cg25416153 High Vaginal fluid Lin et al., 2016 
cg09765089 
cg09765089 High Vaginal fluid Lee et al., 2015 
cg26079753 
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Table 3.6: Methylation markers for identification of semen reported to date. 
tDMR 
(tDMR with cg represents 
a single CpG site) 
Status Proposed fluid of 
specificity 
Reference 
cg17610929 High Semen Lee et al., 2016a 
cg26763282-138d 
cg04382920 Low Semen Vidaki et al., 2016 
cg11768416 
cg22407458 Low 
High 
Semen Forat et al., 2016 
cg05656364 
cg17610929 High Semen Park et al., 2014 
 cg23521140 
DACT1 tDMR Low Semen An et al., 2013; Choi et 
al., 2014; Lee et al., 
2012 
USP49 tDMR Low Semen An et al., 2013; Choi et 
al., 2014; Lee et al., 
2012 
L81528 tDMR High Semen Choi et al., 2014; 
Frumkin et al., 2011 
PRMT2 tDMR Low Semen Lee et al., 2012 
𝐿91762
𝐿68346
 
Methylation Ratio 
Low Semen Frumkin et al., 2011 
ZC3H12D tDMR Low Semen Madi et al., 2012 
cg05261336 High Semen Lin et al., 2016 
cg17610929 
 
cg17610929 High Semen Lee et al., 2015 
cg26763284 
cg17621389 
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BS is the gold standard method used for analysis of DNA methylation (Li and Tollefsbol, 2011; 
Lee et al., 2012; Hernández et al., 2013; Pabinger et al., 2016) because primer design for 
bisulfite PCR is simple and it provides detailed quantitative methylation information for the 
region of interest by determining methylation analysis of individual CpG sites (Huang et al., 
2013a). The bisulfite PCR products can be analysed by direct sequencing or by sub-cloning 
into plasmids and selecting random clones for sequencing to obtain the methylation status of 
CpG sites within DNA molecules (Chen et al., 2010; Chhibber and Schroeder, 2008; 
Hernández et al., 2013; Huang et al., 2013a; Krueger et al., 2012). Direct sequencing is 
effective in determining the amount of methylation at individual CpG sites and the effect of 
DNA methylation on the expression of the gene of interest (Kristensen and Hansen, 2009; 
Parrish et al., 2012). In this study, the focus will be on BS of clones as individual clones are 
able to provide quantitative information. Once the clones are sequenced, the sequencing results 
can be analysed using online software to determine the methylation status. BS is the only 
method other than high throughput bisulfite sequencing methods that provides allele-specific 
methylation status (Huang et al., 2013a).  
MSP is a qualitative technique that is used to detect the presence or absence of methylation 
(Hernández et al., 2013; Huang et al., 2013b; Zhao and Bapat, 2016). MSP employs two 
different sets of methylation specific primers for amplification of the sequence of interest. One 
primer set is known as the unmethylated primers which amplify sodium bisulfite converted 
DNA in the unmethylated state and the second primer set known as methylated primers which 
amplify sodium bisulfite converted DNA in the methylated state (Derks et al., 2004; Liu and 
Maekawa, 2003). MSP is a sensitive technique as it is able to detect one methylated allele in a 
background of thousands of unmethylated alleles. The method is also inexpensive and analyses 
the methylation status of each CpG site present in a CpG island, thereby making it efficient and 
applicable for high-throughput analysis for clinical samples (Fraga and Esteller, 2002; Herman 
et al., 1996). MSP has been used successfully in previous research as shown by Esteller et al. 
(1999) and Herman et al. (1996) for identification of aberrant methylation in squamous cell 
lung carcinoma and detection of hypermethylation patterns in tumor suppressor genes, 
respectively. Other studies have also used MSP to determine methylation analysis for genes 
that have not been previously reported and diseases (Draht et al., 2016; Lan et al., 2014; 
Okazaki et al., 2011). 
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With the recent interest in DNA methylation profiling for body fluid identification, novel 
tDMRs need to be identified to develop a large database of methylation markers. A previous 
study by Kader. (2015, MSc Genetics dissertation) at the University of KwaZulu-Natal, 
identified candidate tDMRs in genes, ZNF282, PTPRS and HPCAL1 based on differential gene 
expression. Genes which were differentially expressed in at least one of the body fluids were 
selected. CpG islands within gene bodies were identified and targeted for primer design for 
validation studies. Thus, the present study centres mainly on the validation of the candidate 
tDMRs in four forensically relevant body fluids, namely, blood, saliva, semen and vaginal 
fluid. The objective was to design primers for MSP and BS to obtain methylation profiles using 
developed primers and determine whether the body fluids display differential DNA 
methylation profiles. Methylation differences among the four human body fluids would lead to 
development of additional tDMRs for body fluid identification. 
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3.2 Materials and methods 
3.2.1 Ethics approval 
The study was conducted according to the methods specified by the Biomedical Research 
Ethics Committee (BREC) at the University of KwaZulu-Natal. The BREC reference number 
is BE187/16 (sub-study of BE221/14) (Appendix A). Samples were collected from volunteers 
after a written consent was signed and a questionnaire answered by each participant (Appendix 
A). 
3.2.2 Sample collection, storage of samples and DNA extraction 
Whole blood was collected in 4 ml EDTA tubes from 10 volunteers at Lab 24 laboratory, 
Mount Edgecombe, Durban. Blood samples were collected and transported to the Genetics 
Laboratory in ice boxes with frozen ice packs. Vaginal fluid was collected from 10 volunteers 
at the King Dinizulu Hospital in Durban using sterile cotton swabs (Dry Swab, Lasec). Semen 
and saliva samples were collected from 10 individuals. Freshly ejaculated semen was collected 
in plastic cups from volunteers at the King Dinizulu Hospital and University of KwaZulu-
Natal, Westville campus. Saliva was collected from University of KwaZulu-Natal, Westville 
in 50 mL microcentrifuge tubes. All samples were immediately processed once collected, with 
the exception of vaginal fluid and semen which were deposited on sterile cotton swabs and air 
dried at room temperature prior to DNA isolation.    
DNA was extracted from each aliquot of blood, saliva and each swab of semen and vaginal 
fluid using Quick-gDNA MiniPrep kit (Zymo Research, Irvine, California, United States) 
according to manufacturer’s instructions. Extracted DNA was quantified using a NanoDrop 
(NanoDrop™ 2000 Spectrophotometer, Waltham, Massachusetts, United States). The 
concentration of blood, saliva, semen and vaginal fluid of each volunteer is listed in Table 1, 
Appendix B. All DNA samples were stored at -20ºC after quantification. 
3.2.3 Bisulfite conversion 
The DNA methylation sites on the extracted DNA has to be preserved when a standard PCR 
amplification is run. Therefore, the genomic DNA was treated with sodium bisulfite in order 
to convert the unmethylated cytosines to uracil and methylated cytosine remain the same (Silva 
et al., 2016) using the EZ DNA Methylation Gold Kit (Zymo Research, Irvine, California, 
United States). In this method the converted uracil is replaced by thymine during the PCR 
amplification process. The bisulfite modified DNA was amplified by site specific PCR primers 
designed to amplify the bisulfite modified target regions. 
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3.2.4 Selection of candidate genes and primer design 
In a previous study by Kader. (2015, MSc Genetics dissertation) genes with differential gene 
expression in human tissues and body fluids were identified. It was proposed that differential 
gene expression in forensically relevant body fluids could be due to differences in methylation 
pattern in the target genes. Three genes namely, ZNF282, PTPRS and HPCAL1 that displayed 
differential gene expression in forensically relevant body fluids viz. blood, semen, saliva and 
vaginal fluid were selected. One CpG island within each gene was selected for primer design. 
Except for the PTPRS gene, for which two CpG islands (referred to as PTPRS 1 and PTPRS 
2) were selected for comparison of methylation patterns within a gene.  
Two methods, MSP and BS were used for methylation analysis. Primers targeting the CpG 
islands for the genes, ZNF282, PTPRS, and HPCAL1 were designed using the MethPrimer 
program (http://www.urogene.org/methprimer/). The amplicon sizes and annealing temperat- 
ures of the primers for BS and MSP are presented in Table 3.8 and Table 3.9. BiSearch is a 
primer design and search tool that used to search various genomes with primers that have been 
designed to prevent non-specific PCR products. In Appendix C, the primers that were designed 
in MethPrimer and tested in Bisearch are presented. The number of CpG sites analysed by the 
MSP and BS primer set is shown in Figure 3.1a and Figure 3.1b for ZNF282 tDMR, Figure 
3.2a and Figure 3.2b for PTPRS 1 tDMR, Figure 3.3a and Figure 3.3b for PTPRS 2 tDMR and 
Figure 3.4a and Figure 3.4b for HPCAL1 tDMR. The chromosomal location of the target CpG 
island within each gene is located in Figure 3.1c (ZNF282), Figure 3.2c (PTPRS- PTPRS 1), 
Figure 3.3c (PTPRS –PTPRS 2) and Figure 3.4c (HPCAL1). The target region amplified by the 
primers will be referred to as candidate tDMRs in the rest of the chapter, for ease of 
understanding. Table 3.7 shows the genomic information for each gene that is studied in the 
present research.  
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a) 
 
b) 
 
c) 
 
Figure 3.1: Target CpG island of ZNF282 gene for primer design a) MSP: Visual representation of the location of the 
primers designed within the CpG island (blue colored area). Two primer sets are indicated by the purple boxes (MF1- 
methylated forward primer and MR1- methylated reverse primer) and green boxes (UF1- unmethylated forward primer and 
UR1- unmethylated reverse primer). Horizontal red line indicates the input sequence and vertical red lines represent CpG 
sites. b) BS: Visual representation of the location of the primers designed out of the CpG island. Primers are indicated by 
red boxes (F1- forward primer and R1- reverse primer). c) UCSC genome browser view of chromosomal location of the 
target CpG island within the gene indicated by the green bar and the position of the CpG island in relation to the introns and 
exons indicated by the blue horizontal line and box. 
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a) 
 
b) 
 
c) 
 
Figure 3.2: Target CpG island of PTPRS (PTPRS 1) gene for primer design a) MSP: Visual representation of the location 
of the primers designed within the CpG island (blue colored area). Two primer sets are indicated by the purple boxes (MF1- 
methylated forward primer and MR1- methylated reverse primer) and green boxes (UF1- unmethylated forward primer and 
UR1- unmethylated reverse primer). Horizontal red line indicates the input sequence and vertical red lines represent CpG 
sites. b) BS: Visual representation of the location of the primers designed out of the CpG island. Primers are indicated by 
red boxes (F1- forward primer and R1- reverse primer). c) UCSC genome browser view of chromosomal location of the 
target CpG island within the gene indicated by the green bar and the position of the CpG island in relation to the introns and 
exons indicated by the blue horizontal line and box. 
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a) 
 
b) 
 
c) 
 
Figure 3.3: Target CpG island of PTPRS (PTPRS 2) gene for primer design a) MSP: Visual representation of the location of 
the primers designed within the CpG island (blue colored area). Two primer sets are indicated by the purple boxes (MF1- 
methylated forward primer and MR1- methylated reverse primer) and green boxes (UF1- unmethylated forward primer and 
UR1- unmethylated reverse primer). Horizontal red line indicates the input sequence and vertical red lines represent CpG 
sites. b) BS: Visual representation of the location of the primers designed. Primers are indicated by red boxes (F1- forward 
primer and R1- reverse primer). c) UCSC genome browser view of chromosomal location of the target CpG island within the 
gene indicated by the green bar and the position of the CpG island in relation to the introns and exons indicated by the blue 
horizontal line and box. 
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a) 
b) 
 
c) 
Figure 3.4:  Target CpG island of HPCAL1 gene for primer design a) MSP: Visual representation of the location of the primers 
designed within the CpG island (blue colored area). Two primer sets are indicated by the purple boxes (MF1- methylated 
forward primer and MR1- methylated reverse primer) and green boxes (UF1- unmethylated forward primer and UR1- 
unmethylated reverse primer). Horizontal red line indicates the input sequence and vertical red lines represent CpG sites. b) 
BS: Visual representation of the location of the primers designed. Primers are indicated by red boxes (F1- forward primer and 
R1- reverse primer). c) UCSC genome browser view of chromosomal location of the target CpG island within the gene 
indicated by by the green bar and the position of the CpG island in relation to the introns and exons indicated by the blue 
horizontal line and box. 
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Table 3.7:  Genomic information for the three genes with candidate tDMRs characterized in this study. 
  HPCAL1 PTPRS 
(PTPRS 1) 
PTPRS 
(PTPRS 2) 
ZNF282 
Chromosomal Location  2 19 19 7 
 
Genomic coordinates of gene 
(UCSC_Genome_Browser 
assembly -Human 
GRCh38/hg38) 
 
 10559217-
10560794 
5222013-
5223851 
5243370-
5244893 
148920473-
148922337 
Genomic coordinates of 
CpG island (UCSC Genome 
Browser_assembly -Human 
GRCh38/hg38) 
 
 MSP: 10419591- 
10420168 
 
BS: 10419852-
10420069 
MSP: 5222292-
5223550 
 
BS: 5222081-
5222264 
MSP: 
5243721-
5244544 
 
BS: 5244124-
5244407 
MSP: 
149223664-
149224961 
 
BS: 
149224792-
149224971 
 
CpG islands number 
 
 54 85 52 58 
Number of CpG sites  MSP: 10 
BS: 21 
MSP: 29 
BS: 5 
MSP: 17 
BS: 25 
MSP: 19 
BS: 8 
 
 
 
Table 3.8: BS primers designed for analysis of methylation in candidate tDMRs. 
tDMR  Primer Sequence Amplicon 
Size (bp) 
Annealing 
Temperature(ºC) 
ZNF282 Forward GGATTTTTTAGATTTGTTTGGTTTG 180 46 
Reverse TCCCTAATAACTTCCCCTAATAACC 
PTPRS  
1 
Forward   TGATTTTGTTTGTTTGTTTGTTTGT 184 47 
Reverse AACCTCTCTTCTACTCTCTCCCTACTC 
PTPRS  
2 
Forward TTTTTTTATTGTATAATTATGGTGGT 283 43 
Reverse ACAACCCAAATCCTATATCCTATTAC 
HPCAL1 Forward AGGGTTTTTTTAAGGATTGTTTTAT 218 45 
Reverse AACCCACTTAAACTTCTACTCCAACT 
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Table 3.10: Universal Methylated Human DNA Standard for assessment of efficiency of bisulfite conversion 
of DNA. 
---ggagtga aggaggccaCGggcaagtCG ccctgaCGcagaCGctccac cagggcCGCG CGctCGcCGt cCGccacata  
cCGctCGtag tattCGtgct cagcctCGta gtggCGcctgaCGtCGCGtt CGCGggtagc taCGatgagg CGgCGacaga 
ccaggcacag ggccccatCG ccctc 
 
 
 
 
 
 
 
Table 3.9: MSP primers designed for analysis of methylation in candidate tDMRs. 
tDMR  Primer Sequence Amplicon Size 
(bp) 
Annealing 
Temperature (ºC) 
PTPRS 1 1MF CGTACGGTTATCGTGTATTTGAC 216 49 
 2MR AACCACGTATATATTCCGACTTACG   
 3UF TGTATGGTTATTGTGTATTTGATGA 215 44 
 4UR ACCACATATATATTCCAACTTACAAC   
PTPRS 2 MF ATGTAAAGAATTAAGTCGTACGGTC 168 46 
 MR CGTAAACAACCTACTAAAAAACGAA   
 UF GTAAAGAATTAAGTTGTATGGTTGG 169 45 
 UR CACCATAAACAACCTACTAAAAAACAA   
HPCAL1 MF GTTTTGTAGGTGTAGTCGTCGTC 113 48 
 MR AACTCGTAATCGATAAACTCCGTA   
 UF GTTTTGTAGGTGTAGTTGTTGTTGT 114 43 
 UR CAACTCATAATCAATAAACTCCATA   
ZNF282 MF GGAGTGCGAGAAGATTTATAGTC 210 48 
 MR TCCTTAAACGACTCCTTATAACGAA   
 UF GGAGTGTGAGAAGATTTATAGTTGT 210 44 
 UR TCCTTAAACAACTCCTTATAACAAA   
1methylated forward, 2methylated reverse, 3unmethylated forward, 4unmethylated reverse 
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3.2.5 MSP reaction 
PCR amplification was carried out using a ZymoTaqTM DNA Polymerase Kit (Zymo Research, 
Irvine, California, United States) in a 25 µL reaction volume containing 12 µL of ZymoTaq 
PCR Buffer, 0.25 µL of dNTP mix (25 µM of each dNTP), 0.15 µM of each primer (Inqaba 
Biotec), 0.2 µL of ZymoTaq DNA Polymerase (5U/µL) and 1 µL of bisulfite converted DNA. 
A Universal Methylated Human DNA Standard (Zymo Research, Irvine, California, United 
States) was bisulfite converted using EZ DNA Methylation Gold Kit (Zymo Research, Irvine, 
California, United States) and was used as a positive control for complete conversion (Table 
3.11). The original sequence for the methylated standard is given in Table 3.11. The PCR was 
conducted in a BIORAD T100TM Thermal Cycler (Bio-Rad Laboratories, Hercules, California, 
United States) under the following conditions: 95ºC for 10 minutes, 30 cycles of 95ºC for 30 
seconds, varying annealing temperatures (Table 3.9) for 30 seconds, and 72ºC for 60 seconds 
and a final extension of 72ºC for 7 minutes. The amplified products were analysed by agarose 
gel electrophoresis using 2% agarose gel stained with 10mg/ml ethidium bromide at 60 volts 
for 60 minutes.  
3.2.6 BS protocol 
3.2.6.1 BS PCR reaction 
DNA samples (10) of the same body fluids across individuals were pooled together such that 
100 ng of DNA from each participant was included. The pooled DNA was modified by bisulfite 
treatment, following the conversion protocol PCR amplification was carried out using a 
ZymoTaqTM DNA Polymerase Kit in a 50 µL reaction volume containing 24 µL of ZymoTaq 
PCR Buffer, 0.5 µL of dNTP mix (25 µM of each dNTP), 0.15 µM of each primer (Inqaba 
Biotec) and 0.4 µL of DNA Polymerase (5U/µL) and 1 µL of bisulfite converted DNA.   The 
PCR was conducted on a BIORAD T100TM Thermal Cycler under the following conditions: 
95ºC for 10 minutes, 30 cycles of 95ºC for 30 seconds, varying annealing temperatures (Table 
3.8) for 30 seconds, and 72ºC for 60 seconds and a final extension of 72ºC for 7 minutes. An 
aliquot of the amplified products was analysed by agarose gel electrophoresis using 2% agarose 
gel stained with 10mg/ml ethidium bromide at 60 volts for 60 minutes to confirm the presence 
of the amplicon.  
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3.2.6.2 Cloning and sequencing of BS reaction products 
The remaining amplified products from the BS PCR reaction were then run on a 1% agarose 
gel and the bands were excised and purified using a Thermo scientific GeneJet Gel Extraction 
Kit according to the manufacturers protocol. The purified amplified products were ligated and 
cloned into pJET1.2 vector using the Thermo Scientific CloneJet PCR cloning Kit according 
to the manufacturers protocol. Following ligation, an aliquot of the ligation reaction was 
transformed using prepared chemically competent cells (Escherichia coli - DH5α). The 
transformed cells were then grown overnight on LB/amp plates. Between five to 10 positive 
clones were isolated from each body fluid. The plasmids were purified with the Thermo 
Scientific GeneJet Plasmid Miniprep Kit according to the manufacturers protocol. The purified 
plasmids were sent to Inqaba biotec for sequencing and this was followed by analysis on online 
software Bisulfite Sequencing DNA Methylation Analysis (BISMA) (http://services.ibc.uni-
stuttgart.de/BDPC/BISMA/). To ensure that the cloning process was efficient a positive and 
negative control was also plated on LB/amp plates. The positive control was positive samples 
from trial runs and the negative control was DH5α cells. Figure 3.5 shows the overview of the 
cloning process. 
3.2.7 Bisulfite sequencing data analysis and DNA methylation profiling  
The BISMA web application was used for analysis of bisulfite sequencing results. The 
methylation results were compiled based on the methylation status results from each body fluid 
sample. To determine the methylation levels of candidate markers in the different body fluid 
samples, sequencing data were aligned against in silico-converted genomic reference 
sequences using BISMA. The output files were compiled using Bisulfite Sequencing Data 
Presentation and Compilation (BDPC) web application (http://biochem.jacobs-university. 
de/BDPC/) to derive information and compare results from each marker in the different body 
fluid samples (Rohde et al., 2008). 
3.2.8 Statistical analysis   
To evaluate the methylation profiles of candidate tDMRs and to determine whether they could 
be used to distinguish individual body fluids, statistical analyses was carried out using the web 
application, QUantification tool for Methylation Analysis (QUMA) (http://quma.cdb.riken 
.jp/). Pairwise comparisons of methylation were made for each marker and CpG locus using 
Chi-square test or Fisher's exact test as appropriate. Differences were statistically significant 
when p-values were less than 0.05. 
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Figure 3.5: Flowchart showing the overview of the BS protocol. 
Purification of PCR products- The remaining amplified products were then run 
on a 1% agarose gel and the bands were excised and purified using a Thermo 
scientific GeneJet Gel Extraction Kit (Thermo Fisher Scientific Inc, Waltham, 
MA, USA).  
Ligation- The ligation reaction was prepared according to the blunting reaction 
using the CloneJet PCR Cloning Kit protocol (Thermo Fisher Scientific Inc, 
Waltham, MA, USA). The volume of DNA was determined based on the 
concentration of DNA after gel extraction.
Transformation- Five microlitres of the ligation product was added to 100μl of chemically competent cells 
(Escherichia coli - DH5α), followed by a 15 minutes incubation on ice, one minute incubation at 45ºC and 10 
minute incubation on ice. 750μl of Luria-Bertani (LB) Broth was added to the reaction in an eppendorf tube 
followed by one hour incubation at 37ºC with shaking. 
After incubation, spread plate technique was used to plate transformed cells on LB/amp plates  followed by 
overnight incubation at 37 ºC. 100μl of chemically competent cells used as negative control and a prior positive 
sample used as positive control. 
Between five-10 positive colonies were selected from plates and inoculated into 5ml of Luria broth (LB), 
followed by an overnight incubation at 37 ºC.
Colony PCR- To determine the presence or absence of insert DNA in plasmid. 
The colony PCR reaction was set up according to PCR section in a 10 μl volume.
Plasmid isolation- Plasmid isolation was conducted using the GeneJET plasmid 
Miniprep Kit (Thermo Fisher Scientific Inc, Waltham, MA, USA). 
Sequencing- Isolated plasmids were sequenced using Sanger sequencing
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3.3 Results 
3.3.1 Methylation profile using MSP 
From a total of 40 body fluid samples collected (10 samples each of blood, vaginal fluid, semen 
and saliva) the following results were obtained for each candidate tDMR primer set. 
3.3.1.1 ZNF282 tDMR 
Blood was methylated at target CpG sites for ZNF282 tDMR as amplification was observed 
with methylated primers in seven out of 10 samples. No amplification was observed with the 
unmethylated primers (Figure 3.6a and b). Vaginal fluid presented similar results, with 
methylation in seven samples and no unmethylation in any of the sample (Figure 3.7a and b). 
In saliva, all samples were methylated (10) and two of these samples also showed 
unmethylation (Figure 3.9a and b). Semen showed contrasting results when compared to other 
body fluids as most of the samples were unmethylated (five) and only one sample showed 
methylation (Figure 3.8a and b). The positive control (Universal Methylated Human DNA 
Standard) showed amplification at 210 bp thus confirming complete bisulfite conversion of 
genomic DNA (Figure 3.6a). In Table 3.11 is the summarized results for the ZNF282 tDMR. 
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Figure 3.6: MSP based methylation profile of blood for the ZNF282 tDMR primer set. a) Products with primers specific 
for methylated cytosine (210 bp). Lane 1 – 100 bp ladder (Thermo Scientific). Lane 2 – Lane 11- blood DNA samples. Lane 
12-  No template control. Lane 13- Universal Methylated Human DNA Standard (Zymo Research). b) Products with primers 
specific for unmethylated cytosine (210 bp). Lane 1 – 100 bp ladder (Thermo Scientific). Lane 2 – Lane 11- blood DNA 
samples. Lane 12-  No template control.  
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Figure 3.7: MSP based methylation profile of vaginal fluid for the ZNF282 tDMR primer set. a) Products with primers 
specific for methylated cytosine (210 bp). Lane 1 – 100 bp ladder (Thermo Scientific). Lane 2 – Lane 11- vaginal fluid DNA 
samples. Lane 12-  No template  control. b) Products with primers specific for unmethylated cytosine (210 bp). Lane 1 – 
100 bp ladder (Thermo Scientific). Lane 2 – Lane 11- vaginal fluid DNA samples. Lane 12-  No template control. 
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Figure 3.8: MSP based methylation profile of semen for the ZNF282 tDMR primer set. a) Products with primers specific 
for methylated cytosine (210 bp). Lane 1 – 100 bp ladder (Thermo Scientific). Lane 2 – Lane 11- semen DNA samples. 
Lane 12-  No template control. b) Products with primers specific for unmethylated cytosine (210 bp). Lane 1 – 100 bp ladder 
(Thermo Scientific). Lane 2 – Lane 11- semen DNA samples. Lane 12-  No template control.  
 
300 bp 
200 bp 
300 bp 
200 bp 
300 bp 
200 bp 
300 bp 
200 bp 
60 
 
3.3.1.2 PTPRS 1 tDMR 
For the PTPRS 1 tDMR amplification with the methylated primer set was observed in nine   
blood samples (Figure 3.10a), nine vaginal fluid samples (Figure 3.11a) and in all 10 saliva 
samples (Figure 3.13a), however, with the unmethylated primer set no amplification was seen 
for blood (Figure 3.10b), vaginal fluid (Figure 3.11b) and saliva (Figure 3.13b) in all 10 
samples in each fluid. Semen showed amplification for both methylated and unmethylated 
primer sets. Most of the samples were unmethylated (nine) with six samples also showing 
methylation (Figure 3.12a and Figure 3.12b). The positive control (Universal Methylated 
Human DNA Standard) showed amplification at 216 bp thus confirming complete bisulfite 
conversion (Figure 3.10a). In Table 3.11 is the summarized results for the PTPRS 1 tDMR. 
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Figure 3.9: MSP based methylation profile of saliva for the ZNF282 tDMR primer set. a) Products with primers specific 
for methylated cytosine (210 bp). Lane 1 – 100 bp ladder (Thermo Scientific). Lane 2 – Lane 11- saliva DNA samples. Lane 
12- No template control. b) Products with primers specific for unmethylated cytosine (210 bp). Lane 1 – 100 bp ladder 
(Thermo Scientific). Lane 2 – Lane 11- saliva DNA samples. Lane 12-  No template control. 
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Figure 3.10: MSP based methylation profile of blood for the PTPRS 1 tDMR primer set. a) Products with primers specific 
for methylated cytosine (216 bp). Lane 1 – 100 bp ladder (Thermo Scientific). Lane 2 – Lane 11- blood DNA samples. Lane 
12- No template control. Lane 13- Universal Methylated Human DNA Standard (Zymo Research). b) Products with primers 
specific for unmethylated cytosine (215 bp). Lane 1 – 100 bp ladder (Thermo Scientific). Lane 2 – Lane 11- blood DNA 
samples. Lane 12- No template control.  
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Figure 3.11:  MSP based methylation profile of vaginal fluid for the PTPRS 1 tDMR primer set. a) Products with primers 
specific for methylated cytosine (216 bp). Lane 1 – 100 bp ladder (Thermo Scientific). Lane 2 – Lane 11- vaginal fluid 
DNA samples. Lane 12- No template control. b) Products with primers specific for unmethylated cytosine (215 bp). Lane 
1 – 100 bp ladder (Thermo Scientific). Lane 2 – Lane 11- vaginal fluid DNA samples. Lane 12- No template control. 
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3.3.1.3 PTPRS 2 tDMR 
All four body fluids displayed amplification for the PTPRS 2 tDMR with methylated and 
unmethylated primers. For blood, methylation and unmethylation was observed in nine and 
nine samples, respectively (Figure 3.14a and b). Vaginal fluid displayed similar results with 
methylation and unmethylation in nine and eight samples, respectively (Figure 3.15a and b). 
Methylation was observed in semen for five samples and unmethylation in seven samples 
(Figure 3.16a and b). For saliva, methylation was observed in eight samples (Figure 3.17a), 
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Figure 3.12:  MSP based methylation profile of semen for the PTPRS 1 tDMR primer set. a) Products with primers specific 
for methylated cytosine (216 bp). Lane 1 – 100 bp ladder (Thermo Scientific). Lane 2 – Lane 11- semen DNA samples. 
Lane 12- No template control. b) Products with primers specific for unmethylated cytosine (215 bp). Lane 1 – 100 bp ladder 
(Thermo Scientific). Lane 2 – Lane 11- semen DNA samples. Lane 12- No template control. 
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Figure 3.13:  MSP based methylation profile of saliva for the PTPRS 1 tDMR primer set. a) Products with primers specific 
for methylated cytosine (216 bp). Lane 1 – 100 bp ladder (Thermo Scientific). Lane 2 – Lane 11- saliva DNA samples. Lane 
12- No template control. b) Products with primers specific for unmethylated cytosine (215 bp). Lane 1 – 100 bp ladder 
(Thermo Scientific). Lane 2 – Lane 11- saliva DNA samples. Lane 12- No template control. 
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however five samples with unmethylated primers showed amplification (Figure 3.17b). 
Complete bisulfite conversion was confirmed with the positive control (Universal Methylated 
Human DNA Standard) showing amplification at 168 bp (Figure 3.14a). In Table 3.11 is the 
summarized results for the PTPRS 2 tDMR. 
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Figure 3.14: MSP based methylation profile of blood for the PTPRS 2 tDMR primer set. a) Products with primers specific 
for methylated cytosine (168 bp). Lane 1 – 100 bp ladder (Thermo Scientific). Lane 2 – Lane 11- blood DNA samples. Lane 
12-  No template control. Lane 13- Universal Methylated Human DNA Standard (Zymo Research) b) Products with primers 
specific for unmethylated cytosine (169 bp). Lane 1 – 100 bp ladder (Thermo Scientific). Lane 2 – Lane 11- blood DNA 
samples. Lane 12-  No template control. 
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Figure 3.15: MSP based methylation profile of vaginal fluid for the PTPRS 2 tDMR primer set. a) Products with primers 
specific for methylated cytosine (168 bp). Lane 1 – 100 bp ladder (Thermo Scientific). Lane 2 – Lane 11- vaginal fluid 
DNA samples. Lane 12-  No template control. b) Products with primers specific for unmethylated cytosine (169 bp). Lane 
1 – 100 bp ladder (Thermo Scientific). Lane 2 – Lane 11- vaginal fluid DNA samples. Lane 12-  No template control. 
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  3.3.1.4 HPCAL1 tDMR 
Blood was methylated at target CpG sites for HPCAL1 tDMR as amplification was observed 
for all 10 samples (Figure 3.18a) and non-specific was observed in two samples and absence 
of amplification in eight samples with unmethylated primers (Figure 3.18b).   For vaginal fluid, 
nine samples showed methylation (Figure 3.19a) and non-specific amplification was observed 
in two samples and eight sample did not amplify with unmethylated primers (Figure 3.19b). 
For semen, methylation was observed for eight samples (Figure 3.20a) and only two samples 
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Figure 3.16: MSP based methylation profile of semen for the PTPRS 2 tDMR primer set. a) Products with primers specific 
for methylated cytosine (168 bp). Lane 1 – 100 bp ladder (Thermo Scientific). Lane 2 – Lane 11- semen DNA samples. 
Lane 12-  No template control. b) Products with primers specific for unmethylated cytosine (169 bp). Lane 1 – 100 bp ladder 
(Thermo Scientific). Lane 2 – Lane 11- semen DNA samples. Lane 12-  No template control. 
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Figure 3.17: MSP based methylation profile of saliva for the PTPRS 2 tDMR primer set. a) Products with primers specific 
for methylated cytosine (168 bp). Lane 1 – 100 bp ladder (Thermo Scientific). Lane 2 – Lane 11- saliva DNA samples. Lane 
12-  No template control. b) Products with primers specific for unmethylated cytosine (169 bp). Lane 1 – 100 bp ladder 
(Thermo Scientific). Lane 2 – Lane 11- saliva DNA samples. Lane 12- No template control.  
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displayed unmethylation (Figure 3.20b). All 10 saliva samples did not produce consistent 
amplification with methylation primers (Figure 3.21a). However, all 10 saliva samples 
displayed unmethylation (Figure 3.21b). The positive control (Universal Methylated Human 
DNA Standard) confirmed complete bisulfite conversion with amplification at 113 bp (Figure 
3.18a). In Table 3.11 is the summarized results for the HPCAL1 tDMR. 
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Figure 3.18: MSP based methylation profile of blood for the HPCAL1 tDMR primer set. a) Products with primers specific 
for methylated cytosine (113 bp). Lane 1 – 100 bp ladder (Thermo Scientific). Lane 2 – Lane 11- blood DNA samples. Lane 
12- No template control. Lane 13- Universal Methylated Human DNA Standard (Zymo Research). b) Products with primers 
specific for unmethylated cytosine (114 bp). Lane 1 – 100 bp ladder (Thermo Scientific). Lane 2 – Lane 11- blood DNA 
samples. Lane 12- No template control. 
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Figure 3.19: MSP based methylation profile of vaginal fluid for the HPCAL1 tDMR primer set. a) Products with primers 
specific for methylated cytosine (113 bp). Lane 1 – 100 bp ladder (Thermo Scientific). Lane 2 – Lane 11- vaginal fluid DNA 
samples. Lane 12- No template control. b) Products with primers specific for unmethylated cytosine (114 bp). Lane 1 – 100 
bp ladder (Thermo Scientific). Lane 2 – Lane 11- vaginal fluid DNA samples. Lane 12- No template control. 
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Figure 3.20: MSP based methylation profile of semen for the HPCAL1 tDMR primer set. a) Products with primers specific 
for methylated cytosine (113 bp). Lane 1 – 100 bp ladder (Thermo Scientific). Lane 2 – Lane 11- semen DNA samples. 
Lane 12- No template control. b) Products with primers specific for unmethylated cytosine (114 bp). Lane 1 – 100 bp ladder 
(Thermo Scientific). Lane 2 – Lane 11- semen DNA samples. Lane 12- No template control. 
                                       1           2             3               4            5             6            7             8            9            10         11         12       
a)     
b)    
  
 
Figure 3.21: MSP based methylation profile of saliva for the HPCAL1 tDMR primer set. a) Products with primers specific 
for methylated cytosine (113 bp). Lane 1 – 100 bp ladder (Thermo Scientific). Lane 2 – Lane 11- saliva DNA samples. Lane 
12- No template control. b) Products with primers specific for unmethylated cytosine (114 bp). Lane 1 – 100 bp ladder 
(Thermo Scientific). Lane 2 – Lane 11- saliva DNA samples. Lane 12- No template control. 
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Table 3.11: Summary of results for all four candidate tDMRs using MSP. 
   Methylated primer set Unmethylated primer set 
tDMR  No. of 
samples 
Methylated Not 
amplified 
Unmethylated Not 
amplified 
ZNF282 Blood 10 7 3 0 10 
Vaginal 
fluid 
10 7 3 0 10 
Semen 10 1 9 5 5 
Saliva 10 10 0 2 8 
PTPRS 1 Blood 10 9 1 0 10 
Vaginal 
fluid 
10 9 1 0 10 
Semen 10 6 4 9 1 
Saliva  10 10 0 0 10 
PTPRS 2 Blood 10 9 1 9 1 
Vaginal 
fluid 
10 9 1 8 2 
Semen 10 5 5 7 3 
Saliva 10 8 2 5 5 
HPCAL1 Blood 10 10 0 2_(non-specific) 8 
Vaginal 
fluid 
10 9 1 2_(non-specific) 8 
Semen 10 8 2 2 8 
Saliva  10 2_(non-
specific) 
8 10 0 
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3.3.2 Methylation profiling using BS 
A total of 10 DNA samples of each body fluid were pooled for BS analysis. A study by Byun 
et al. (2009) demonstrated that DNA methylation profiles are similar between the same tissue 
from different individuals rather than different tissue of the same individual. Thus, DNA was 
pooled to obtain an estimation of the average methylation levels. The following results were 
obtained for each candidate tDMR using the BS analysis. The BISMA methylation analysis 
program was used to establish DNA methylation profiles and analyse BS sequencing data. The 
Chi-square and Fisher’s exact tests were used for statistical analysis and was carried out in the 
QUMA program.  
3.3.2.1 Methylation profiles of body fluid using the ZNF282 tDMR 
The ZNF282 tDMR primer set targeted eight CpG sites. A total of 40 clones were sent for 
sequencing (10 clones for each body fluid), however only 33 clones could be analysed as these 
clones met the criteria of BISMA program which is a threshold sequence identity percentage 
of 90% or above. Overall hypermethylation (95%) was displayed in all clones for blood, with 
three clones (f, g and h) showing unmethylation (5%) at CpG 7, CpG 8 and CpG 3, respectively 
(Figure 3.22). For saliva, hypermethylation (98%) was displayed in all clones, with one clone 
(h) showing unmethylation at CpG 8 (Figure 3.22). In vaginal fluid, hypermethylation (97%) 
was observed, with two clones (e and h) showing an unexpected cytosine nucleotide at CpG 2 
and unmethylation and CpG 6, respectively (Figure 3.22). Conversely, in semen for the 
ZNF282 tDMR, hypomethylation (99%)was observed, with one clone (a) showing methylation 
(1%) at CpG 4 (Figure 3.22). In Table 3.12 is the summarized results for the ZNF282 tDMR. 
Statistical analysis showed that methylation patterns between semen and all other body fluids 
(blood, vaginal fluid and saliva) were significantly different (p < 0.05) (Table 3.13). 
Methylation patterns at individual CpG sites were also significantly different (p < 0.05) 
(Appendix D: Table 1-8) at all eight CpG sites for semen compared to all other body fluids for 
the ZNF282 tDMR. 
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Figure 3.22: Body fluid specific methylation of the ZNF282 tDMR. Each row indicates a single clone of bisulfite PCR 
products and each column indicates individual CpG site in the region of interest. Different methylation states of the CpG sites 
are indicated by colours (blue represents unmethylated; red represents methylated; white represents unknown). 
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Table 3.12: Overview of bisulfite sequencing results for body fluids analysed using BISMA for the ZNF282 
tDMR. 
Body Fluid Number_of  clones 
sequenced 
Overall 
Methylation (%) 
Overall 
Unmethylation (%) 
Unknown 
CpG sites (%) 
Blood 8 95 5 0 
Saliva 8 98 2 0 
Semen 9 1 99 0 
Vaginal fluid 8 97 1.5 1.5 
 
 
3.3.2.2 Methylation profiles of body fluids using the PTPRS 1 tDMR 
The PTPRS 1 tDMR primer set targeted five CpG sites. A total of 40 clones were sent for 
sequencing (10 clones for each body fluid), however only 14 clones were analysed for all body 
fluids using the BISMA program. The threshold sequence identity percentage was 90%, thus 
the clones that were not analysed were below the threshold. All saliva and vaginal fluid clones 
displayed 100% methylation (completely methylated) (Figure 3.23). For blood, 
hypermethylation (80%) was observed and one clone (b) displayed unmethylation (20%) at 
CpG 1 and CpG 2 (Figure 3.23). For semen, hypermethylation (93%) was observed with two 
clones (e and f) displaying unmethylation (7%) at CpG 1 and CpG 2 respectively (Figure 3.23). 
In Table 3.14 is the summarized results for the PTPRS 1 tDMR.Statistical analysis showed that 
methylation patterns between blood, vaginal fluid, semen and saliva were not significantly 
different from each other (p > 0.05) (Table 3.15) and that methylation patterns at individual 
CpG sites were not significantly different (p > 0.05) (Appendix E: Table 1-5) for the PTPRS 1 
tDMR.  
Table 3.13: Pairwise comparison of total DNA methylation for ZNF282 tDMR in blood, saliva, semen and 
vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below.  
 Blood Saliva Semen Vaginal fluid 
Blood 1    
Saliva 0.3380 1   
Semen 0.0000 0.0000 1  
Vaginal fluid  0.6182 1.0000 0.0000 1 
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Figure 3.23:   Body fluid specific methylation of the PTPRS 1 tDMR. Each row indicates a single clone of bisulfite PCR 
products and each column indicates individual CpG site in the region of interest. Different methylation states of the CpG sites 
are indicated by colours (blue represents unmethylated; red represents methylated; white represents unknown). 
CpG sites 
C
lo
n
e
s 
CpG sites 
C
lo
n
e
s 
CpG sites 
C
lo
n
e
s 
CpG sites 
C
lo
n
e
s 
a 
 
b  
a 
 
b 
 
c 
  
a 
 
b 
 
c 
 
d 
 
e 
 
f 
a 
 
b 
 
c 
  
72 
 
Table 3.14: Overview of bisulfite sequencing results for body fluids analysed using BISMA for the PTPRS 1 
tDMR. 
Body Fluid Number of  clones 
sequenced 
Overall 
Methylation (%) 
Overall 
Unmethylation (%) 
CpG sites 
unknown (%) 
Blood 2 80 20 0 
Saliva 3 100 0 0 
Semen 6 93 7 0 
Vaginal fluid 3 100 0 0 
 
Table 3.15: Pairwise comparison of total DNA methylation for PTPRS 1 tDMR in blood, saliva, semen and 
vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 Blood Saliva Semen Vaginal fluid 
Blood 1    
Saliva 0.4000 1   
Semen 0.2860 1.0000 1  
Vaginal fluid  0.4000 1.0000 0.5000 1 
 
3.3.2.3 Methylation profiles of body fluid using the PTPRS 2 tDMR 
The PTPRS 2 tDMR primer set targeted 25 CpG sites. A total of 20 clones were sent for 
sequencing (five clones for each body fluid), however only 14 clones were analysed for all 
body fluids using the BISMA program. The threshold sequence identity percentage was 90%, 
thus the clones that were not analysed were below the threshold. In blood, hypermethylation 
(96%) was observed in all clones, however one clone (b) displayed a cytosine nucleotide at an 
unexpected position in CpG 3 and unmethylated at CpG 4 (Figure 3.24). In all clones for saliva, 
hypermethylation (98%) was displayed and two clones (b and d) showed an unexpected 
cytosine at CpG 3 and an unmethylation at CpG 23 (Figure 3.24). Semen displayed 
hypermethylation (71%) with one clone (b) showing an unexpected cytosine at CpG 4 and 
unmethylation at CpG 21 (Figure 3.24). In clone c in semen for PTPRS 2 tDMR, CpG 1-15, 
17, 18, 21-23 all displayed unmethylation. In vaginal fluid, hypermethylation (95%) was 
observed in all clones, with clones (a, d and e) displaying an unexpected cytosine at CpG 6- 
CpG 8 and two other clones displaying unmethylation at CpG 4, CpG 10 and CpG 22, 
respectively. In Table 3.16 is the summarized results for the PTPRS 2 tDMR.Statistical analysis 
showed that methylation patterns between blood, vaginal fluid, semen and saliva were not 
statistically different from each other (p > 0.05) (Table 3.17) and that methylation patterns at 
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individual CpG sites were not significantly different (p > 0.05) (Appendix F: Table 1-25) for 
the PTPRS 2 tDMR 
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Figure 3.24: Body fluid specific methylation of the PTPRS 2 tDMR.  Each row indicates a single clone of bisulfite PCR 
products and each column indicates individual CpG site in the region of interest. Different methylation states of the CpG sites 
are indicated by colours (blue represents unmethylated; red represents methylated; white represents unknown). 
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Table 3.16: Overview of bisulfite sequencing results for body fluids analysed using BISMA for the PTPRS 2 
tDMR. 
Body Fluid Number of  clones 
sequenced 
Overall 
Methylation (%) 
Overall 
Unmethylation (%) 
CpG sites 
unknown (%) 
Blood 2 96 2 2 
Saliva 4 98 1 1 
Semen 3 71 28 1 
Vaginal fluid 5 95 2.5 2.5 
 
Table 3.17: Pairwise comparison of total DNA methylation for PTPRS 2 tDMR in blood, saliva, semen and 
vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 Blood Saliva Semen Vaginal fluid 
Blood 1    
Saliva 0.6000 1   
Semen 1.0000 0.4860 1  
Vaginal fluid  0.7140 1.0000 0.5710 1 
 
3.3.2.4 Methylation profiles of body fluid using the HPCAL1 tDMR 
There were no sequencing results obtained for the HPCAL1 tDMR as non-specific 
amplification was observed for bisulfite PCR in all body fluids. The gel results for bisulfite are 
shown in Appendix G. 
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3.4 Discussion 
Analysis of methylation status at tDMRs is emerging as a promising method of body fluid 
identification in forensics. However, so far a limited number of tDMR based markers have 
been verified (Fu et al., 2015).  The aim of the present study was to analyse differential DNA 
methylation in candidate tDMRs for identification of four forensically relevant body fluids: 
blood, saliva, semen and vaginal fluid. The analysis of these tDMRs will lead to development 
of novel DNA methylation markers for forensic purposes.   
The candidate genes were selected from a previous study (Kader, 2015, MSc Genetics 
dissertation) based on differential gene expression in blood, saliva, semen and vaginal fluid. 
Genes overexpressed in the target body fluids were identified from Tissue–specific Gene 
Expression and Regulation (TiGER) database (Appendix H: Figure 1-3) and gene body CpG 
islands, spanning an exon/intron region were selected for methylation analysis. It was proposed 
that differential gene expression could be associated with differential methylation. Several 
studies have provided evidence of correlation between DNA methylation and gene expression 
(Kulis et al., 2013; Schilling and Rehli, 2007). Differential expression of genes in different 
tissues may be regulated by DNA methylation. While promoter hypermethylation is associated 
with gene repression, gene body methylation is more prevalent and is associated with increased 
gene expression (Jones, 2012). It has been proposed that gene body methylation possibly 
inhibits spurious intragenic transcription which slows efficient transcriptional elongation 
(Wierstra, 2008). The relationship between gene body methylation and gene expression has 
been described as non-monotonic and bell-shaped (Jjingo et al., 2012). This means that genes 
that are highly or lowly expressed have a low level of gene body methylation and genes that 
are mid-level expressed have the highest level of gene body methylation (Jjingo et al., 2012). 
Tissue-specific methylation occurs largely within CpG islands found in gene bodies and CpG 
island shores (Davies et al., 2012; Deaton et al., 2011; Irizarry et al., 2009; Maunakea et al., 
2010).   
As gene expression information was available for blood but not for saliva, semen and vaginal 
fluid, surrogate tissues representative of each body fluid of interest were chosen. The criteria 
for selection of surrogate tissue was: 1) it must have expression data associated with it, 2) it 
should be the main source of the fluid component in question. Hence, cervix was selected as 
the surrogate tissue for vaginal fluid and prostate and testis were selected as surrogate tissue 
for semen. Genes which were specifically up regulated in the tissue of interest were chosen. 
76 
 
The ZNF282 gene showed overexpression in cervix, with median expression in blood, low 
expression in prostate but no expression in testis (Appendix H: Figure 1).  The PTPRS gene 
showed higher expression in prostate, median expression in blood, low expression in testis and 
no expression in cervix (Appendix H: Figure 2). The HPCAL1 gene was overexpressed in 
cervix, median expression in testis and blood, and low expression in prostate (Appendix H: 
Figure 3). No expression information was available for salivary glands at TiGER database, 
however, differential expression in any one fluid in comparison to other was considered 
adequate to select the genes. 
In this study, it was proposed that the candidate tDMRs for genes ZNF282, PTPRS and 
HPCAL1 would successfully differentiate between blood, saliva, semen and vaginal fluid. 
Hence, they were selected for methylation analysis by BS and MSP. To the best of our 
knowledge these candidate tDMRs have not been previously reported.  
3.4.1 Methylation profiling of candidate tDMRs by MSP and BS 
A MSP was designed to differentiate between methylated and unmethylated cytosines in four 
candidate tDMRs in genes, ZNF282, PTPRS and HPCAL1. MSP is a cost effective technique 
that enables detection of methylation in small quantities of DNA and allows detection of 
methylation and unmethylation simultaneously of a single sample (Esteller et al., 1999; 
Herman et al., 1996). DNA is first denatured to create single-stranded DNA and then modified 
with sodium bisulfite followed by PCR amplification using two pairs of primers, with one pair 
specific for methylated DNA and the other unmethylated DNA. Primer design for both MSP 
and BS is important for efficient analysis of methylation patterns. For maximum discrimination 
between methylated and unmethylated sites, MSP primers contain a minimum of one CpG site 
at the 3’ end as well as many CpG sites within the primer sequences (Li and Dahiya, 2002).   
However, as MSP is a qualitative method, therefore, BS was used for further validation to 
confirm and quantify body fluid specific differential DNA methylation of the candidate tDMRs 
used in the present study. BS is the gold standard method of methylation analysis because it is 
a quantitative method which provides detailed information on the methylation status of 
individual CpG sites for the region of interest (Huang et al., 2013a). The sodium bisulfite 
modified DNA is PCR amplified using primers that are specific for the modified DNA but do 
not contain any CpG sites in their sequence. The resulting PCR product is sequenced directly 
or after cloning (Li and Dahiya, 2002).  
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3.4.1.1 ZNF282 tDMR 
With MSP analysis, the ZNF282 tDMR was successful in differentiating semen from blood, 
saliva and vaginal fluid because of the hypomethylation pattern observed in semen and 
hypermethylation pattern observed in all other body fluids examined. Observation of 
amplification by unmethylated primers in semen and amplification by methylated primers in 
all other body fluid indicates that all eight CpG sites in semen were hypomethylated and all 
CpG sites in all other body fluids were hypermethylated. 
BS analysis confirmed the results that were obtained by MSP. Semen showed hypomethylation 
in all clones (nine) sequenced and all other body fluids showed hypermethylation pattern. 
Statistical analysis showed that there was no difference observed between all clones for each 
body fluid (p > 0.05). Based on the methylation data, the statistical analysis indicated that 
blood, saliva and vaginal fluid were not significantly different form each other however, semen 
differed from all other body fluids (p < 0.05) at each of the eight CpG sites as well as for overall 
methylation. Thus, ZNF282 tDMR can be successfully used as a novel semen-specific 
hypomethylation marker. 
Previous studies have also reported semen-specific hypomethylation markers, such as, 
cg22407458 (Forat et al., 2016), PRMT (Lee et al., 2012), ZC3H12D (Madi et al., 2012), 
cg04382920 (SEU1) and cg11768416 (SEU2) (Vidaki et al., 2016). A study by Lee et al. 
(2012) used MSP and BS analysis to identify tDMRs in two genes DACT1 and USP49 which 
were able to differentiate semen from blood, saliva, menstrual blood and vaginal fluid.  
3.4.1.2 PTPRS 1 and PTPRS 2 tDMRs 
 Two CpG islands were targeted in the PTPRS gene and were referred to as PTPRS 1 and 
PTPRS 2 tDMR. The PTPRS 1 tDMR differentiated semen from blood, vaginal fluid and saliva 
by MSP analysis because both hypermethylation and hypomethylation was observed in semen 
and only hypermethylation was seen in all other body fluids. Observation of amplification by 
both methylated and unmethylated primers indicated that some target CpG sites were 
methylated and some were unmethylated. Presence of both methylation and unmethylation at 
the same site could be due to allele-specific methylation which arises from parental alleles 
having different methylation patterns (Meaburn et al., 2010; Shoemaker et al., 2010). Previous 
studies have identified semen-specific hypermethylated markers cg05261336 (Lin et al., 2016) 
and cg17610929 (gene ACCN4) and cg23521140 (gene ACCN4) (Park et al., 2014) and 
cg17621389 and cg26763284 (Lee et al., 2015) and hypomethylated markers mentioned above. 
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The PTPRS 2 tDMR displayed both hypermethylation and hypomethylation patterns for all 
body fluids. This result is a reflection on heterogeneity of methylation and cell types within a 
tissue (Song et al., 2005). Therefore, PTPRS 2 tDMR was unable to differentiate between body 
fluids as no unique methylation pattern in any one body fluid was observed.  
Based on the result of the MSP study, it was expected that the PTPRS 1 tDMR would be able 
to distinguish semen from all other body fluids and that PTPRS 2 tDMR would not differentiate 
between body fluids. However, BS analysis did not show any significant difference in overall 
methylation for both PTPRS 1 and PTPRS 2 tDMRs as well as at individual CpG sites (five 
and 25, respectively) (p > 0.05). There was no significant difference observed between all 
clones for each body fluid (p > 0.05) for both tDMRs. A probable explanation for no 
differentiation between all body fluids for PTPRS 1 tDMR could be because only a few clones 
met the sequence identity threshold (90%) set by BISMA analysis tool. Therefore, analyzing 
more clones could result in confirmation of methylation differences between body fluids. 
Though MSP indicates PTPRS 1 tDMR to be a semen-specific marker, further evaluation using 
more clones is required.  
3.4.1.3 HPCAL1 tDMR 
The HPCAL1 candidate tDMR displayed hypermethylation in blood, semen and vaginal fluid, 
conversely saliva samples displayed hypomethylation at the target CpG sites.  Thus, the tDMR 
could be a candidate saliva-specific hypomethylation marker. Previous studies have identified 
saliva-specific hypermethylation markers: cg21597595 (named Spei1) (Forat et al., 2016), 
cg09652652-2d (Lee et al., 2015), cg09107912 (gene FNDC1) and cg16732616 (gene 
DMRTA2) (Lin et al., 2016), BCAS4 (Madi et al., 2012) and cg26107890 (gene SLC12A8) and 
cg20691722 (gene SOX2OT) (Park et al., 2014). However, the previously reported markers 
just targeted one CpG site while HPCAL1 tDMR targets 10 CpG sites, thus confirming more 
reliability. 
The HPCAL1 tDMR could not be further analysed using BS due to non-specific amplification 
that was consistently observed in PCR reactions. During PCR amplification of bisulfite 
converted DNA, all cytosine nucleotides that are not methylated are converted to thymine 
nucleotides, thus the DNA sequence predominantly consists of adenine, guanine and thymine 
(approximately 50%). Therefore, non-specific amplification and low specificity of 
hybridization with primers may be due to polymerase slippage because DNA sequences are 
adenine and thymine rich (Arányi et al., 2006; Tusnády et al., 2005).  
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3.5. Conclusions 
The present study analysed methylation profiles of four candidate tDMRs in genes ZNF282, 
PTPRS (PTPRS 1 and PTPRS 2 tDMRs) and HPCAL1. The objective was to target the 
identified tDMRs to design PCR primers for efficient identification of semen, saliva, blood and 
vaginal fluid by MSP and BS. Among the tDMRs examined using MSP, ZNF282 tDMR and 
PTPRS 1 tDMR showed potential to be used as semen-specific markers and HPCAL1 as a 
saliva-specific marker. Since MSP is a qualitative method, BS was used for further validation 
to quantify and confirm body fluid specific differential DNA methylation of the candidate 
tDMR markers. BS results confirmed that the ZNF282 tDMR showed semen-specific 
differential DNA methylation from all other body fluids and can be used as a biomarker in 
forensic applications. However, PTPRS 1 and HPCAL 1 tDMR require further evaluation using 
a bigger sample size and sequencing of more clones. Future research will involve tissue-
specific DNA methylation profiling to identify and validate more markers for blood, saliva, 
semen and vaginal fluid. Furthermore, the development of multiplex methods to analyse body 
fluids with numerous markers in one reaction (Vidaki et al., 2016). In addition, multiplexing 
reduces the time and amount of starting DNA required which is important in a forensics setting 
where DNA is either scarce or degraded (Lee et al., 2015).  Further investigation on the 
sensitivity of methods and stability of candidate tDMRs methylation profiles used for 
differentiation between body fluids is necessary to allow efficient use for forensic purposes.  
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Chapter 4 
Analysis of the sensitivity and 
stability of methylation profiles of 
tDMR markers for human body fluid 
identification 
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Abstract  
The use of tissue-specific differentially methylated regions (tDMRs) is emerging as a 
promising method for body fluid identification. In the previous chapter, methylation specific 
PCR (MSP) and bisulfite sequencing (BS) was used to validate differential methylation in 
candidate tDMRs for identification of blood, saliva, semen and vaginal fluid. The ZNF282 
tDMR was selected as a suitable marker for semen identification based on consistent 
hypomethylation patterns with both MSP and BS analysis. However, to allow successful use 
of methylation markers the stability of their methylation profile needs to be tested under 
environmental conditions found commonly at crime scenes and the detection limit of 
methylation methods should also be evaluated. Thus, the present study was undertaken to 
determine the sensitivity of methylation analysis methods and to analyse the stability of 
methylation profile of ZNF282 tDMR marker under forensic simulation conditions. For the 
sensitivity test, DNA from blood was five-fold serially diluted from 25 ng to 1 ng and tested 
by MSP.  DNA concentrations greater than 10 ng provided reliable detection. For the stability 
study blood was deposited on a piece of cloth and saliva, semen and vaginal fluid were 
deposited on cotton swabs and kept at room temperature, wet in an exsiccator, outside on the 
ground, sprayed with alcohol and bleach for 50 days and compared to samples that were not 
exposed to any environmental conditions (0 days). Semen displayed maximum DNA 
degradation under all conditions and vaginal fluid was most stable. Blood, saliva and semen 
provided results only for outside on the ground. Blood, saliva, semen and vaginal fluid provided 
results for outside on the ground condition. Overall a decrease in methylation level was 
observed for all body fluids, except, semen. However, saliva and semen displayed a significant 
difference (p < 0.05) in methylation level for outside on the ground. Vaginal fluid provided 
results in all conditions (at room temperature, wet in an exsiccator, outside on the ground, 
sprayed with alcohol and bleach). No significant change in methylation profile of ZNF282 
tDMR marker was observed after 50 days under simulated conditions. Thus, ZNF282 tDMR 
maintained differential methylation profile under environmental insults and can be used as a 
novel marker for semen identification. Future studies will include analysis of methylation 
levels of methylation markers under diverse simulated conditions and for different human 
ethnic groups. 
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4.1 Introduction 
In forensic investigations, genetic fingerprinting is an efficient method used to identify 
suspects, however, analysis of biological material that is found at crime scenes can be used to 
determine the course of events that have occurred as well as link the evidence found to the 
crime committed (An et al., 2013; Choi et al., 2014; Lee et al., 2012; Ma et al., 2013).  Most 
times there is very little biological material found at a crime scene and identifying the biological 
material in a non-destructive manner is essential for further analysis (Kader and Ghai, 2015). 
Additionally, challenges arise when body fluids are exposed to various environmental 
conditions which affect the stability and integrity of the DNA.  
The most common forensically relevant body fluids found at crime scenes are: blood, saliva, 
semen and vaginal fluid. The composition of each fluid is unique, hence, current methods 
identify body fluids based on the components of each body fluid. The main components of 
human body fluids such as, blood, saliva, semen and vaginal fluid are shown in Table 4.1 
(Gaensslen, 1983; Greenfield and Sloan, 2003; Virkler and Lednev, 2009).  There are several 
components that are common in more than one body fluid, however the difference in 
contribution of the component makes tests effective. For example, amylase is present in a large 
quantity in saliva compared to smaller quantities in semen and vaginal fluid. Other examples 
are, the difference in the ratio of citrate to lactate present in semen and vaginal fluid. Urea is a 
major component in urine but it is also found in semen and sweat, however, it is used to identify 
urine due to the high concentration in urine (Virkler and Lednev, 2009). Thus, using DNA 
molecules as an alternate source of identification for body fluids will be beneficial since it is a 
stable molecule.  
Analysis of DNA is a standard forensic method for investigating and solving various criminal 
cases. In majority of cases a limited amount of biological material is found and/or DNA that is 
highly degraded resulting in fragmented DNA (Lee et al., 2013). Current methods that are used 
for identification of biological material require DNA that is intact and of good quality (Diegoli 
et al., 2012). Extracting essential information is a difficult task especially when the samples 
have been damaged (Alvarez-Cubero et al., 2012). Thus, it is important that the methods used 
to identify body fluids are definitive, regardless of the factors that may affect the stability of 
the DNA. The successful recovery of DNA and the extent to which the DNA is degraded 
depends on two main factors, time and environmental conditions (Fondevila et al., 2008). A 
study by Raymond et al. (2009) showed that environmental influences have a greater effect on 
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DNA degradation in comparison to the time of exposure. Environmental influences such as 
temperature, humidity, pH and soil chemistry could modify the rate of degradation (Burger et 
al., 1999; Fondevila et al., 2008; Forat et al., 2016; Hall and Ballantyne, 2004).  
Table 4.1: Composition of human body fluids (Altman and Katz, 1961; Li, 2008; Spinrad, 1994). 
Blood  Saliva  Semen  Vaginal fluid  
-Hemoglobin 
-Fibrinogen 
-Erythrocytes 
-Albumin 
-Glucose 
-Immunoglobulins 
-Amylase  
-Lysozyme 
-Mucin 
-Buccal epithelial cells 
-Thiocyanate 
-Potassium 
-Bicarbonate 
-Phosphorus 
-Glucose 
-Immunoglobulins 
-Acid phosphatase 
-Prostate-specific antigen 
-Spermatozoa 
-Choline 
-Spermine 
Semenogelin 
-Zinc 
-Citric acid 
-Lactic acid 
-Fructose 
-Urea 
-Ascorbic acid 
-Immunoglobulins 
-Acid phosphatase 
-Lactic acid 
-Citric acid 
-Urea 
-Vaginal peptidase 
-Glycogenated epithelial 
cells 
-Acetic acid 
-Pyridine 
-Squalene 
-Immunoglobulins 
 
Forensic biological material that are exposed to various physical, biochemical and 
microbiological factors at crime sites, degrade or destroy the biological components that are 
used for body fluid or tissue identification (Forat et al., 2016). DNA molecules exposed to high 
temperatures results in a faster degradation rate and low temperatures result in reduction of the 
rate of degradation (Höss et al., 1996; Willerslev et al., 2004). At high temperatures, the 
presence of microorganisms are greater and chemical reactions are sped up. Also, high 
temperature and humidity levels increase the effects of UV radiation on DNA damage (Foran, 
2006). Dry environments decrease the rate of degradation, however, the presence of water 
would increase the rate of degradation as moisture encourages the growth of bacteria and also 
provides the substrate with hydrolytic enzymes (Gill-King, 1997). Furthermore, in dry 
conditions the hydrolytic and oxidative damage of DNA is decreased. The presence of 
microorganisms as well as their metabolites can lead to the complete degradation of DNA 
(Burger et al., 1999). An environment that has a pH that is low results in DNA as well as 
protective matter (bone and teeth) being destroyed (Burger et al., 1999).  A study by Ambers 
et al. (2014) and Raymond et al. (2009) found that DNA recovery of samples left in outside 
surfaces decreased significantly overtime, whereas if samples are found in a cool and dark, low 
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traffic environment or dry state that DNA recovery is stable. Thus, environmental conditions 
play a role in the quality and quantity of DNA recovered from body fluids.  
Identification of tissue-specific differentially methylated regions (tDMRs) markers seems to 
be a beneficial method for the identification of body fluids due to high specificity and 
sensitivity and its compatibility with short tandem repeat (STR) typing. Forensic researchers 
have been putting in an effort to identify and develop new tDMR markers for identification of 
body fluids. Even though DNA is stable when exposed to exogenous conditions, very little is 
known about the stability of DNA that is methylated. Hence, determining the stability of 
methylation profiles of tDMRs for human body fluids requires further research. Development 
of novel tDMR markers for accurate and reliable identification and differentiation of human 
body fluids is essential. In the present chapter, the sensitivity of four tDMRs (ZNF282, PTPRS 
1, PTPRS 2 and HPCAL1) were analysed and the stability of the ZNF282 tDMR was analysed 
under simulated forensic conditions. In the previous study, the ZNF282 tDMR was validated 
as a semen-specific hypomethylation marker by both methylation specific PCR (MSP) and 
bisulfite sequencing (BS). The other tDMRs (PTPRS 1, PTPRS 2 and HPCAL1) were not 
found to be specific to a single body fluid. To ensure the efficacy of these tDMR markers, the 
present study was performed to determine the sensitivity and stability of using tDMRs for 
identification of human body fluids and its applicability in forensic casework.  
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4.2 Materials and methods 
4.2.1 Ethics approval 
The study was conducted according to the methods specified by the Biomedical Research 
Ethics Committee (BREC) at the University of KwaZulu-Natal. The BREC reference number 
is BE187/16 (sub-study of BE221/14). Samples were collected from volunteers after a written 
consent was signed and a questionnaire answered by each participant (Appendix A). 
4.2.2 Sample collection, storage of samples and DNA extraction 
Whole blood was collected in 4 ml EDTA tubes from 20 volunteers at Lab 24 laboratory, 
Mount Edgecombe, Durban. Blood samples were collected and transported to the Genetics 
Laboratory in ice boxes with frozen ice packs. Vaginal fluid was collected from 20 volunteers 
at the King Dinizulu Hospital, Durban using sterile cotton swabs (Dry Swab, Lasec). Semen 
and saliva samples were collected from 10 volunteers. Freshly ejaculated semen was collected 
in plastic cups from volunteers at the King Dinizulu Hospital and University of KwaZulu-
Natal, Westville campus. Saliva was collected from University of KwaZulu-Natal, Westville 
in 50 mL microcentrifuge tubes.  
DNA was extracted from blood, saliva, semen and vaginal fluid using Quick-gDNA MiniPrep 
kit (Zymo Research, Irvine, California, United States) according to manufacturer’s instructions. 
Extracted DNA was quantified using a NanoDrop (NanoDrop™ 2000 Spectrophotometer, 
Waltham, Massachusetts, United States). Following quantification, isolated DNA samples 
were stored frozen at -20°C until processing (to maintain DNA integrity and arrest microbial 
growth). The concentration of blood, saliva, semen and vaginal fluid is listed in Table 1-Table 
5, Appendix I.  
4.2.3 Bisulfite conversion 
The DNA methylation sites on the extracted DNA has to be preserved when a standard PCR 
amplification is run. Therefore, the genomic DNA was treated with sodium bisulfite in order 
to convert the unmethylated cytosines to uracil and methylated cytosine remain the same (Silva 
et al., 2016) using the EZ DNA Methylation Gold Kit (Zymo Research, Irvine, California, 
United States). In this method the converted uracil is replaced by thymine during the PCR 
amplification process. The bisulfite modified DNA was amplified by site specific PCR primers 
designed to amplify the bisulfite modified target regions. 
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 4.2.4 Primer design 
Primers that were used are presented in Table 4.2 for MSP reactions and Table 4.3 for BS 
reactions 
 
 
4.2.5 MSP sensitivity 
Sensitivity testing was carried out using a five-fold serial dilution of DNA (25, 20, 15, 10, 5,1 
ng) to evaluate the minimum quantity required to obtain the predictable body fluid methylation 
profile. Three different blood samples were used for sensitivity testing.   
4.2.5.1 MSP PCR reaction 
PCR amplification was carried out using a ZymoTaqTM DNA Polymerase Kit (Zymo Research, 
Irvine, California, United States) in a 25 µL reaction volume containing 12 µL of ZymoTaq 
PCR Buffer, 0.25 µL of dNTP mix (25 µM of each dNTP), 0.15 µM of each primer (Inqaba 
Biotec), 0.2 µL of ZymoTaq DNA Polymerase (5U/µL) and 1 µL of bisulfite converted DNA. 
The PCR was conducted in a BIORAD T100TM Thermal Cycler (Bio-Rad Laboratories, 
Hercules, California, United States) under the following conditions: 95ºC for 10 minutes, 30 
Table 4.2: MSP primers for sensitivity analysis. 
tDMR  Primer Sequence Amplicon 
Size(bp) 
Annealing 
Temperature      (ºC) 
PTPRS 1 1MF CGTACGGTTATCGTGTATTTGAC 216 49 
 2MR AACCACGTATATATTCCGACTTACG   
PTPRS 2 MF ATGTAAAGAATTAAGTCGTACGGTC 168 46 
 MR CGTAAACAACCTACTAAAAAACGAA   
HPCAL1 MF GTTTTGTAGGTGTAGTCGTCGTC 113 48 
 MR AACTCGTAATCGATAAACTCCGTA   
ZNF282 MF GGAGTGCGAGAAGATTTATAGTC 210 48 
 MR TCCTTAAACGACTCCTTATAACGAA   
1methylated forward, 2methylated reverse   
Table 4.3: BS primer for ZNF282 tDMR for forensic simulation study. 
tDMR Primer Sequence Amplicon 
Size (bp) 
Annealing 
Temperature(ºC) 
ZNF282 Forward GGATTTTTTAGATTTGTTTGGTTTG 180 46 
Reverse TCCCTAATAACTTCCCCTAATAACC 
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cycles of 95ºC for 30 seconds, varying annealing temperatures for 30 seconds (Table 4.2), and 
72ºC for 60 seconds and a final extension of 72ºC for 7 minutes. The amplified products were 
analysed by agarose gel electrophoresis using 2 % agarose gel stained with 10mg/ml ethidium 
bromide at 60 volts for 60 minutes.  
4.2.6 Forensic simulation study 
To simulate forensic conditions, blood, saliva, semen and vaginal fluid were exposed to five 
types of environmental influences: dry at room temperature (condition A), wet in an exsiccator 
(condition B), outside on the ground (condition C), sprayed with alcohol (condition D) and 
sprayed with bleach (condition E). Saliva, semen and vaginal fluid were kept on cotton swabs 
and blood on a piece of cloth for each condition (Table 4.4).  A total of 20 samples, 5 samples 
each of blood, saliva, semen and vaginal fluid were analysed after t0 days (samples not exposed 
to any environmental insults and analysed immediately after sampling). A total of 100 samples, 
25 samples each of blood, saliva, semen and vaginal fluid were analysed (five samples each 
for every condition) for the forensic simulation study over t50 days. Five replicates for each 
body fluid and condition was prepared. The replicate DNA samples of the same body fluids in 
the same condition were pooled together such that 100 ng of DNA sample was included. The 
pooled DNA was modified by bisulfite treatment. The initial analysis was done immediately 
after sample collection and DNA was isolated from 20 samples (t0 days). Subsequently, DNA 
was isolated from 100 samples which were tested after t50 days of storage in five types of 
environmental influences. In Table 4.5 is the summary of the number of samples subjected to 
five different environmental conditions for two different time periods. This was done to test 
the effect of environmental insults on methylation profile of each body fluid to determine the 
extent of DNA degradation, subsequent DNA recovery and methylation profile. 
 
Table 4.4: Sample collection and preparation of human body fluids for forensic validation according to the 
recommendations by Setzer et al. (2008). 
Body Fluid Collection method Amount of Body Fluid 
utilized (μl) 
Type of material on which each 
body fluid was applied  
Saliva Sterile 50ml 
centrifuge tube 
50 Cotton swab 
Blood  Sterile EDTA 
collection tube 
50 0.5cm X 0.5cm 
Pieces of plain cloth  
Semen Sterile Plastic cups 50 Cotton swab 
Vaginal Fluid Sterile cotton swabs 50 Cotton swab 
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4.2.7 BS protocol 
4.2.7.1 BS PCR reaction 
PCR amplification was carried out using a ZymoTaqTM DNA Polymerase Kit in a 50 µL 
reaction volume containing 24 µL of ZymoTaq PCR Buffer, 0.5 µL of dNTP mix (25 µM of 
each dNTP), 0.15 µM of each primer (Inqaba Biotec) and 0.4 µL of DNA Polymerase (5U/µL) 
and 1 µL of bisulfite converted DNA.  The PCR was conducted on a BIORAD T100TM Thermal 
Cycler under the following conditions: 95ºC for 10 minutes, 30 cycles of 95ºC for 30 seconds, 
46ºC for 30 seconds, and 72ºC for 60 seconds and a final extension of 72ºC for 7 minutes. An 
aliquot of the amplified products (five microlitres) was analysed by agarose gel electrophoresis 
using 2 % agarose gel stained with 10mg/ml ethidium bromide at 60 volts for 60 minutes to 
confirm the presence of the amplicon.  
4.2.7.2 Cloning and sequencing of BS reaction products 
The remaining amplified products was then run on a 1% agarose gel and the bands were excised 
and purified using a Thermo scientific GeneJet Gel Extraction Kit according to the 
manufacturers protocol. The purified products were ligated and cloned into pJET1.2 vector 
using the Thermo Scientific CloneJet PCR cloning Kit according to the manufacturers protocol. 
Following ligation, an aliquot of the ligation reaction (five microlitres) was transformed using 
prepared chemically competent cells (Escherichia coli - DH5α). The transformed cells were 
then grown overnight on LB/amp plates. Five positive clones were isolated from each body 
Table 4.5: Number of samples subjected to five different environmental conditions for two different time periods. 
The 20 samples consist of five blood, five saliva, five semen and five vaginal fluid samples. 
Environmental 
conditions 
Time (days) Number of 
samples 
Time (days) Number of samples 
per body fluid 
None 0 20 50 0 
Dry at room 
temperature 
- - 50 20 
Wet in an exsiccator - - 50 20 
Outside on the 
ground 
- - 50 20 
Sprayed with 
alcohol 
- - 50 20 
Sprayed with bleach - - 50 20 
TOTAL  20  100  
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fluid in each condition. The plasmids were purified with the Thermo Scientific GeneJet 
Plasmid Miniprep Kit according to the manufacturers protocol. The purified plasmids were 
sent to Inqaba biotec for sequencing and this was followed by analysis on online software 
Bisulfite Sequencing DNA Methylation Analysis (BISMA) (http://services.ibc.uni-
stuttgart.de/BDPC/BISMA/). To ensure that the cloning process was efficient a positive and 
negative control was also plated on LB/amp plates. The positive control was positive samples 
from trial runs and the negative control was DH5α cells. Figure 4.1 shows the overview of the 
cloning process. 
 
4.2.8 Bisulfite sequencing data analysis and DNA methylation profiling 
The BISMA web application was used for analysis of bisulfite sequencing results. The 
methylation results were compiled based on the methylation status results from each body fluid 
sample. To determine the methylation levels of candidate markers in the different body fluid 
samples, sequencing data were aligned against in silico-converted genomic reference 
sequences using BISMA. The output files were compiled using Bisulfite Sequencing Data 
Presentation and Compilation (BDPC) web application (http://biochem.jacobs-university. 
de/BDPC/) to compile the derived information and compare results from each marker in the 
different body fluid samples (Rohde et al., 2008). 
4.2.9 Statistical analysis   
To evaluate the differences in methylation under forensic simulation conditions, statistical 
analyses was carried out using the web application, QUantification tool for Methylation 
Analysis (QUMA) (http://quma.cdb.riken.jp/). Pairwise comparisons of methylation were 
made for each marker and CpG locus using Chi-square test or Fisher's exact test as appropriate 
Differences were statistically significant when p-values were less than 0.05.  
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Figure 4.1: Flowchart showing the overview of the BS protocol. 
Purification of PCR products- The remaining amplified products were then run 
on a 1% agarose gel and the bands were excised and purified using a Thermo 
scientific GeneJet Gel Extraction Kit (Thermo Fisher Scientific Inc, Waltham, 
MA, USA).  
Ligation- The ligation reaction was prepared according to the blunting reaction 
using the CloneJet PCR Cloning Kit protocol (Thermo Fisher Scientific Inc, 
Waltham, MA, USA). The volume of DNA was determined based on the 
concentration of DNA after gel extraction.
Transformation-Five microlitres of the ligation product was added to 100μl of chemically competent cells 
(Escherichia coli - DH5α), followed by a 15 minutes incubation on ice, one minute incubation at 45ºC and 10 
minute incubation on ice. 750μl of Luria-Bertani (LB) Broth was added to the reaction in an eppendorf tube 
followed by one hour incubation at 37ºC with shaking. 
After incubation, spread plate technique was used to plate transformed cells on LB/amp plates  followed by 
overnight incubation at 37 ºC. 100μl of chemically competent cells used as negative control and a previous 
positive sample used as positive control. 
Five positive colonies were selected from plates and inoculated into 5ml of Luria broth (LB), followed by an 
overnight incubation at 37 ºC.
Colony PCR- To determine the presence or absence of insert DNA in plasmid. 
The colony PCR reaction was set up according to PCR section in a 10 μl volume.
Plasmid isolation- Plasmid isolation was conducted using the GeneJET plasmid 
Miniprep Kit (Thermo Fisher Scientific Inc, Waltham, MA, USA). 
Sequencing- Isolated plasmids were sequenced using Sanger sequencing
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4.3 Results 
4.3.1 Sensitivity test 
The sensitivity study was done to determine the minimum quantity of DNA with which 
accurate and reliable results could be obtained for methylation analysis. One of the four body 
fluids (blood) was selected for the sensitivity test and MSP was selected as method of 
methylation analysis as it is sensitive and less time consuming. DNA from blood was five-fold 
serially diluted from 25, 20, 15, 10, 5, to 1 ng. All dilutions were bisulfite modified.  
 
The detection limit with HPCAL1 and PTPRS 1 tDMR was 5 ng/µl (Figure 4.2a and 4.2b). 
PTPRS 2 showed amplification with minimum of 15 ng DNA (Figure 4.2c). And for ZNF282 
tDMR marker (Figure 4.2d) the detection limit was 10 ng. The MSP reaction was done in 
triplicate and similar results were obtained.  
 
 
 
 
1                   2                   3                   4                    5                    6                  7                  8     
a) HPCAL1   
 
   
b) PTPRS 1   
c) PTPRS 2  
d) ZNF282   
 
Figure 4.2: Evaluation of senstivity of MSP reaction. Products with primers specific for methylated cytosine. a) HPCAL1 
tDMR b) PTPRS 1 tDMR c) PTPRS 2 tDMR d) ZNF282 tDMR. Lane 1 (a, b, c, d): 100bp ladder (Thermo scientific), Lane 
2 – Lane 7 (a, b, c, d): The five-fold dilutions of blood with DNA concentrations (25, 20, 15, 10, 5, to 1 ng) and Lane 8: No 
template control. 
200 bp 
100 bp 
300 bp 
200 bp 
300 bp 
200 bp 
200 bp 
100 bp 
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4.3.2. Forensic simulation study 
A forensic simulation study was conducted to determine the robustness and stability of the 
methylation profile of the ZNF282 tDMR marker in human blood, saliva, semen and vaginal 
fluid under five different simulated environmental conditions: dry at room temperature 
(condition A), wet in an exsiccator (condition B), outside on the ground (condition C), sprayed 
with alcohol (condition D) and sprayed with bleach (condition E). Two factors that could 
influence DNA methylation patterns were controlled in this study: age (time of exposure) and 
simulated environmental conditions.  
4.3.2.1 Methylation profile of body fluids using the ZNF282 tDMR analysed 
immediately after collection (t0 days) 
The ZNF282 tDMR primer set targets eight CpG sites. A total of 20 clones were sequenced 
(five clones for each body fluid) and sequencing results were analysed for all body fluids using 
the BISMA program. Overall hypermethylation (100%) was displayed for blood and saliva 
(Figure 4.3). For vaginal fluid, hypermethylation (98%) was observed, with one clones (e) 
showing an unexpected cytosine nucleotide at CpG 2 (Figure 4.3). Conversely, in semen, as 
expected, hypomethylation (100%) was observed (Figure 4.3). Table 4.6 shows the summary 
of bisulfite sequencing results for body fluids analysed using BISMA for the ZNF282 tDMR 
at t0 days. Statistical analysis showed that overall methylation patterns between semen and all 
other body fluids (blood, vaginal fluid and saliva) were significantly different (p < 0.05) (Table 
4.7). Methylation patterns at individual CpG sites were also significantly different (p < 0.05) 
at all eight CpG sites for semen compared to all other body fluids for the ZNF282 tDMR 
(Appendix J: Table 1-8). 
Table 4.6: Overview of bisulfite sequencing results for body fluids analysed using BISMA for the ZNF282 
tDMR at t0 days. 
Body Fluid Number of  clones 
that produced 
results 
Overall 
Methylation (%) 
Overall 
Unmethylation (%) 
Unknown 
CpG sites 
(%) 
Blood 5 100 0 0 
Saliva 5 100 0 0 
Semen 5 0 0 0 
Vaginal fluid 5 98 0 2 
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Table 4.7: Pairwise comparison of overall DNA methylation for ZNF282 tDMR marker in blood, saliva, semen 
and vaginal fluid at t0 days. The p-values obtained from the Fisher’s Exact test are indicated below.  
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000 1   
Semen 0.0008 0.0008 1  
Vaginal fluid  1.0000 1.0000 0.0008 1 
     Blood 
 
     Saliva 
 
     Semen 
 
     Vaginal fluid 
 
 
Figure 4.3:  Bisulfite sequencing results for the ZNF282 tDMR marker at t0 days.  Each row indicates a single clone of 
bisulfite PCR products and each column indicates individual CpG site in the region of interest. Different methylation states 
of the CpG sites are indicated by colours (blue represents unmethylated; red represents methylated; white represents 
unknown). Overall methylation results for all 8 CpG sites were: 100% for blood, 100% for saliva, 0% for semen and 98% for 
vaginal fluid.  
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4.3.2.2 DNA recovery after exposure to environmental conditions for t50 
days 
Recovery of DNA from different conditions were compared. All four body fluids were 
degraded when kept in all five conditions for t50 days as compared to t0 days. The DNA 
concentrations show on average an overall decrease for all four body fluids after t50 days 
(Appendix I: Table 2-5) compared to the DNA concentrations of body fluids at t0 days 
(Appendix I: Table 1). 
After t50 days, vaginal fluid provided the highest DNA concentration (332.4 ng/μl) (Appendix 
I: Table 5) and semen provided the lowest DNA concentration (0.2 ng/μl) (Appendix I: Table 
4). The DNA concentrations of blood, saliva and semen in conditions A, B, D and E were quite 
low (Appendix I Table 2-4) and following bisulfite conversion and PCR reactions no 
amplification was obtained, thus could not be further processed for cloning and sequencing. 
For condition C (outside on the ground), all body fluids provided a good concentration of DNA, 
where, blood provided the highest DNA concentration (84.3ng/μl) (Appendix I: Table 2) and 
saliva provided the lowest DNA concentration (5.5 ng/μl) (Appendix I: Table 3). In most 
conditions, vaginal fluid samples provided the highest DNA concentrations (Appendix I: Table 
5).  
4.3.2.3 Effects of simulated forensic conditions on methylation profile of 
ZNF282 tDMR after t50 days 
4.3.2.3.1 Methylation profile ZNF282 tDMR after placing all fluids 
outside on the ground (condition C) 
A total of 20 clones were sequenced (five clones for each body fluid), however only 13 clones 
produced results to be analysed using the BISMA software. The threshold sequence identity 
percentage was 90%, thus the clones that were not analysed were below the threshold. Blood 
samples showed an overall hypermethylation (96%) in all clones, with one clone (a) showing 
an unexpected cytosine nucleotide at CpG 3 (Figure 4.4). For saliva, hypermethylation (72%) 
was observed, with one clone showing unmethylation at all eight CpG sites and another clone 
showing unmethylation only at CpG 3 (Figure 4.4). An overall methylation of 94% was 
observed in vaginal fluid, with one clone showing an unexpected cytosine nucleotide at CpG 3 
(Figure 4.4). Conversely, hypomethylation (100%) was observed in semen (Figure 4.4). Table 
4.8 shows the summary of bisulfite sequencing results for body fluids exposed to condition C 
(outside on the ground) for the ZNF282 tDMR after t50 days. Statistical analysis showed a 
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significant difference in methylation patterns in saliva and semen when compared to all other 
body fluids (p > 0.05) (Table 4.9).  
Table 4.8: Overview of bisulfite sequencing results analysed using BISMA for body fluids exposed to 
condition C (outside on the ground) for the ZNF282 tDMR marker after t50 days. 
Body Fluid Number of  clones 
that produced 
results 
Overall 
Methylation (%) 
Overall 
Unmethylation (%) 
Unknown 
CpG sites  
(%) 
Blood 3 96 0 4 
Saliva 4 72 28 0 
Semen 4 0 100 0 
Vaginal fluid 2 94 0 6 
 
 
 
 
Table 4.9: Pairwise comparison of total DNA methylation for ZNF282 tDMR for Condition C in blood, saliva, semen and 
vaginal fluid after t50 days. The p-values obtained from the Fisher’s Exact test are indicated below.  
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 0.0000 1   
Semen 0.0000 0.0002 1  
Vaginal fluid  1.0000 0.0008 0.0000 1 
 
 
 
 
 
 
 
 
96 
 
Blood 
 
Saliva 
 
Semen 
 
Vaginal fluid 
 
 
Figure 4.4: Bisulfite sequencing results of the ZNF282 tDMR marker for outside on the ground (condition C). 
Each row indicates a single clone of bisulfite PCR products and each column indicates individual CpG site in 
the region of interest. Different methylation states of the CpG sites are indicated by colours (blue represents 
unmethylated; red represents methylated; white represents unknown). Overall methylation results for all 8 CpG 
sites were:  96% for blood, 72% for saliva, 0% for semen and 94% for vaginal fluid. 
 
4.3.2.3.2 Methylation profile of ZNF282 tDMR upon exposure to all 
conditions in vaginal fluid only 
From a total of 25 sequenced clones, only 21 clones produced results to be analysed using the 
BISMA software. The threshold sequence identity percentage was 90%, thus the clones that 
were not analysed were below the threshold. The overall methylation for condition A (dry at 
room temperature) was 81%, with three clones (c and d) showing unmethylation at CpG 2 and 
CpG 6 and another clone (b) showing an unexpected cytosine nucleotide at CpG 5 and CpG 8 
(Figure 4.5). For condition B (wet in an exsiccator), hypermethylation was observed (98%) 
with one clone showing an unexpected cytosine nucleotide at CpG 3 (clone d) (Figure 4.5). 
Condition C (outside on the ground) showed that there was hypermethylation (94%), with one 
clone showing an unexpected cytosine nucleotide at CpG 3 (clone b) (Figure 4.5). For condition 
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D (sprayed with alcohol), the clones displayed hypermethylation (98%) and one clone (clone 
e) showed unmethylation at CpG 3 (Figure 4.5). For condition E (sprayed with bleach), 
hypermethylation (98%) was displayed for all clones and an unexpected cytosine nucleotide at 
CpG 3 (clone e) (Figure 4.5). Table 4.10 shows the summary of bisulfite sequencing results for 
vaginal fluid exposed to all conditions for the ZNF282 tDMR after t50 days. Statistical analysis 
showed that methylation patterns of vaginal fluid in all conditions were not statistically 
different from each other (p > 0.05) (Table 4.11) and that methylation patterns at individual 
CpG sites were also not significantly different (p > 0.05) for the ZNF282 tDMR for vaginal 
fluid in all conditions (Appendix L: Table 1-8). 
 
 
 
Table 4.10: Overview of bisulfite sequencing results for vaginal fluid analysed using BISMA for the ZNF282 
tDMR marker under all forensic simulation conditions: dry at room temperature (condition A), wet in an 
exsiccator (condition B) outside on the ground (condition C), sprayed with alcohol (Condition D) and sprayed 
with bleach (Condition E). 
Body Fluid Number of  clones 
that produced 
results 
Overall 
Methylation (%) 
Overall 
Unmethylation (%) 
 Unknown 
CpG sites(%) 
Condition A 4 81 13 6 
Condition B 5 98 0 2 
Condition C 2 94 0 6 
Condition D 5 98 2 0 
Condition E 5 98 2 0 
Table 4.11:  Pairwise comparison of total DNA methylation for ZNF282 tDMR for all conditions in vaginal fluid. The p-
values obtained from the Fisher’s Exact test are indicated below. 
 Vaginal fluid A Vaginal fluid B Vaginal fluid C Vaginal fluid D Vaginal fluid E 
Vaginal fluid A 1     
Vaginal fluid B 0.1110 1    
Vaginal fluid C 0.4839 1.0000 1   
Vaginal fluid D 0.1934 1.0000 1.0000 1  
Vaginal fluid E 
 
0.1934 1.0000 1.0000 1.0000  1 
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Condition A 
 
Condition B 
 
Condition C 
 
Condition D 
 
Condition E 
 
 
Figure 4.5:  Bisulfite sequencing results for the ZNF282 tDMR in vaginal fluid under all forensic simulation 
conditions: dry at room temperature (condition A), wet in an exsiccator (condition B) outside on the ground 
(condition C), sprayed with alcohol (Condition D) and sprayed with bleach (Condition E). Each row indicates 
a single clone of bisulfite PCR products and each column indicates individual CpG site in the region of interest. 
Different methylation states of the CpG sites are indicated by colours (blue represents unmethylated; red 
represents methylated; white represents unknown). Overall methylation results for all 8 CpG sites in vaginal 
fluid samples were:  81% for condition A, 98% for condition B, 94% for condition C, 98% for condition D and 
98% for condition E. 
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4.3.2.3.3 Methylation profiles of ZNF282 tDMR before (t0 days) and 
after exposure to forensic simulated conditions (t50 days) 
A comparison between t0 days methylation profiles and t50 days methylation profiles of 
forensic simulated conditions was conducted to establish whether there was a difference in the 
degree of methylation for the ZNF282 tDMR marker. The methylation results in Figure 4.3 
were compared to the methylation results in Figure 4.4 and Figure 4.5. Statistical analysis 
showed that methylation patterns between all body fluids at t0 days and t50 days for condition 
C (outside on the ground) were not statistically different from each other (p > 0.05) (Table 
4.12) and that methylation patterns at individual CpG sites were also not significantly different 
(p > 0.05) for the ZNF282 tDMR for all body fluids (Appendix K: Table 1-8).  
 The vaginal fluid methylation results in Figure 4.3 were compared to the vaginal fluid 
methylation results in all conditions (Figure 4.5). Statistical analysis showed that methylation 
patterns between the vaginal fluid at t0 days and t50 days for all conditions (dry at room 
temperature (condition A), wet in an exsiccator (condition B), outside on the ground (condition 
C), sprayed with alcohol (condition D) and sprayed with bleach (condition E) was not 
statistically different from each other (p > 0.05) (Table 4.13) and that methylation patterns at 
individual CpG sites were also not significantly different (p > 0.05) for the ZNF282 tDMR 
between the vaginal fluid not exposed to any condition and vaginal fluid in all conditions 
(Appendix L: Table 9-16). 
 For condition C, methylation level decreased in all body fluids, however, semen methylation 
level remained the same after t50 days (Table 4.14). For all vaginal fluid samples in conditions 
A and C the methylation level decreased, however, methylation levels in conditions B, D and 
E was stable (Table 4.14). The methylation status of CpG sites for all body fluids in condition 
C showed that there was a decrease in methylation at every CpG site (8 CpG sites) for saliva, 
however, vaginal fluid and blood showed CpG 3 showed a decrease, while semen was stable 
at all CpG sites (8 CpG sites) (Table 4.15). The methylation status of vaginal fluid samples in 
all condition remained stable at most CpG sites, except, CpG 2, CpG 3, CpG 5, CpG 6 and 
CpG 8 (Table 4.15)  
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Table 4.14: Overall change in DNA methylation level in each body fluid after t50 days of subjection to five forensic 
simulation conditions (A- dry at room temperature, B- wet in an exsiccator and C- outside on the ground, D- sprayed 
with alcohol and E- sprayed with bleach). Up or down arrows indicate increase or decrease in DNA methylation 
level and a dash indicates no change in methylation level. 
Body fluid Vaginal fluid Saliva Semen Blood 
Condition A B C D E C C C 
Overall 
methylation 
↓ - ↓ - - ↓ - ↓ 
 
 
 
 
 
 
 
 
Table 4.12:  Pairwise comparison of total DNA methylation for ZNF282 tDMR marker under Condition 
C compared between t0 days and t50 days in blood, saliva, semen and vaginal fluid. The p-values 
obtained from the Fisher’s Exact test are indicated below. 
 t0 days 
 Blood Saliva Semen Vaginal fluid 
t50 days 0.4910 0.2360 1.0000 1.0000 
Table 4.13: Pairwise comparison of total DNA methylation for ZNF282 tDMR under all forensic 
simulation conditions compared between t0 days and t50 days in vaginal fluid. The p-values obtained from 
the Fisher’s Exact test are indicated below. 
 t0 days 
 Vaginal fluid  
A 
 Vaginal fluid 
B  
Vaginal fluid 
 C 
Vaginal fluid  
D 
Vaginal fluid  
E 
t50 days 0.1670 1.0000 1.0000 1.0000 1.0000 
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Table 4.15: Change in DNA methylation at each CpG site in each body fluid after t50 days of subjection to 
five forensic simulation conditions (A- dry at room temperature, B- wet in an exsiccator and C- outside on 
the ground, D- sprayed with alcohol and E- sprayed with bleach). Up or down arrows indicate increase or 
decrease in DNA methylation level and a dash indicates no change in methylation level. 
Body fluid Vaginal fluid Saliva Semen Blood 
Condition A B C D E C C C 
CpG 1 - - - - - ↓ - - 
CpG 2 ↓ ↑ ↑ ↑ ↑ ↓ - - 
CpG 3 - ↓ ↓ ↓ ↓ ↓ - ↓ 
CpG 4 - - - - - ↓ - - 
CpG 5 ↓ - - - - ↓ - - 
CpG 6 ↓ - - - - ↓ - - 
CpG 7 - - - - - ↓ - - 
CpG 8 ↓ - - - - ↓ - - 
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4.4 Discussion 
Identifying body fluids that are recovered from crime scenes is an important factor for 
determining the outcome of criminal investigations. Using tDMRs as epigenetic markers is 
proposed as a new method to determine the origin and source of biological material that are 
found at crime scenes. The CpG sites located within a tDMR have unique methylation patterns 
in various tissues and cells, thus can be used to differentiate between body fluids. For tDMR 
markers to efficiently differentiate between body fluids, it is important to determine the limits 
of DNA quantities that can be detected by methylation analysis as well as the stability of the 
analytical substrate (Forat et al., 2016; Silva et al., 2016). The objective of the present study 
was to analyse potential tDMRs for genes ZNF282, PTPRS and HPCAL1 using MSP to assess 
the minimum quantity of DNA required for methylation analysis and to determine the effect of 
environmental conditions on the stability of methylation profile of ZNF282 tDMR marker. 
4.4.1 Sensitivity study 
DNA methylation based tissue identification methods require a small amount of DNA in order 
to obtain DNA profiles. Biological fluids at crime scenes are mostly found in either low 
amounts, are contaminated or degraded resulting in isolation of poor quantity and quality of 
DNA. Thus, a sensitivity study was conducted to determine the minimum amount of DNA 
needed to obtain accurate results using MSP.  
Based on analysis with all four candidate tDMR markers, it can be concluded that DNA 
samples with a concentration greater than 10 ng would be ideal for analysis of methylation 
status because of the loss of DNA due to bisulfite conversion (Grunau et al., 2001). Also, PCR 
bias often occurs at the amplification stage, especially when working with bisulfite converted 
DNA that have low DNA concentrations. As a result, amplification is more efficient at 
unmethylated sites, however in certain instances an inverse bias can occur and amplification is 
more efficient at methylated site (Moskalev et al., 2011). A study by Park et al. (2014) 
performed a pyrosequencing analysis on varying DNA concentrations (500, 100, 50, 15, 10, or 
five ng) following bisulfite conversion. The results showed that DNA that had a concentration 
between 500 ng to 10 ng was successfully used in pyrosequencing analysis. However, a study 
by Madi et al. (2012) showed that bisulfite converted DNA with a concentration as low as five 
ng was able to be analysed using pyrosequencing.  
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4.4.2 Forensic simulation  
In the previous study, the ZNF282 tDMR was identified as a semen-specific hypomethylation 
marker. The present study aimed to examine the stability of methylation profile of ZNF282 
tDMR marker under simulated forensic conditions and to determine the effect of simulated 
forensic influences on DNA stability and recovery. The DNA of body fluids that were analysed 
immediately (t0 days and not exposed to any simulated conditions) was used as a control and 
compared to DNA of body fluids that were exposed to the five different environmental 
influences for t50 days: dry at room temperature (condition A), wet in an exsiccator (condition 
B) outside on the ground (condition C), sprayed with alcohol (condition D) and sprayed with 
bleach (condition E). 
4.4.2.1 DNA recovery 
DNA degradation was observed in all four body fluids that were kept in all five conditions for 
t50 days. The highest DNA concentration was observed for vaginal fluid samples (the highest 
was 332.4 ng/µl) and semen samples provided the lowest yield (as low as 0.2 ng/µl). In blood, 
condition A, B, D and E had a maximum effect on DNA degradation and for saliva and semen 
all conditions resulted in DNA degradation after t50 days of exposure. However, for vaginal 
fluid, all conditions had minimal effect on DNA degradation. DNA degradation has been 
reported in similar studies in which DNA was exposed to various environmental conditions 
over various time periods (Ambers et al., 2014; Parker, 2011). Ambers et al. (2014) examined 
the effects of three environmental conditions: UV radiation, temperature and humidity on DNA 
recovery and stability of bloodstains. The DNA in the bloodstains that were exposed to the 
temperature and humidity conditions remained quite durable and resistant to damage, probably 
due to being in a dry state. However, the bloodstains exposed to UV radiation varied in the 
degree of damage to the DNA. A possible explanation for this observed difference could be 
due to the composition of blood and that certain constituents of blood may absorb some UV 
radiation to provide a protective barrier to the DNA. Also, exposure to UV radiation produce 
photoproducts and cause DNA strand breakage, decreasing the chances of obtaining profiles 
(Hall and Ballantyne, 2004). The study by Parker. (2011) showed that body fluids exposed to 
microbes, UV radiation, moisture and high temperatures does effect the stability of DNA, 
however, dry conditions are favourable as the degradation process is reduced. Hence, exposure 
of body fluids to environmental influences such as temperature, humidity, chemicals and 
microbes as well as time of exposure, has an effect on the DNA recovery (Fondevila et al., 
2008; Raymond et al., 2009; Ostojic and Wurmbach, 2017). 
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4.4.2.2 Methylation profile of ZNF282 tDMR marker analysed 
`immediately after collection (t0 days) for all body fluids  
Body fluids at t0 days were not subjected to any environmental simulation. As expected, 
methylation pattern for semen was significantly different from all other body fluids (p < 0.05). 
This difference was a result of semen showing hypomethylation and all other body fluids 
showing hypermethylation. Semen-specific hypomethylated markers have been previously 
reported: DACT1 and USP49 (An et al., 2013; Choi et al., 2014; Lee et al., 2012), ZC3H12D 
(Madi et al., 2012) and cg04382920 and cg11768416 (Vidaki et al., 2016).  
4.4.2.3 Methylation profile of ZNF282 tDMR analysed after t50 days of 
exposure to simulated forensic conditions 
Endogenous and exogenous nucleases that are present in host cells and environment, 
respectively may result in DNA damage and modifications which affect the analysis of body 
fluids (Alaeddini et al., 2010). This can lead to inhibition of amplification processes. 
Additionally, when body fluids are exposed to environmental influences for long periods of 
time, the DNA in most instances will contain many lesions resulting in DNA damage and 
fragmentation, which affect DNA methylation analysis (Jun, 2010). Due to environmental 
impacts, the analytical CpG methylation state or the whole PCR template may be affected and 
result in changes in the methylation status.  
In forensic simulation studies, methylation profiles under all conditions was obtained only for 
vaginal fluid. The remaining body fluids (blood, semen and saliva) yielded low DNA 
concentrations under conditions A (dry at room temperature), B (wet in and exsiccator), D 
(sprayed with alcohol) and E (sprayed with bleach) and hence, did not yield PCR product after 
bisulfite conversion and could not be further analysed.  
Similar forensic simulation study conducted by Silva et al. (2016) showed that there were no 
significant differences observed in the methylation level of the samples exposed to 
environmental conditions compared to samples that were not exposed environmental 
conditions. However, a study by Forat et al. (2016) showed that the methylation status of 
samples exposed to humid environment conditions was effected but did not inhibit correct 
identification of body fluids.   
All four body fluids provided methylation results for condition C (outside on the ground) only. 
The simulation study showed that methylation data for t50 days differed from methylation data 
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after t0 days. The overall methylation level for each body fluid exposed to environmental 
influences and analysed after t50 days compared to body fluid samples analysed immediately 
after sampling (t0 days), showed an overall decrease in methylation level of saliva, vaginal 
fluid and blood after exposure to condition C whereas, semen methylation status remained the 
same as for t0 days. 
Statistical analysis showed that there was a significant difference observed in the overall 
methylation level of saliva and semen in condition C compared to blood and vaginal fluid (p < 
0.05) in condition C. Individual CpG site statistical analysis showed a significant difference 
between blood and semen but not the other body fluids (p < 0.05). All vaginal fluid samples 
under all conditions showed that there was no significant difference in the overall methylation 
status (p > 0.05) and at individual CpG sites showed no significant difference (p > 0.05).  
Any changes in the methylation status that occurred in body fluids after t50 days may be a 
result of spontaneous deamination in the natural environment of cells due to bacteria and fungi 
(Garvin et al., 2013; Forat et al., 2016). Other factors that may influence changes in methylation 
status are temperature, humidity, rain and chemicals (Meakin and Jamieson, 2013). 
Environmental influences can also result in DNA degradation and therefore can possibly inhibit 
DNA-based tissue identification. This can lead to erroneous tissue identification because 
methylated loci that are not amplified due to degradation can be mistaken to be unmethylated 
(Frumkin et al., 2011). 
Even though the methylation levels changed after exposure to condition C (outside on the 
ground), semen still displayed 100% hypomethylation and blood, saliva and vaginal fluid 
>72% methylation. This further supports that the ZNF282 tDMR marker is a stable semen-
specific hypomethylation marker. To the best of our knowledge this tDMR marker has not been 
previously identified and reported. 
Furthermore, a comparison analysis was done between t0 days and t50 days for all body fluids. 
Statistical comparisons were made between methylation profiles obtained at t0 days and after 
t50 days. The statistical comparison of body fluids not exposed to environmental influences to 
all body fluids in condition C and vaginal fluid under all conditions for the ZNF282 tDMR, 
showed that there were no significant differences in the methylation status. This indicates that 
methylation status remains fairly stable when exposed to environmental influences. 
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4.5 Conclusion 
The expected outcome of the research outlined in the present study, was to establish the 
sensitivity of methylation profiles for ZNF282, PTPRS 1, PTPRS 2 and HPCAL1 tDMRs using 
MSP and to determine the stability of methylation profile for the ZNF282 tDMR under 
forensically simulated conditions. DNA methylation analysis using bisulfite treatment methods 
(MSP and BS) is able to identify body fluids from low concentration DNA as well as degraded 
DNA. Thus, DNA methylation profiling for differentiation between body fluids and tissues 
appears to be a promising method for forensic applications. DNA methylation based methods 
are compatible with STR typing and can be incorporated into the current forensic workflow 
(Lee et al., 2016b). 
In the future, DNA methylation analysis studies using different body fluid samples will be 
useful to identify novel DNA methylation markers which will add to the current markers that 
have been identified. This will enable the development of an efficient database of markers 
which can be used globally for discrimination between forensically relevant body fluids 
(Frumkin et al., 2011; Park et al., 2014).  Furthermore, tDMRs that have been identified should 
be tested on larger sample sizes that include individuals of varying ages and ethnic groups as 
well as in a mixture of body fluids. Other forensic simulations such as the effect of microbes 
and longer exposure periods should also be investigated. This will improve the accuracy and 
reliability of using tDMR markers for body fluid identification.  
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Chapter 5 
General discussion and Conclusion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
108 
 
5.1 Purpose of study 
In most crime scenes, human body fluids that are recovered provide strong evidence that can 
be used to identify perpetrators and victims (An et al., 2012; Choi et al., 2014; Lee et al., 2012). 
Several types of body fluids are found at crime scenes; including saliva, blood, semen, vaginal 
fluid, menstrual blood, but also skin samples and urine (Sijen, 2015). Identifying the origin of 
the source and distinguishing between different types of body fluids may play a crucial role in 
linking evidence and the crime.  
Currently in forensic casework, conventional presumptive and confirmatory tests are used to 
identify human body fluids. These tests are based on catalytic, immunological and enzymatic 
assays which identify specific components or cells in body fluids (Frumkin et al., 2011; Virkler 
and Lednev, 2009).  The assays use a large amount of sample which is not readily available at 
crime scenes. Furthermore, they lack sensitivity and specificity which is crucial in forensic 
investigations, are prone to false positive results, and moreover, there are different tests for 
each body fluid, thus large amount of precious evidence is used (Haas et al., 2009; Virkler and 
Lednev, 2009). To overcome the limitations associated with presumptive and confirmatory 
tests, RNA-based methods were developed for identification of body fluids (Hanson et al., 
2009; Juusola and Ballantyne, 2007; Setzer et al., 2008; Zubakov et al., 2008), however, RNA 
is unstable, prone to degradation and uses a large amount of samples. Short tandem repeat 
(STR) DNA typing is routinely employed for the identification of people using DNA from 
body fluids found at crime scenes. However, STR DNA typing cannot be used to determine 
the sources and origin of various body fluids (Xu et al., 2014).  Thus, using DNA methylation-
based markers have been suggested as being a valuable method for identification of body fluids 
as it is more stable and less susceptible to environmental influences (Xu et al., 2014). DNA is 
easily amplified by standard PCR techniques thus facilitating the use of minute amounts of 
samples. Every cell in the human genome has specific regions in DNA sequences that differ in 
DNA methylation patterns (Slieker et al., 2013; Song et al., 2009). These specific regions are 
known as tissue-specific differentially methylated regions (tDMRs) and can be useful in 
identification of body fluids (An et al., 2012; Choi et al., 2014). However, despite these 
advantages, thus far a limited number of tDMR markers have been validated for body fluid 
differentiation.  
Considering the importance of identifying body fluids in forensic investigations, the present 
study aimed to investigate whether DNA methylation patterns of potential tDMRs can be used 
to differentiate between four forensically relevant human body fluids; namely blood, saliva, 
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semen and vaginal fluid. Blood samples were collected from 20 volunteers at Lab 24 
laboratory, Mount Edgecombe, Durban. Vaginal fluid samples were collected from 20 
volunteers at the King Dinizulu Hospital, Durban. Semen and saliva samples were collected 
from 10 volunteers at the King Dinizulu Hospital and University of KwaZulu-Natal, Westville 
campus. The potential tDMRs included in this study were located in three genes, namely, 
ZNF282, PTPRS and HPCAL1. Primers were designed for each gene at one CpG island, 
however, for the PTPRS gene, two CpG islands were targeted (referred to as PTPRS 1 and 
PTPRS 2) for comparison of methylation patterns within the gene. These gene-based tDMRs 
were identified as potential candidates for body fluid identification in a previous study 
conducted at University of KwaZulu-Natal, Westville (Kader, 2015, MSc Genetics 
dissertation) based on differential gene expression.  
For profiling DNA methylation of the potential tDMRs in four body fluids; namely blood, 
saliva, semen and vaginal fluid, methylation specific PCR (MSP) and bisulfite sequencing (BS) 
techniques were employed. MSP is a simple, sensitive and cost effective qualitative method 
that determines the presence or absence of methylation (Herman et al., 1996; Hernández et al., 
2013; Huang et al., 2013b). It is also able to produce methylation profiles for DNA samples 
that have low concentrations and that are of low quality. Furthermore, CpG sites are analysed 
without using methylation restriction enzymes (Herman et al., 1996; Dhingra et al., 2014). 
However, since the method does not provide quantitative results, BS was used to validate the 
methylation profiles using pooled DNA from each body fluid. The BS method is useful for 
site-specific or allele-specific methylation analysis (Huang et al., 2013a; Shen and Waterland, 
2007). Although BS is limited by the cost and time taken to perform the method (Hernández et 
al., 2013) it still remains the gold standard method for methylation analysis that provides 
quantitative information (Huang et al., 2013a) since it facilitates detailed information at every 
CpG site in the target region. 
In addition, since only minute quantities of DNA are generally recovered from crime scenes, 
the study set out to determine the minimum amount of DNA required to produce a stable 
methylation profile. Furthermore, DNA quality from crime scenes are usually compromised. 
Hence, the effects of environmental influences on DNA were examined to determine if the 
methylation profiles of the candidate tDMRs would remain stable.  
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5.2 Summary of findings 
The first objective of the study was to establish methylation profiles for ZNF282, PTPRS 1, 
PTPRS 2 and HPCAL1 tDMRs using MSP and thereafter, BS. Based on the observed 
methylation profiles, MSP identified two semen-specific markers (ZNF282 tDMR and PTPRS 
1 tDMR) and one saliva-specific marker (HPCAL1 tDMR).  
The ZNF282 tDMR displayed hypermethylation for blood, saliva and vaginal fluid, but 
hypomethylation in semen only. The BS PCR reaction followed by sequencing, showed similar 
results to MSP for the ZNF282 tDMR, as there was significant difference between methylation 
profiles of semen and all other body fluids. Thus, based on the BS results, it was concluded 
that the ZNF282 tDMR can be used as a semen-specific hypomethylation marker. Using the 
same methods as the present study, Lee et al. (2012) identified two semen-specific markers 
(DACT1 and USP49) that displayed hypomethylation patterns in semen and hypermethylation 
patterns in blood, menstrual blood, saliva and vaginal fluid. Studies by Choi et al. (2014) and 
An et al. (2013) also observed that DACT1 and USP49 gene based markers could differentiate 
semen from all other body fluids. Other semen-specific markers which have been identified 
include cg22407458 (Forat et al., 2016), PRMT2 (Lee et al., 2012), ZC3H12D (Madi et al., 
2012) and cg04382920 and cg11768416 (Vidaki et al., 2016), all of which are hypomethylated 
in semen when compared to other fluids. Semen-specific hypermethylation markers include 
single CpG site based markers: L81528 (Choi et al., 2014; Frumkin et al., 2011), cg05656364 
(Forat et al., 2016), cg26763284 and cg17621389 (Lee et al., 2015), cg26763282-138d and 
cg17610929 (Lee et al., 2016a) cg05261336 (Lin et al., 2016) and cg23521140 (Park et al., 
2014). However, most of these markers target just one CpG site which is not reliable and are 
yet to be validated, whereas in the present study the MSP results for ZNF282 tDMR were 
validated and reproduced using BS. 
The MSP analysis for the PTPRS 1 tDMR displayed hypermethylation for blood, saliva and 
vaginal fluid, however, both hypermethylation and hypomethylation was observed for semen. 
However, BS was unable to distinguish semen from all other body fluids for the PTPRS 1 
tDMR. The PTPRS 2 tDMR displayed both hypermethylation and hypomethylation patterns 
for all body fluids using MSP. Thus, no unique methylation patterns were observed to 
distinguish body fluids. Furthermore, the BS analysis was not able to differentiate between 
body fluids for both PTPRS 1 and PTPRS 2 tDMRs. Thus, the PTPRS 1 and PTPRS 2 tDMRs 
are not reliable markers for body fluid identification and requires further interrogation, perhaps 
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using a larger sample size for BS analysis with inclusion of more clones for sequencing or 
targeting different CpG islands of the gene.  
The MSP study also identified a potential saliva-specific marker. For blood, semen and vaginal 
fluid, the HPCAL1 tDMR, displayed hypermethylation. However, saliva displayed 
hypomethylation patterns. While reliable and reproducible saliva-specific markers are not 
common, the BCAS4 gene was identified as a potential saliva-specific hypermethylation 
marker by Madi et al. (2012). Further validation studies were conducted by Silva et al. (2016) 
by testing the sensitivity, species specificity, effect of degradation and mixed samples on the 
BCAS4 marker. The BCAS4 marker showed robust and reliable results. Similarly, other studies 
have also identified potential saliva-specific hypermethylated markers, such as, cg21597595 
and cg15227982 (Forat et al., 2016), cg09652652 (Lee et al., 2015), cg09652652-2d (Lee et 
al., 2016a), cg09107912 (gene FNDC1) and cg16732616 (gene DMRTA2) (Lin et al., 2016) 
and cg26107890 (gene SLC12A8) and cg20691722 (gene SOX2OT) (Park et al., 2014). 
However, in the present study BS was unable to validate the HPCAL1 tDMR as a saliva-
specific marker due to non-specific amplification for all body fluids. Therefore, the MSP results 
could not be confirmed by BS. Design of new primers for BS PCR reactions could be an option 
for future analysis. 
Biological material found at crime scenes may be found in small quantities and exposed to 
environmental insults (Forat et al., 2016). Thus, the second objective of the study was to 
perform a sensitivity study to determine the lowest concentration of DNA required to obtain 
methylation profiles and the forensic simulation study was conducted to determine whether 
environmental influences have an effect on DNA methylation stability and DNA recovery.  
For the sensitivity study, a five-fold serial dilution of DNA (25, 20, 15, 10, 5,1 ng) was prepared 
to determine the minimum amount required to obtain methylation profiles by MSP. The results 
determined that successful amplification can be obtained with a DNA concentration of 10 ng 
and more using the MSP method. Other studies that have also conducted sensitivity tests were 
also able to generate good methylation profiles at lower DNA concentrations (Antunes et al., 
2016a; Madi et al., 2012; Lee et al., 2015; Lin et al., 2016; Silva et al., 2016). However, these 
studies used different methods such as, pyrosequencing, multiplex SNaPshot or multiplex 
methylation sensitive restriction enzyme PCR.  
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Since MSP and BS showed that the ZNF282 tDMR marker was semen-specific, a forensic 
simulation study was conducted to determine if similar methylation profile could be obtained 
from body fluids exposed to the environment insults. Body fluids were subjected to five 
different simulated environment conditions, namely, dry at room temperature, wet in an 
exsiccator, outside on the ground, sprayed with alcohol and sprayed with bleach for 50 days 
(t50 days). BS was used to analyse the methylation status of the ZNF282 tDMR in blood, saliva, 
semen and vaginal fluid. Body fluids not exposed to any environment insults (t0 days) were 
analysed immediately after sample collection. As expected, semen displayed hypomethylation 
patterns which differentiated from all other body fluids that displayed hypermethylation 
patterns. After t50 days, environmental conditions had maximum detrimental effect on DNA 
recovery from semen, saliva and blood, however, high DNA quantity and quality was obtained 
from vaginal fluid. Methylation profile of saliva, semen, blood and vaginal fluid was obtained 
only for the outside on the ground condition. A significant difference in methylation profiles 
was observed for saliva and semen only. Only vaginal fluid methylation profile for ZNF282 
could be analysed under all five environmental conditions. Vaginal fluid showed no significant 
difference in methylation under different conditions. Furthermore, no significant difference in 
methylation levels was observed between body fluids at t0 days and t50 days. However, the 
ZNF282 tDMR maintained hypomethylation patterns in semen as compared to 
hypermethylation patterns in other body fluids under environmental insults. Studies by 
Frumkin et al. (2011) and Silva et al. (2016) showed that even if DNA is degraded and 
subjected to environmental insults such as varying temperatures, there is no significant 
difference in the methylation profiles of markers. A study by Forat et al. (2016) exposed body 
fluids to three different conditions (dry on room temperature, humid/wet in an exsiccator and 
outside on the ground) and demonstrated that the most significant change in methylation 
profiles was observed in humid conditions. Methylation profiles of samples left outside were 
stable after a six-month period (Forat et al., 2016). Similar results were obtained in the present 
study, as duration and exposure of samples to the outside environment did not affect the 
methylation levels of the ZNF282 marker. 
Future work should involve developing multiplex assays which will require minute amount of 
sample and the examination of multiple body fluids in a single reaction (Choi et al., 2014).  
However, there is still much research required prior to using these developed methods routinely 
in forensic laboratories (Choi et al., 2014). Identification of more tDMRs using various body 
fluids will be advantageous in building a database of the current tDMRs as well as making the 
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methylation-based analysis more robust for body fluid identification. This will pave the way 
for the application of differential DNA methylation as an efficient and reliable method for 
identification of body fluids in forensic investigations. 
5.3 Conclusion and future work 
The ZNF282 tDMR was found to be a semen-specific hypomethylation marker. To our 
knowledge, the ZNF282 tDMR has not previously been reported for identification and 
differentiation of forensically relevant body fluids. Future research would include: examining 
the identified marker on a sample size that is larger and more diverse, comprising individuals 
of different ethnic groups, age groups, diverse geographical locations, as well as comparing 
methylation profiles of the marker obtained from healthy and diseased individuals. 
Additionally, exposure to the environment for longer and different time periods such as 30 
days, 60 days, 90 days, and exposure to more simulated forensic conditions, such as different 
types of surfaces, UV radiation, a range of temperatures and soil microbes. Further validation 
can be conducted by testing tDMR marker in mixture analysis, artificial samples and non-
human species. Additionally, research should be conducted to establish if variable DNA 
methylation affects normal or disease functional phenotypes in every tissue type (Igarashi et 
al., 2008). The results of such rigorous analysis of the tDMR marker using these conditions 
may enhance and compliment the methylation data obtained in the present study. 
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Information Sheet and Consent to Participate in Research - Volunteers 
 
Date:  February 2016 - December 2017 
Good day  
My name is Natalie Naidoo from UKZN – Westville, School of Life Sciences (Genetics). 
Contact Number: 031 260 8617. Email address: (naidoo.n0308@gmail.com)  
You are being invited to participate in a research study. The title of the study is “Methylation 
Profiling and validation of candidate tDMRs for identification of human blood, saliva, 
semen and vaginal fluid and its application in forensics”. This research study is towards the 
Masters of Science Degree of the Principal Investigator Ms. Natalie Naidoo.  
The main purpose of this study is to evaluate a new test that will hopefully be used one day by 
the police, to easily identify body fluids such as, saliva, blood, semen and vaginal fluid found 
at a crime scene. The test uses genetic material (DNA) to determine whether a specimen is a 
body fluid. If this test works as well as we hope, then your participation will be seen as to have 
contributed towards helping the police solving many crimes.  
To participate in this study, we will need you to provide us with the following specimen 
………………………... We will also ask you to answer a few easy questions about yourself 
such as your age, weight, etc. we will not record any information, for example, name and 
hospital number, that will make it possible for anyone, including ourselves, to identify you in 
future. No one will be able to link you with the questionnaire, the specimen or the results. You 
may choose to not answer our questions. You will not be penalized in any way. 
Your specimen will be taken to the UKZN Genetics department in Westville and stored in a 
freezer at -20˚C. genetic material will be taken from the specimen and this will be used to 
evaluate the new test. Everything will be stored until the study has been completed, after which 
all specimens will be destroyed. Your specimen and information will no circumstances be used 
for any other purpose than for this study. 
 The study will provide no direct benefits to participants. There are no risks involved if you 
participate in this study. Participation in this research is voluntary and you may withdraw 
participation at any point. In the event of refusal/withdrawal of participation you will not incur 
any penalty or loss. 
All your details will be kept confidential not revealed to anyone else. We will provide you with 
a code name such as Volunteer 1, and this code will be written onto the tubes used for the 
sample collection as well as the accompanying body fluid data collection form.  
This study has been ethically reviewed and approved by the UKZN Biomedical Research 
Ethics Committee (Approval Number: BE187/16 (sub-study of BE221/14)). 
In the event of any problems or concerns/questions you may contact the researcher or the 
UKZN Biomedical Research Ethics Committee, contact details as follows: 
 
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 
Email: BREC@ukzn.ac.za  
 
147 
 
INFORMED CONSENT 
 
I (Full Name/s and Surname …………………………………………………) have 
been informed about the study entitled “Methylation Profiling and validation of 
candidate tDMRs for identification of human blood, saliva, semen and vaginal fluid 
and its application in forensics” by …………………………………………………. 
 
I understand the purpose and procedures of the study. 
 
I have been given an opportunity to ask questions about the study and have had answers 
to my satisfaction. 
 
I declare that my participation in this study is entirely voluntary and that I may withdraw 
at any time without affecting any treatment or care that I would usually be entitled to. 
  
If I have any further questions/concerns or queries related to the study I understand 
that I may contact the researcher at UKZN – Westville, School of Life Sciences 
(Genetics). Contact Number: 031 260 8617. Email address: Natalie Naidoo 
(naidoo.n0308@gmail.com). 
 
If I have any questions or concerns about my rights as a study participant, or if I am 
concerned about an aspect of the study or the researchers then I may contact: 
  
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 
Email: BREC@ukzn.ac.za  
 
____________________      ____________________ 
Signature of Participant                            Date 
 
 
____________________   _____________________ 
Signature of Witness                                Date 
(Where applicable)      
 
 
____________________   _____________________ 
Signature of Translator                            Date 
(Where applicable) 
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Questionnaire- Please tick the appropriate boxes where necessary. 
1. Age 
Below 30                     
 
Between 30 – 50          
              
Above 50                 
2. Sex 
Male      
     
Female                 
3. Weight  
Below 40 kg                  
 
 Between 40 – 70 kg               
 
 Above 70 kg               
4. Do you smoke? 
Yes                       
 
No      
5. Do you consume alcohol? 
Yes                      
 
 No               
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6. Have you ever had a blood transfusion? 
 Yes    
 
 No                
 
 
7. Do you suffer from any chronic illnesses? If yes, please elaborate. 
…………………………………………………………………………………………
………………………………………………………………………………………… 
8. Do you suffer from any cardiovascular illnesses? If yes, please elaborate. 
…………………………………………………………………………………………
………………………………………………………………………………………… 
9. Have you undergone any medical procedures? If yes, please elaborate.  
…………………………………………………………………………………………
………………………………………………………………………………………… 
10. Do you take any medication? This includes steroids. If yes, please elaborate. 
…………………………………………………………………………………………
………………………………………………………………………………………… 
11. Your assistance is well appreciated. Kindly note that the present study is not for 
diagnostic purposes. All information disclosed will be kept confidential. 
 
 
 
 
 
 
 
 
 
150 
 
Appendix B 
 
Table 1: Concentration of DNA obtained from blood, vaginal fluid, semen and saliva. 
 
Sample ID Nucleic Acid Concentration 
Blood 1 16,1 ng/µl 
Blood 2 21,5 ng/µl 
Blood 3 21,3 ng/µl 
Blood 4 23,5 ng/µl 
Blood 5 25,7 ng/µl 
Blood 6 15,9 ng/µl 
Blood 7 39,7 ng/µl 
Blood 8 24 ng/µl 
Blood 9 53,5 ng/µl 
Blood 10 22,9 ng/µl 
Blood 11 25 ng/µl 
Vaginal fluid 1 101,7 ng/µl 
Vaginal fluid 2 494,8 ng/µl 
Vaginal fluid 3 54,3 ng/µl 
Vaginal fluid 4 124,4 ng/µl 
Vaginal fluid 5 179,4 ng/µl 
Vaginal fluid 6 60,3 ng/µl 
Vaginal fluid 7 206,7 ng/µl 
Vaginal fluid 8 44,6 ng/µl 
Vaginal fluid 9 64,2 ng/µl 
Vaginal fluid 10 38,3 ng/µl 
Semen 1 26,2 ng/µl 
Semen 2 10,6 ng/µl 
Semen 3 12,8 ng/µl 
Semen 4 25,7 ng/µl 
Semen 5 11,4 ng/µl 
Semen 6 19,2 ng/µl 
Semen 7 19,8 ng/µl 
Semen 8 16,3 ng/µl 
Semen 9 15,8 ng/µl 
Semen 10 17,8 ng/µl 
Saliva 1 14,6 ng/µl 
Saliva 2 36,5 ng/µl 
Saliva 3 36,1 ng/µl 
Saliva 4 182,3 ng/µl 
Saliva 5 187,5 ng/µl 
Saliva 6 79 ng/µl 
Saliva 7 107,8 ng/µl 
Saliva 8 21,1 ng/µl 
Saliva 9 54,2 ng/µl 
Saliva 10 64 ng/µl 
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Figure 1: BiSearch results depicting specificity of MSP primers for methylated cytosine of ZNF282 tDMR. 
 
 
 
 
 
 
 
Figure 2: BiSearch results depicting specificity of MSP primers for unmethylated cytosine of ZNF282 
tDMR. 
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Figure 3: BiSearch results depicting specificity of MSP primers for methylated cytosine of PTPRS 1 tDMR. 
 
 
 
 
 
 
 
Figure 4: BiSearch results depicting specificity of MSP primers for unmethylated cytosine of PTPRS 1 
tDMR. 
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Figure 5: BiSearch results depicting specificity of MSP primers for methylated cytosine of PTPRS 2 tDMR. 
 
 
 
 
 
 
 
Figure 6: BiSearch results depicting specificity of MSP primers for unmethylated cytosine of PTPRS 2 
tDMR. 
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Figure 7: BiSearch results depicting specificity of MSP primers for methylated cytosine of HPCAL1 tDMR. 
 
 
 
 
 
 
 
Figure 8: BiSearch results depicting specificity of MSP primers for unmethylated cytosine of HPCAL1 
tDMR. 
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Figure 9: BiSearch results depicting specificity of BS primers designed for ZNF282 tDMR. 
 
 
 
 
 
 
 
 
Figure 10: BiSearch results depicting specificity of BS primers designed for PTPRS 1 tDMR.  
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Figure 11: BiSearch results depicting specificity of BS primers designed for PTPRS 2 tDMR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 12: BiSearch results depicting specificity of BS primers designed for HPCAL1 tDMR. 
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Appendix D 
 
Table 1:  Pairwise comparison of total DNA methylation at CpG 1 for ZNF282 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.0001  0.0000  1  
Vaginal fluid  1.0000  1.0000  0.0001  1 
 
 
Table 2: Pairwise comparison of total DNA methylation at CpG 2 for ZNF282 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.0001  0.0000  1  
Vaginal fluid  1.0000  1.0000  0.0001  1 
 
 
Table 3: Pairwise comparison of total DNA methylation at CpG 3 for ZNF282 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 0.4667  1   
Semen 0.0009  0.0000  1  
Vaginal fluid  1.0000  1.0000  0.0001  1 
 
 
Table 4: Pairwise comparison of total DNA methylation at CpG 4 for ZNF282 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.0014  0.0004  1  
Vaginal fluid  1.0000  1.0000  0.0014  1 
 
 
Table 5: Pairwise comparison of total DNA methylation at CpG 5 for ZNF282 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.0001  0.0000  1  
Vaginal fluid  1.0000  1.0000  0.0001  1 
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Table 6: Pairwise comparison of total DNA methylation at CpG 6 for ZNF282 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.0001  0.0000  1  
Vaginal fluid  1.0000  0.4667  0.0009  1 
 
 
Table 7: Pairwise comparison of total DNA methylation at CpG 7 for ZNF282 tDMR in blood, saliva, semen 
and vaginal fluid. The p -values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 0.4667 1   
Semen 0.0009  0.0000  1  
Vaginal fluid  1.0000  1.0000  0.0001  1 
 
 
Table 8: Pairwise comparison of total DNA methylation at CpG 8 for ZNF282 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.0009  0.0004  1  
Vaginal fluid  1.0000  1.0000  0.0001  1 
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Table 4: Pairwise comparison of total DNA methylation at CpG 4 for PTPRS 1 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 1.0000  1.0000  1  
Vaginal fluid  1.0000  1.0000  1.0000  1 
 
 
Table 5: Pairwise comparison of total DNA methylation at CpG 5 for PTPRS 1 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 1.0000  1.0000  1  
Vaginal fluid  1.0000  1.0000  1.0000  1 
 
 
 
 
Table 1:  Pairwise comparison of total DNA methylation at CpG 1 for PTPRS  1 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 0.3077  1   
Semen 1.0000  1.0000 1  
Vaginal fluid  0.3077  1.0000  1.0000  1 
Table 2: Pairwise comparison of total DNA methylation at CpG 2 for PTPRS  1 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 0.0769  1   
Semen 0.5301  0.4706  1  
Vaginal fluid  0.0769  1.0000  0.4706  1 
Table 3: Pairwise comparison of total DNA methylation at CpG 3 for PTPRS  1 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 0.3333  1   
Semen 1.0000  1.0000  1  
Vaginal fluid  0.3077  1.0000  1.0000  1 
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Appendix F 
 
 
 
Table 2: Pairwise comparison of total DNA methylation at CpG 2 for PTPRS 2 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.3333  0.2000  1  
Vaginal fluid  1.0000  1.0000  0.2000  1 
 
 
Table 3: Pairwise comparison of total DNA methylation at CpG 3 for PTPRS 2 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.3333  0.2000 1  
Vaginal fluid  1.0000  1.0000  0.2000  1 
 
 
Table 4: Pairwise comparison of total DNA methylation at CpG 4 for PTPRS 2 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 0.3333  1   
Semen 1.0000  0.2000  1  
Vaginal fluid  1.0000  1.0000  0.4000  1 
 
 
Table 5: Pairwise comparison of total DNA methylation at CpG 5 for PTPRS 2 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000   1   
Semen 0.3333  0.2000  1  
Vaginal fluid  1.0000  1.0000  0.2000  1 
 
 
 
 
 
 
 
Table 1:  Pairwise comparison of total DNA methylation at CpG 1 for PTPRS  2 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.3333  0.2000  1  
Vaginal fluid  1.0000  1.0000  0.2000  1 
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Table 6: Pairwise comparison of total DNA methylation at CpG 6 for PTPRS 2 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.3333  0.2000  1  
Vaginal fluid  1.0000  1.0000  0.2000  1 
 
 
Table 7: Pairwise comparison of total DNA methylation at CpG 7 for PTPRS 2 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.3333  0.2000  1  
Vaginal fluid  1.0000  1.0000  0.2000  1 
 
 
Table 8: Pairwise comparison of total DNA methylation at CpG 8 for PTPRS 2 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.3333 0.2000  1  
Vaginal fluid  1.0000  1.0000  0.2000  1 
 
 
Table 9: Pairwise comparison of total DNA methylation at CpG 9 for PTPRS 2 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.3333 0.2000  1  
Vaginal fluid  1.0000 1.0000  0.2000  1 
 
 
Table 10: Pairwise comparison of total DNA methylation at CpG 10 for PTPRS 2 tDMR in blood, saliva, 
semen and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.3333  0.2000  1  
Vaginal fluid  1.0000 1.0000  0.4000  1 
 
 
Table 11: Pairwise comparison of total DNA methylation at CpG 11 for PTPRS 2 tDMR in blood, saliva, 
semen and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.3333  0.2000  1  
Vaginal fluid  1.0000  1.0000  0.2000 1 
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Table 12: Pairwise comparison of total DNA methylation at CpG 12 for PTPRS 2 tDMR in blood, saliva, 
semen and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.3333  0.2000  1  
Vaginal fluid  1.0000  1.0000  0.2000  1 
 
 
Table 13: Pairwise comparison of total DNA methylation at CpG 13 for PTPRS 2 tDMR in blood, saliva, 
semen and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.3333  0.2000  1  
Vaginal fluid  1.0000  1.0000  0.2000  1 
 
 
Table 14: Pairwise comparison of total DNA methylation at CpG 14 for PTPRS 2 tDMR in blood, saliva, 
semen and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.3333  0.2000  1  
Vaginal fluid  1.0000  1.0000  0.2000  1 
 
 
Table 15: Pairwise comparison of total DNA methylation at CpG 15 for PTPRS 2 tDMR in blood, saliva, 
semen and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.3333  0.2000  1  
Vaginal fluid  1.0000  1.0000  0.2000  1 
 
 
Table 16: Pairwise comparison of total DNA methylation at CpG 16 for PTPRS 2 tDMR in blood, saliva, 
semen and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 1.0000  1.0000  1  
Vaginal fluid  1.0000  1.0000 1.0000  1 
 
 
Table 17: Pairwise comparison of total DNA methylation at CpG 17 for PTPRS 2 tDMR in blood, saliva, 
semen and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.3333  0.2000  1  
Vaginal fluid  1.0000  1.0000   0.2000 1 
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Table 18: Pairwise comparison of total DNA methylation at CpG 18 for PTPRS 2 tDMR in blood, saliva, 
semen and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000 1   
Semen 0.3333  0.2000 1  
Vaginal fluid  1.0000 1.0000 0.2000  1 
 
 
Table 19: Pairwise comparison of total DNA methylation at CpG 19 for PTPRS 2 tDMR in blood, saliva, 
semen and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 1.0000 1.0000  1  
Vaginal fluid  1.0000  1.0000  1.0000  1 
 
 
Table 20: Pairwise comparison of total DNA methylation at CpG 20 for PTPRS 2 tDMR in blood, saliva, 
semen and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 1.0000  1.0000  1  
Vaginal fluid  1.0000  1.0000  1.0000  1 
 
 
Table 21: Pairwise comparison of total DNA methylation at CpG 21 for PTPRS 2 tDMR in blood, saliva, 
semen and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.3333  0.2000  1  
Vaginal fluid  1.0000  1.0000  0.2000  1 
 
 
Table 22: Pairwise comparison of total DNA methylation at CpG 22 for PTPRS 2 tDMR in blood, saliva, 
semen and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.3333  0.2000  1  
Vaginal fluid  1.0000  1.0000  0.4000  1 
 
 
Table 23: Pairwise comparison of total DNA methylation at CpG 23 for PTPRS 2 tDMR in blood, saliva, 
semen and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.3333  0.4000  1  
Vaginal fluid  1.0000  1.0000  0.2000 1 
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Table 24: Pairwise comparison of total DNA methylation at CpG 24 for PTPRS 2 tDMR in blood, saliva, 
semen and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 1.0000  1.0000  1  
Vaginal fluid  1.0000  1.0000  1.0000  1 
 
 
Table 25: Pairwise comparison of total DNA methylation at CpG 25 for PTPRS 2 tDMR in blood, saliva, 
semen and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 1.0000 1.0000  1  
Vaginal fluid  1.0000  1.0000  1.0000  1 
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Appendix G 
 
                                                     1            2             3           4            5             6   
 
 
Figure 1:  BS PCR reaction of all four body fluids for the HPCAL1 tDMR primer set. Products with primers 
showing non-specific amplification. Lane 1 – 100 bp ladder (Thermo Scientific). Lane 2 – Lane 5- blood, 
saliva, semen and vaginal fluid DNA samples, respectively. Lane 6- No template. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
300 bp 
200 bp 
100 bp 
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Appendix H 
 
 
Figure 1: Expressed sequence tag (EST) profile of ZNF282 gene in Tissue-specific Gene Expression 
and Regulation (TiGER) database.  
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Figure 2: Expressed sequence tag (EST) profile of PTPRS gene in Tissue-specific Gene Expression and Regulation 
(TiGER) database.   
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Figure 3: Expressed sequence tag (EST) profile of HPCAL1 gene in Tissue-specific Gene Expression 
and Regulation (TiGER) database.  
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Appendix I 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1:  DNA concentrations of five samples analysed for each body fluid not 
exposed to environmental insults (t0 days). 
 
Sample ID Nucleic Acid Concentration 
Blood 1 14 ng/µl 
Blood 2 15,3 ng/µl 
Blood 3 41,1 ng/µl 
Blood 4 28,1 ng/µl 
Blood 5 35,6 ng/µl 
Vaginal fluid 1 205,3 ng/µl 
Vaginal fluid  2 168,6 ng/µl 
Vaginal fluid  3 155,3 ng/µl 
Vaginal fluid  4 163,9 ng/µl 
Vaginal fluid  5 197,1 ng/µl 
Semen 1 26,2 ng/µl 
Semen  2 10,6 ng/µl 
Semen  3 25,7 ng/µl 
Semen  4 11,4 ng/µl 
Semen  5 19,2 ng/µl 
Saliva 1 36,5 ng/µl 
Saliva  2 182,3 ng/µl 
Saliva  3 187,5 ng/µl 
Saliva  4 107,8 ng/µl 
Saliva  5 54,2 ng/µl 
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Table 2:  DNA concentrations of five samples analysed for blood after t50 days.  
 
Sample ID Nucleic Acid Concentration 
 
 
 
Condition A 
Blood 1 3.5  ng/µl 
Blood 2 4.8  ng/µl 
Blood 3 3  ng/µl 
Blood 4 4.4  ng/µl 
Blood 5 
 
4  ng/µl 
 
 
 
Condition B 
Blood 1 5.1  ng/µl 
Blood 2 4.7  ng/µl 
Blood 3 4.5  ng/µl 
Blood 4 5.5  ng/µl 
Blood 5 3.5  ng/µl 
  
 
 
Condition C 
Blood 1 12.6  ng/µl 
Blood 2 84.3  ng/µl 
Blood 3 10.3  ng/µl 
Blood 4 8.5  ng/µl 
Blood 5 13.2  ng/µl 
 
 
 
Condition D 
Blood 1 5.6  ng/µl 
Blood 2 3.1  ng/µl 
Blood 3 1.7  ng/µl 
Blood 4 4.1  ng/µl 
Blood 5 2.2  ng/µl 
 
 
 
Condition E 
Blood 1 16.2  ng/µl 
Blood 2 2.4  ng/µl 
Blood 3 3.3  ng/µl 
Blood 4 3.9  ng/µl 
Blood 5 4.6  ng/µl 
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Table 3:  DNA concentrations of five samples analysed for saliva after t50 days. 
 
Sample ID Nucleic Acid Concentration 
 
 
 
Condition A 
Saliva 1 1.4  ng/µl 
Saliva 2 14.9  ng/µl 
Saliva 3 6.5  ng/µl 
Saliva 4 9.6  ng/µl 
Saliva 5 12.3  ng/µl 
 
 
 
Condition B 
Saliva 1 3.1  ng/µl 
Saliva 2 12.1  ng/µl 
Saliva 3 10.8  ng/µl 
Saliva 4 4.5  ng/µl 
Saliva 5 9.7  ng/µl 
 
 
 
Condition C 
Saliva 1 6.4  ng/µl 
Saliva 2 10.6  ng/µl 
Saliva 3 11.6  ng/µl 
Saliva 4 5.5  ng/µl 
Saliva 5 9.4  ng/µl 
 
 
 
Condition D 
Saliva 1 1.8  ng/µl 
Saliva 2 9.7  ng/µl 
Saliva 3 13.9  ng/µl 
Saliva 4 14.3 ng/µl 
Saliva 5 12.3  ng/µl 
 
 
 
Condition E 
Saliva 1 1.9  ng/µl 
Saliva 2 1.5  ng/µl 
Saliva 3 6  ng/µl 
Saliva 4 4.5  ng/µl 
Saliva 5 3.6  ng/µl 
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Table 4:  DNA concentrations of five samples analysed for semen after t50 days. 
 
Sample ID Nucleic Acid Concentration 
 
 
 
Condition A 
Semen 1 1  ng/µl 
Semen 2 0.2  ng/µl 
Semen 3 0.3  ng/µl 
Semen 4 0.8  ng/µl 
Semen 5 2  ng/µl 
 
 
 
Condition B 
Semen 1 1.3  ng/µl 
Semen 2 1.3  ng/µl 
Semen 3 0.6  ng/µl 
Semen 4 2.2  ng/µl 
Semen 5 0.5  ng/µl 
 
 
 
Condition C 
Semen 1 13.3  ng/µl 
Semen 2 16  ng/µl 
Semen 3 12.5  ng/µl 
Semen 4 15.9  ng/µl 
Semen 5 16.8  ng/µl 
 
 
 
Condition D 
Semen 1 0.7  ng/µl 
Semen 2 1.6  ng/µl 
Semen 3 1.4  ng/µl 
Semen 4 0.4  ng/µl 
Semen 5 0.8  ng/µl 
 
 
 
Condition E 
Semen 1 0.5  ng/µl 
Semen 2 0.8  ng/µl 
Semen 3 0.5  ng/µl 
Semen 4 1  ng/µl 
Semen 5 2  ng/µl 
173 
 
 
Table 5:  DNA concentrations of five samples analysed for vaginal fluid after t50 days. 
 
Sample ID Nucleic Acid Concentration 
 
 
 
Condition A 
Vaginal fluid 1 143.8  ng/µl 
Vaginal fluid 2 35  ng/µl 
Vaginal fluid 3 130  ng/µl 
Vaginal fluid 4 62.3  ng/µl 
Vaginal fluid 5 102.6  ng/µl 
 
 
 
Condition B 
Vaginal fluid 1 156  ng/µl 
Vaginal fluid 2 44.4  ng/µl 
Vaginal fluid 3 120.8  ng/µl 
Vaginal fluid 4 52.6  ng/µl 
Vaginal fluid 5 113  ng/µl 
 
 
 
Condition C 
Vaginal fluid 1 12.7  ng/µl 
Vaginal fluid 2 12.8  ng/µl 
Vaginal fluid 3 11.2  ng/µl 
Vaginal fluid 4 10.5  ng/µl 
Vaginal fluid 5 13.5  ng/µl 
 
 
 
Condition D 
Vaginal fluid 1 165.9  ng/µl 
Vaginal fluid 2 1.3  ng/µl 
Vaginal fluid 3 0.7  ng/µl 
Vaginal fluid 4 142.8  ng/µl 
Vaginal fluid 5 50.6  ng/µl 
 
 
 
Condition E 
Vaginal fluid 1 3  ng/µl 
Vaginal fluid 2 332.4  ng/µl 
Vaginal fluid 3 171.6  ng/µl 
Vaginal fluid 4 1.4  ng/µl 
Vaginal fluid 5 200.6  ng/µl 
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Table 3: Pairwise comparison of total DNA methylation at CpG 3 for ZNF282 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.0079 0.0079  1  
Vaginal fluid  1.0000  1.0000  0.0179  1 
 
 
Table 4: Pairwise comparison of total DNA methylation at CpG 4 for ZNF282 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.0079  0.0079  1  
Vaginal fluid  1.0000  1.0000  0.0179  1 
 
 
Table 5: Pairwise comparison of total DNA methylation at CpG 5 for ZNF282 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.0079  0.0079  1  
Vaginal fluid  1.0000  1.0000  0.0179  1 
 
 
 
 
Table 1:  Pairwise comparison of total DNA methylation at CpG 1 for ZNF282 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.0079  0.0079  1  
Vaginal fluid  1.000  1.000  0.0179  1 
Table 2: Pairwise comparison of total DNA methylation at CpG 2 for ZNF282 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.0079  0.0079  1  
Vaginal fluid  1.0000 1.0000  0.0179  1 
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Table 6: Pairwise comparison of total DNA methylation at CpG 6 for ZNF282 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.0079  0.0079  1  
Vaginal fluid  1.0000  1.0000  0.0179  1 
 
 
Table 7: Pairwise comparison of total DNA methylation at CpG 7 for ZNF282 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 1.0000  1   
Semen 0.0079  0.0079  1  
Vaginal fluid  1.0000  1.0000  0.0179  1 
 
 
Table 8: Pairwise comparison of total DNA methylation at CpG 8 for ZNF282 tDMR in blood, saliva, semen 
and vaginal fluid. The p-values obtained from the Fisher’s Exact test are indicated below. 
 
 Blood  Saliva  Semen Vaginal fluid 
Blood 1    
Saliva 0.4444  1   
Semen 0.0079  0.0079  1  
Vaginal fluid  1.0000  1.0000  0.0179  1 
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Table 3: Pairwise comparison of DNA methylation at CpG 3 of the ZNF282 tDMR for comparison of t0 days 
to t50 days in Condition C (outside on the ground). The p-values obtained from the Chi-square test or Fisher’s 
exact test are indicated below. 
 
 t0 days 
 Blood  Saliva  Semen Vaginal fluid 
t50 days  1.0000  0.2857  1.0000  1.0000  
 
 
Table 4: Pairwise comparison of DNA methylation at CpG 4 of the ZNF282 tDMR for comparison of t0 days 
to t50 days in Condition C (outside on the ground). The p-values obtained from the Chi-square test or Fisher’s 
exact test are indicated below. 
 
 t0 days 
 Blood  Saliva  Semen Vaginal fluid 
t50 days  1.0000  0.2857  1.0000  1.0000  
 
 
Table 5: Pairwise comparison of DNA methylation at CpG 5 of the ZNF282 tDMR for comparison of t0 days 
to t50 days in Condition C (outside on the ground). The p-values obtained from the Chi-square test or Fisher’s 
exact test are indicated below. 
 
 t0 days 
 Blood  Saliva  Semen Vaginal fluid 
t50 days  1.0000  0.2857  1.0000  1.0000  
 
 
Table 6: Pairwise comparison of DNA methylation at CpG 6 of the ZNF282 tDMR for comparison of t0 days 
to t50 days in Condition C (outside on the ground). The p-values obtained from the Chi-square test or Fisher’s 
exact test are indicated below. 
 
 t0 days 
 Blood  Saliva  Semen Vaginal fluid 
t50 days  1.0000  0.2857  1.0000  1.0000  
 
 
Table 1: Pairwise comparison of DNA methylation at CpG 1 of the ZNF282 tDMR for comparison of t0 days 
to t50 days in Condition C (outside on the ground). The p-values obtained from the Chi-square test or Fisher’s 
exact test are indicated below. 
 
 t0 days 
 Blood  Saliva  Semen Vaginal fluid 
t50 days  1.0000  0.2857 1.0000 1.0000  
Table 2: Pairwise comparison of DNA methylation at CpG 2 of the ZNF282 tDMR for comparison of t0 days 
to t50 days in Condition C (outside on the ground). The p-values obtained from the Chi-square test or Fisher’s 
exact test are indicated below. 
 
 t0 days 
 Blood  Saliva  Semen Vaginal fluid 
t50 days  1.0000  0.2857  1.0000  1.0000  
177 
 
Table 7: Pairwise comparison of DNA methylation at CpG 7 of the ZNF282 tDMR for comparison of t0 days 
to t50 days in Condition C (outside on the ground). The p-values obtained from the Chi-square test or Fisher’s 
exact test are indicated below. 
 
 t0 days 
 Blood  Saliva  Semen Vaginal fluid 
t50 days  1.0000 0.2857  1.0000  1.0000   
 
 
Table 8: Pairwise comparison of DNA methylation at CpG 8 of the ZNF282 tDMR for comparison of t0 days 
to t50 days in Condition C (outside on the ground). The p-values obtained from the Chi-square test or Fisher’s 
exact test are indicated below. 
 
 t0 days 
 Blood  Saliva  Semen Vaginal fluid 
t50 days  0.4444  0.2857  1.0000  1.0000  
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Table 1:  Pairwise comparison of DNA methylation at CpG 1 of the ZNF282 tDMR for vaginal fluid in all 
conditions. The p-values obtained from the Chi-square test or Fisher’s exact test are indicated below. A= dry at 
room temperature, B= wet in an exsiccator, C= outside on the ground, D= sprayed with alcohol and E= sprayed 
with bleach. 
 
 Vaginal fluid 
A 
Vaginal fluid 
B 
Vaginal fluid 
C 
Vaginal fluid 
D 
Vaginal fluid E 
Vaginal fluid A 1     
Vaginal fluid B 1.0000  1    
Vaginal fluid C 1.0000  1.0000  1   
Vaginal fluid D 1.0000  1.0000 1.0000 1  
Vaginal fluid E 1.0000 
 
1.0000  1.0000  1.0000  1 
Table 2:  Pairwise comparison of DNA methylation at CpG 2 of the ZNF282 tDMR for vaginal fluid in all 
conditions. The p-values obtained from the Chi-square test or Fisher’s exact test are indicated below.  A= dry at 
room temperature, B= wet in an exsiccator, C= outside on the ground, D= sprayed with alcohol and E= sprayed 
with bleach. 
 
 Vaginal fluid 
A 
Vaginal fluid 
B 
Vaginal fluid 
C 
Vaginal fluid 
D 
Vaginal fluid E 
Vaginal fluid A 1     
Vaginal fluid B 0.3333 1    
Vaginal fluid C 1.0000  1.0000  1   
Vaginal fluid D 0.2857  1.0000 1.0000  1  
Vaginal fluid E 0.2857 1.0000 1.0000  1.0000 1 
Table 3:  Pairwise comparison of DNA methylation at CpG 3 of the ZNF282 tDMR for vaginal fluid in all 
conditions. The p-values obtained from the Chi-square test or Fisher’s exact test are indicated below. A= dry at 
room temperature, B= wet in an exsiccator, C= outside on the ground, D= sprayed with alcohol and E= sprayed 
with bleach. 
 
 Vaginal fluid 
A 
Vaginal fluid 
B 
Vaginal fluid 
C 
Vaginal fluid 
D 
Vaginal fluid E 
Vaginal fluid A 1     
Vaginal fluid B 1.0000 1    
Vaginal fluid C 1.0000 1.0000  1   
Vaginal fluid D 1.0000 1.0000 1.0000 1  
Vaginal fluid E 1.0000  1.0000 1.0000  1.0000  1 
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Table 4:  Pairwise comparison of DNA methylation at CpG 4 of the ZNF282 tDMR for vaginal fluid in all 
conditions. The p-values obtained from the Chi-square test or Fisher’s exact test are indicated below. A= dry at 
room temperature, B= wet in an exsiccator, C= outside on the ground, D= sprayed with alcohol and E= sprayed 
with bleach. 
 
 Vaginal fluid 
A 
Vaginal fluid 
B 
Vaginal fluid 
C 
Vaginal fluid 
D 
Vaginal fluid E 
Vaginal fluid A 1     
Vaginal fluid B 1.0000 1    
Vaginal fluid C 1.0000 1.0000 1   
Vaginal fluid D 1.0000 1.0000  1.0000 1  
Vaginal fluid E 1.0000 1.0000 1.0000  1.0000  1 
Table 5:  Pairwise comparison of DNA methylation at CpG 5 of the ZNF282 tDMR for vaginal fluid in all 
conditions. The p-values obtained from the Chi-square test or Fisher’s exact test are indicated below. A= dry at 
room temperature, B= wet in an exsiccator, C= outside on the ground, D= sprayed with alcohol and E= sprayed 
with bleach. 
 
 Vaginal fluid 
A 
Vaginal fluid 
B 
Vaginal fluid 
C 
Vaginal fluid 
D 
Vaginal fluid E 
Vaginal fluid A 1     
Vaginal fluid B 1.0000 1    
Vaginal fluid C 1.0000  1.0000 1   
Vaginal fluid D 1.0000  1.0000 1.0000  1  
Vaginal fluid E 1.0000 1.0000 1.0000  1.0000 1 
Table 6:  Pairwise comparison of DNA methylation at CpG 6 of the ZNF282 tDMR for vaginal fluid in all 
conditions. The p-values obtained from the Chi-square test or Fisher’s exact test are indicated below. A= dry at 
room temperature, B= wet in an exsiccator, C= outside on the ground, D= sprayed with alcohol and E= sprayed 
with bleach. 
 
 Vaginal fluid 
A 
Vaginal fluid 
B 
Vaginal fluid 
C 
Vaginal fluid 
D 
Vaginal fluid E 
Vaginal fluid A 1     
Vaginal fluid B 0.3333 1    
Vaginal fluid C 1.0000 1.0000 1   
Vaginal fluid D 0.2857 1.0000 1.0000 1  
Vaginal fluid E 0.2857 1.0000  1.0000 1.0000 1 
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Table 7:  Pairwise comparison of DNA methylation at CpG 7 of the ZNF282 tDMR for vaginal fluid in all 
conditions. The p-values obtained from the Chi-square test or Fisher’s exact test are indicated below. A= dry at 
room temperature, B= wet in an exsiccator, C= outside on the ground, D= sprayed with alcohol and E= sprayed 
with bleach. 
 
 Vaginal fluid 
A 
Vaginal fluid 
B 
Vaginal fluid 
C 
Vaginal fluid 
D 
Vaginal fluid E 
Vaginal fluid A 1     
Vaginal fluid B 1.0000 1    
Vaginal fluid C 1.0000 1.0000 1   
Vaginal fluid D 1.0000 1.0000 1.0000 1  
Vaginal fluid E 1.0000 1.0000 1.0000  1.0000  1 
Table 8:  Pairwise comparison of DNA methylation at CpG 8 of the ZNF282 tDMR for vaginal fluid in all 
conditions. The p-values obtained from the Chi-square test or Fisher’s exact test are indicated below. A= dry at 
room temperature, B= wet in an exsiccator, C= outside on the ground, D= sprayed with alcohol and E= sprayed 
with bleach. 
 
 Vaginal fluid 
A 
Vaginal fluid 
B 
Vaginal fluid 
C 
Vaginal fluid 
D 
Vaginal fluid E 
Vaginal fluid A 1     
Vaginal fluid B 1.0000 1    
Vaginal fluid C 1.0000 1.0000 1   
Vaginal fluid D 1.0000 1.0000 1.0000 1  
Vaginal fluid E 1.0000 1.0000 1.0000 1.0000 1 
Table 9: Pairwise comparison of DNA methylation at CpG 1 of the ZNF282 tDMR for all conditions in 
vaginal fluid for comparison between t0 days and t50 days. The p-values obtained from the Chi-square test 
or Fisher’s exact test are indicated below. A= dry at room temperature, B= wet in an exsiccator, C= outside 
on the ground, D= sprayed with alcohol and E= sprayed with bleach. 
 
 t0 days 
 Vaginal fluid 
A 
Vaginal fluid 
B 
Vaginal fluid 
C 
Vaginal fluid 
D 
Vaginal fluid 
E 
t50 days 1.0000 1.0000 1.0000 1.0000 1.0000  
Table 10: Pairwise comparison of DNA methylation at CpG 2 of the ZNF282 tDMR for all conditions in 
vaginal fluid for comparison between t0 days and t50 days. The p-values obtained from the Chi-square test 
or Fisher’s exact test are indicated below. A= dry at room temperature, B= wet in an exsiccator, C= outside 
on the ground, D= sprayed with alcohol and E= sprayed with bleach. 
 
 t0 days 
 Vaginal fluid 
A 
Vaginal fluid 
B 
Vaginal fluid 
C 
Vaginal fluid 
D 
Vaginal fluid 
E 
t50 days 0.4000 1.0000  1.0000 1.0000 1.0000 
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Table 11: Pairwise comparison of DNA methylation at CpG 3 of the ZNF282 tDMR for all conditions in 
vaginal fluid for comparison between t0 days and t50 days. The p-values obtained from the Chi-square test 
or Fisher’s exact test are indicated below. A= dry at room temperature, B= wet in an exsiccator, C= outside 
on the ground, D= sprayed with alcohol and E= sprayed with bleach. 
 
 t0 days 
 Vaginal fluid 
A 
Vaginal fluid 
B 
Vaginal fluid 
C 
Vaginal fluid 
D 
Vaginal fluid 
E 
t50 days 1.0000 1.0000 1.0000 1.0000 1.0000 
Table 12: Pairwise comparison of DNA methylation at CpG 4 of the ZNF282 tDMR for all conditions in 
vaginal fluid for comparison between t0 days and t50 days. The p-values obtained from the Chi-square test 
or Fisher’s exact test are indicated below. A= dry at room temperature, B= wet in an exsiccator, C= outside 
on the ground, D= sprayed with alcohol and E= sprayed with bleach. 
 
 t0 days 
 Vaginal fluid 
A 
Vaginal fluid 
B 
Vaginal fluid 
C 
Vaginal fluid 
D 
Vaginal fluid 
E 
t50 days 1.0000  1.0000 1.0000 1.0000 1.0000 
Table 13: Pairwise comparison of DNA methylation at CpG 5 of the ZNF282 tDMR for all conditions in 
vaginal fluid for comparison between t0 days and t50 days. The p-values obtained from the Chi-square test 
or Fisher’s exact test are indicated below. A= dry at room temperature, B= wet in an exsiccator, C= outside 
on the ground, D= sprayed with alcohol and E= sprayed with bleach. 
 
 t0 days 
 Vaginal fluid 
A 
Vaginal fluid 
B 
Vaginal fluid 
C 
Vaginal fluid 
D 
Vaginal fluid 
E 
t50 days 1.0000 1.0000 1.0000 1.0000 1.0000 
Table 14: Pairwise comparison of DNA methylation at CpG 6 of the ZNF282 tDMR for all conditions in 
vaginal fluid for comparison between t0 days and t50 days. The p-values obtained from the Chi-square test 
or Fisher’s exact test are indicated below. A= dry at room temperature, B= wet in an exsiccator, C= outside 
on the ground, D= sprayed with alcohol and E= sprayed with bleach. 
 
 t0 days 
 Vaginal fluid 
A 
Vaginal fluid 
B 
Vaginal fluid 
C 
Vaginal fluid 
D 
Vaginal fluid 
E 
t50 days 1.0000 1.0000 1.0000 1.0000 1.0000 
Table 15: Pairwise comparison of DNA methylation at CpG 7 of the ZNF282 tDMR for all conditions in 
vaginal fluid for comparison between t0 days and t50 days. The p-values obtained from the Chi-square test 
or Fisher’s exact test are indicated below. A= dry at room temperature, B= wet in an exsiccator, C= outside 
on the ground, D= sprayed with alcohol and E= sprayed with bleach. 
 
 t0 days 
 Vaginal fluid 
A 
Vaginal fluid 
B 
Vaginal fluid 
C 
Vaginal fluid 
D 
Vaginal fluid 
E 
t50 days 1.0000 1.0000 1.0000 1.0000 1.0000  
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Table 16: Pairwise comparison of DNA methylation at CpG 8 of the ZNF282 tDMR for all conditions in 
vaginal fluid for comparison between t0 days and t50 days. The p-values obtained from the Chi-square test 
or Fisher’s exact test are indicated below. A= dry at room temperature, B= wet in an exsiccator, C= outside 
on the ground, D= sprayed with alcohol and E= sprayed with bleach. 
 
 t0 days 
 Vaginal fluid 
A 
Vaginal fluid 
B 
Vaginal fluid 
C 
Vaginal fluid 
D 
Vaginal fluid 
E 
t50 days 1.0000 1.0000 1.0000 1.000 1.0000  
